<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002486</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>331</s160></s100><s200><s210>1</s210><s211>130</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 1Val Lys Leu Gln Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr1               5                   10                  15Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly            20                  25                  30Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly        35                  40                  45Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys    50                  55                  60Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu65                  70                  75                  80Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ser                85                  90                  95Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Ser            100                 105                 110Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Lys Leu Val Tyr Pro Leu        115                 120                 125Ala Pro    130</s400><s200><s210>2</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 2Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn1               5                   10</s400><s200><s210>3</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 3Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>4</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 4Leu Tyr Asn Gly Asn Ser Leu Asp Tyr1               5</s400><s200><s210>5</s210><s211>125</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 5Gly Asp Ile Leu Leu Thr Gln Ser Pro Leu Ser Leu Thr Val Thr Ala1               5                   10                  15Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn            20                  25                  30Ser Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly        35                  40                  45Gln Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly    50                  55                  60Val Pro Ala Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu65                  70                  75                  80Thr Ile Ser Ser Val Gln Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln                85                  90                  95Asn Ala Tyr Ser Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu            100                 105                 110Ile Asn Arg Ala Asp Ala Ala Pro Thr Gly Ser Ile Phe        115                 120                 125</s400><s200><s210>6</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 6Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Ser Tyr Leu1               5                   10                  15Thr</s400><s200><s210>7</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 7Trp Ala Ser Thr Arg Glu Ser1               5</s400><s200><s210>8</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 8Gln Asn Ala Tyr Ser Phe Pro Phe Thr1               5</s400><s200><s210>9</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 9Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>10</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 10Gly Tyr Thr Phe Ser Met Asn1               5</s400><s200><s210>11</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 11Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg</s400><s200><s210>12</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 12Trp Ala Ser Thr Leu Glu Ser1               5</s400><s200><s210>13</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 13Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>14</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 14Gln Asn Ala Tyr Phe Phe Pro Phe Thr1               5</s400><s200><s210>15</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 15Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>16</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 16Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>17</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 17Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>18</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 18Leu Tyr Arg Gly Asn Ser Leu Asp Tyr1               5</s400><s200><s210>19</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 19Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg</s400><s200><s210>20</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 20Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>21</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 21Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>22</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 22Trp Ile Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>23</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 23Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Gln Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg</s400><s200><s210>24</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 24Lys Ser Ser Gln Ser Leu Leu Asn Trp Gly Asn Gln Lys Ser Tyr Leu1               5                   10                  15Thr</s400><s200><s210>25</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 25Trp Ala Ser Thr Leu Gln Ser1               5</s400><s200><s210>26</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 26Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>27</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 27Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Gln Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>28</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 28Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>29</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 29Trp Ile Asn Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>30</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 30Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Trp Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Val Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>31</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 31Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Trp Lys Ser Tyr Leu1               5                   10                  15Thr</s400><s200><s210>32</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 32Trp Ala Ser Thr Leu Val Ser1               5</s400><s200><s210>33</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 33Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>34</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 34Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Trp Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Val Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>35</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 35Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Met Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>36</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 36Trp Ala Ser Thr Leu Met Ser1               5</s400><s200><s210>37</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 37Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>38</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 38Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Met Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>39</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 39Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Ile Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Arg Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>40</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 40Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Ile Lys Ser Tyr Leu1               5                   10                  15Thr</s400><s200><s210>41</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 41Trp Ala Ser Thr Leu Arg Ser1               5</s400><s200><s210>42</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 42Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>43</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 43Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Ile Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Arg Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>44</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 44Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Thr Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>45</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 45Trp Ile Asn Met Tyr Thr Gly Glu Thr Thr Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>46</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 46Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Tyr Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>47</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 47Trp Ala Ser Thr Leu Tyr Ser1               5</s400><s200><s210>48</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Thr Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>49</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 49Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Tyr Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>50</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 50Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>51</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 51Trp Ile Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>52</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 52Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Phe Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>53</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 53Trp Ala Ser Thr Leu Phe Ser1               5</s400><s200><s210>54</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 54Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>55</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 55Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Phe Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>56</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 56Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Arg Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>57</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 57Trp Ile Asn Met Tyr Thr Gly Arg Pro Thr Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>58</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 58Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Arg Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>59</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 59Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Gln Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>60</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 60Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>61</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 61Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Gln Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>62</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 62Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Trp Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Val Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>63</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 63Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>64</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 64Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Trp Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Val Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>65</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 65Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Phe Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>66</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 66Tyr Trp Ala Ser Thr Leu Phe Ser1               5</s400><s200><s210>67</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 67Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>68</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 68Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Phe Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>69</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 69Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Tyr Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>70</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 70Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Thr Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>71</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 71Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Tyr Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>72</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 72Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Met Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>73</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 73Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>74</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 74Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Met Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>75</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 75Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Ile Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Arg Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>76</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 76Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>77</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 77Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Ile Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Arg Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>78</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 78Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>79</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 79Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>80</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 80Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>81</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 81Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>82</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 82Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>83</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 83Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>84</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 84Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Thr Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser        115</s400><s200><s210>85</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 85Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Thr Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>86</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 86Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>87</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 87Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>88</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 88Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>89</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 89Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>90</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 90Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>91</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 91Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>92</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 92Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>93</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 93Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>94</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 94Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>95</s210><s211>220</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 95Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp        115                 120                 125Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn    130                 135                 140Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu145                 150                 155                 160Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp                165                 170                 175Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr            180                 185                 190Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser        195                 200                 205Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys    210                 215                 220</s400><s200><s210>96</s210><s211>445</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 96Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Arg Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr            100                 105                 110Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro        115                 120                 125Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val    130                 135                 140Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala145                 150                 155                 160Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly                165                 170                 175Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly            180                 185                 190Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys        195                 200                 205Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys    210                 215                 220Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu225                 230                 235                 240Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu                245                 250                 255Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys            260                 265                 270Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys        275                 280                 285Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu    290                 295                 300Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys305                 310                 315                 320Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys                325                 330                 335Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser            340                 345                 350Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys        355                 360                 365Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln    370                 375                 380Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly385                 390                 395                 400Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln                405                 410                 415Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn            420                 425                 430His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>97</s210><s211>121</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 97Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr            20                  25                  30Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly            100                 105                 110Gln Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>98</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 98Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser1               5                   10</s400><s200><s210>99</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 99Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>100</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 100Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr1               5                   10</s400><s200><s210>101</s210><s211>108</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 101Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser            20                  25                  30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu        35                  40                  45Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65                  70                  75                  80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>102</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 102Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala1               5                   10</s400><s200><s210>103</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 103Asp Ala Ser Ser Arg Ala Thr1               5</s400><s200><s210>104</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 104Gln Gln Tyr Gly Ser Leu Pro Trp Thr1               5</s400><s200><s210>105</s210><s211>120</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 105Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Ile Met Met Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ser Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr Trp Gly Gln            100                 105                 110Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>106</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 106Gly Phe Thr Phe Ser Ser Tyr Ile Met Met1               5                   10</s400><s200><s210>107</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 107Ser Ile Tyr Pro Ser Gly Gly Ile Thr Phe Tyr Ala Asp Thr Val Lys1               5                   10                  15Gly</s400><s200><s210>108</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 108Ile Lys Leu Gly Thr Val Thr Thr Val Asp Tyr1               5                   10</s400><s200><s210>109</s210><s211>110</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 109Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1               5                   10                  15Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr            20                  25                  30Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu        35                  40                  45Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe    50                  55                  60Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser                85                  90                  95Ser Thr Arg Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu            100                 105                 110</s400><s200><s210>110</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 110Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser1               5                   10</s400><s200><s210>111</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 111Asp Val Ser Asn Arg Pro Ser1               5</s400><s200><s210>112</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 112Ser Ser Tyr Thr Ser Ser Ser Thr Arg Val1               5                   10</s400><s200><s210>113</s210><s211>118</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 113Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser            20                  25                  30Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Leu Val Thr Val Ser Ser        115</s400><s200><s210>114</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 114Gly Phe Thr Phe Ser Asp Ser Trp Ile His1               5                   10</s400><s200><s210>115</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 115Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1               5                   10                  15Gly</s400><s200><s210>116</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 116Arg His Trp Pro Gly Gly Phe Asp Tyr1               5</s400><s200><s210>117</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 117Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala            20                  25                  30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala                85                  90                  95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>118</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 118Arg Ala Ser Gln Asp Val Ser Thr Ala Val Ala1               5                   10</s400><s200><s210>119</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 119Ser Ala Ser Phe Leu Tyr Ser1               5</s400><s200><s210>120</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 120Gln Gln Tyr Leu Tyr His Pro Ala Thr1               5</s400><s200><s210>121</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 121Ser Gly Gly Gly Gly1               5</s400><s200><s210>122</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 122Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>123</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 123Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1               5                   10                  15Gly Gly Gly Ser            20</s400><s200><s210>124</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 124Gly Ser Ser Arg Ser Ser1               5</s400><s200><s210>125</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 125Gly Ser Gly Ser Ser Ser Ser Ser Arg Ser Ser Ser Gly Ser Gly Gly1               5                   10                  15Gly</s400><s200><s210>126</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 126Ser Gly Gly Arg Gly Gly1               5</s400><s200><s210>127</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 127Gly Ser Ser Gly Ser Ser Ser Arg Gly Gly Ser Gly Ser Ser Ser1               5                   10                  15</s400><s200><s210>128</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 128Ser Ser Ser Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly1               5                   10                  15</s400><s200><s210>129</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 129Gly Ser Ser Gly Ser1               5</s400><s200><s210>130</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 130Gly Gly Gly Gly Ser Gly Ser Gly Ser Ser Gly Ser Ser Ser Gly1               5                   10                  15</s400><s200><s210>131</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 131Gly Gly Gly Gly Ser Gly1               5</s400><s200><s210>132</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 132Gly Ser Ser Ser Gly Gly Gly Ser Gly Gly Ser Ser Ser Ser Ser Ser1               5                   10                  15</s400><s200><s210>133</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 133Ser Gly Gly Ser1</s400><s200><s210>134</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 134Gly Gly Gly Ser1</s400><s200><s210>135</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 135Ser Ser Gly Ser Gly Gly Gly Ser Ser Ser Gly Ser Ser Gly Gly1               5                   10                  15</s400><s200><s210>136</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 136Ser Gly Gly Arg Ser Gly Ser Gly Ser Gly Ser Asn Gly Gly Gly1               5                   10                  15</s400><s200><s210>137</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 137Gly Gly Ser Gly Gly Gly1               5</s400><s200><s210>138</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 138Gly Ser Ser Gly Arg Gly Ser Ser Gly Gly Ser Gly Gly Ser Ser Gly1               5                   10                  15</s400><s200><s210>139</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 139Gly Gly Ser Gly1</s400><s200><s210>140</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 140Gly Gly Gly Ser Ser1               5</s400><s200><s210>141</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 141Gly Ser Gly Ser Gly Gly1               5</s400><s200><s210>142</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 142Ser Gly Ser Ser Gly Ser Ser Ser Ser Ser Gly Ser Gly Ser Gly1               5                   10                  15</s400><s200><s210>143</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 143Ser Ser Gly Ser Gly Gly1               5</s400><s200><s210>144</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 144Ser Gly Ser Ser Gly Ser Ser Ser Ser Gly Ser Gly Ser Gly1               5                   10</s400><s200><s210>145</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 145Gly Ser Gly Ser1</s400><s200><s210>146</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 146Ser Ser Gly Gly Ser Ser Gly Ser Ser Gly Ser Gly Ser Ser Gly Gly1               5                   10                  15</s400><s200><s210>147</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 147Ser Gly Gly Gly Ser1               5</s400><s200><s210>148</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 148Ser Ser Ser Ser Ser Gly Gly Gly Gly Ser Gly Gly Ser Ser Ser Gly1               5                   10                  15</s400><s200><s210>149</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 149Ser Ser Ser Gly Gly Gly1               5</s400><s200><s210>150</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 150Gly Gly Gly Gly Gly1               5</s400><s200><s210>151</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 151Ser Gly Gly Ser Gly Gly1               5</s400><s200><s210>152</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 152Gly Ser Ser Gly1</s400><s200><s210>153</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 153Ser Ser Gly Ser Ser Ser Gly Ser Arg Ser Gly Ser Ser Ser Gly Gly1               5                   10                  15Ser</s400><s200><s210>154</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 154Ser Gly Gly Gly Gly Gly1               5</s400><s200><s210>155</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 155Gly Gly Gly Ser Gly1               5</s400><s200><s210>156</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 156Gly Ser Ser Ser Gly Gly Ser Ser Gly Ser Gly Gly Gly Gly Gly Gly1               5                   10                  15Gly</s400><s200><s210>157</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 157Ser Ser Ser Gly Gly1               5</s400><s200><s210>158</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 158Ser Gly Gly Gly Ser Ser Gly Ser Gly Gly Gly Arg Ser Gly Ser1               5                   10                  15</s400><s200><s210>159</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 159Ser Gly Ser Gly Gly Ser1               5</s400><s200><s210>160</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 160Gly Ser Gly Gly Gly Gly Ser Ser Gly Ser Ser Gly Ser Gly Gly Ser1               5                   10                  15Gly</s400><s200><s210>161</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 161Ser Ser Ser Gly Ser Ser1               5</s400><s200><s210>162</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 162Gly Gly Gly Gly Ser Ser Gly Ser Gly Ser Ser Ser Arg Ser Ser Gly1               5                   10                  15Gly</s400><s200><s210>163</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 163Gly Ser Gly Gly Gly1               5</s400><s200><s210>164</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 164Gly Gly Gly Gly Ser1               5</s400><s200><s210>165</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 165Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>166</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa is Gly or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(41)..(41)</s222><s223>Xaa is Gly or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(55)..(55)</s222><s223>Xaa is Pro or Arg</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(107)..(107)</s222><s223>Xaa is Gln or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(114)..(114)</s222><s223>Xaa is Ser or Cys</s223></s220></s200><s400> 166Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Xaa Lys Xaa Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Xaa Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Xaa Gly Thr Leu Val Thr            100                 105                 110Val Xaa Ser        115</s400><s200><s210>167</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(32)..(32)</s222><s223>Xaa is Ser or Trp</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(49)..(49)</s222><s223>Xaa is Ala or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(61)..(61)</s222><s223>Xaa is Glu or Gln</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(106)..(106)</s222><s223>Xaa is Gln or Cys</s223></s220></s200><s400> 167Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Xaa            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Xaa Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Xaa Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Xaa Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>168</s210><s211>115</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(39)..(39)</s222><s223>Xaa is Gly or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(41)..(41)</s222><s223>Xaa is Gly or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(107)..(107)</s222><s223>Xaa is Gln or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(114)..(114)</s222><s223>Xaa is Ser or Cys</s223></s220></s200><s400> 168Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn            20                  25                  30Trp Val Arg Gln Ala Pro Xaa Lys Xaa Leu Glu Trp Val Ala Trp Ile        35                  40                  45Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg    50                  55                  60Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met65                  70                  75                  80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu                85                  90                  95Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Xaa Gly Thr Leu Val Thr            100                 105                 110Val Xaa Ser        115</s400><s200><s210>169</s210><s211>113</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(49)..(49)</s222><s223>Xaa is Ala or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(106)..(106)</s222><s223>Xaa is Gln or Cys</s223></s220></s200><s400> 169Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Xaa Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Xaa Gly Thr Lys Val Glu Ile            100                 105                 110Lys</s400><s200><s210>170</s210><s211>121</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Gln or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Gly or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(44)..(44)</s222><s223>Xaa is Gly or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(113)..(113)</s222><s223>Xaa is Gln or Cys</s223></s220></s200><s400> 170Glu Val Xaa Leu Val Glu Ser Gly Xaa Gly Leu Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr            20                  25                  30Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Xaa Leu Glu Trp Val        35                  40                  45Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala Phe Asp Tyr Trp Gly            100                 105                 110Xaa Gly Thr Leu Val Thr Val Ser Ser        115                 120</s400><s200><s210>171</s210><s211>108</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(44)..(44)</s222><s223>Xaa is Ala or Cys</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(101)..(101)</s222><s223>Xaa is Gln or Cys</s223></s220></s200><s400> 171Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser            20                  25                  30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Xaa Pro Arg Leu Leu        35                  40                  45Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65                  70                  75                  80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro                85                  90                  95Trp Thr Phe Gly Xaa Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>172</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 172Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>173</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 173Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Cys Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Cys Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>174</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 174Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Cys Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Cys Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Cys Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Cys Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>175</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 175Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Cys Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Cys Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>176</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 176Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Cys Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Cys Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>177</s210><s211>724</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 177Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Cys Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Cys Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly                245                 250                 255Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu            260                 265                 270Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val        275                 280                 285Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro    290                 295                 300Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp305                 310                 315                 320Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser                325                 330                 335Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly            340                 345                 350Ser Leu Pro Trp Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Ser        355                 360                 365Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val    370                 375                 380Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr385                 390                 395                 400Phe Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Cys Leu Glu Trp                405                 410                 415Val Ala Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp            420                 425                 430Phe Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu        435                 440                 445Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr    450                 455                 460Cys Ala Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly465                 470                 475                 480Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser                485                 490                 495Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu            500                 505                 510Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu        515                 520                 525Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser    530                 535                 540His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu545                 550                 555                 560Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr                565                 570                 575Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn            580                 585                 590Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro        595                 600                 605Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln    610                 615                 620Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val625                 630                 635                 640Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val                645                 650                 655Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro            660                 665                 670Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr        675                 680                 685Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val    690                 695                 700Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu705                 710                 715                 720Ser Pro Gly Lys</s400><s200><s210>178</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 178Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Gln Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>179</s210><s211>723</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 179Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Ser Arg Ser Ser Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Gly Ser Gly Ser Ser Ser Ser Ser Arg Ser Ser Ser Gly Ser Gly Gly                245                 250                 255Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro            260                 265                 270Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser        275                 280                 285Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu    290                 295                 300Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu                325                 330                 335Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu            340                 345                 350Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly        355                 360                 365Arg Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln    370                 375                 380Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe385                 390                 395                 400Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val                405                 410                 415Ala Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe            420                 425                 430Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr        435                 440                 445Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys    450                 455                 460Ala Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr465                 470                 475                 480Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser                485                 490                 495Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly            500                 505                 510Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met        515                 520                 525Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His    530                 535                 540Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val545                 550                 555                 560His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr                565                 570                 575Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly            580                 585                 590Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile        595                 600                 605Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val    610                 615                 620Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser625                 630                 635                 640Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu                645                 650                 655Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro            660                 665                 670Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val        675                 680                 685Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met    690                 695                 700His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser705                 710                 715                 720Pro Gly Lys</s400><s200><s210>180</s210><s211>723</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 180Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Gln Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Ser Arg Ser Ser Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Gly Ser Gly Ser Ser Ser Ser Ser Arg Ser Ser Ser Gly Ser Gly Gly                245                 250                 255Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro            260                 265                 270Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser        275                 280                 285Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu    290                 295                 300Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu                325                 330                 335Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu            340                 345                 350Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly        355                 360                 365Arg Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln    370                 375                 380Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe385                 390                 395                 400Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val                405                 410                 415Ala Trp Ile Asn Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe            420                 425                 430Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr        435                 440                 445Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys    450                 455                 460Ala Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr465                 470                 475                 480Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser                485                 490                 495Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly            500                 505                 510Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met        515                 520                 525Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His    530                 535                 540Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val545                 550                 555                 560His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr                565                 570                 575Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly            580                 585                 590Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile        595                 600                 605Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val    610                 615                 620Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser625                 630                 635                 640Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu                645                 650                 655Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro            660                 665                 670Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val        675                 680                 685Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met    690                 695                 700His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser705                 710                 715                 720Pro Gly Lys</s400><s200><s210>181</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 181Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Ser Ser Gly Ser Ser Ser Arg Gly Gly Ser Gly Ser Ser Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>182</s210><s211>720</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 182Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser225                 230                 235                 240Ser Ser Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Glu                245                 250                 255Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu            260                 265                 270Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile    290                 295                 300Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro                325                 330                 335Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp            340                 345                 350Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Ser Gly Ser        355                 360                 365Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly    370                 375                 380Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn385                 390                 395                 400Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile                405                 410                 415Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg            420                 425                 430Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met        435                 440                 445Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu    450                 455                 460Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr465                 470                 475                 480Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr                485                 490                 495His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser            500                 505                 510Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg        515                 520                 525Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro    530                 535                 540Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala545                 550                 555                 560Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val                565                 570                 575Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr            580                 585                 590Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr        595                 600                 605Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu    610                 615                 620Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys625                 630                 635                 640Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser                645                 650                 655Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp            660                 665                 670Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser        675                 680                 685Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala    690                 695                 700Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715                 720</s400><s200><s210>183</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 183Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Ser Gly Ser Ser Gly Ser Ser Ser Gly Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>184</s210><s211>720</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 184Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Gly Ser Gly Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Gly Ser Ser Ser Gly Gly Gly Ser Gly Gly Ser Ser Ser Ser Ser Ser                245                 250                 255Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly            260                 265                 270Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser        275                 280                 285Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu    290                 295                 300Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser305                 310                 315                 320Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu                325                 330                 335Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro            340                 345                 350Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Ser        355                 360                 365Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly    370                 375                 380Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn385                 390                 395                 400Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile                405                 410                 415Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg            420                 425                 430Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met        435                 440                 445Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu    450                 455                 460Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr465                 470                 475                 480Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr                485                 490                 495His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser            500                 505                 510Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg        515                 520                 525Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro    530                 535                 540Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala545                 550                 555                 560Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val                565                 570                 575Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr            580                 585                 590Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr        595                 600                 605Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu    610                 615                 620Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys625                 630                 635                 640Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser                645                 650                 655Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp            660                 665                 670Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser        675                 680                 685Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala    690                 695                 700Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715                 720</s400><s200><s210>185</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 185Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu        115                 120                 125Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe    130                 135                 140Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys145                 150                 155                 160Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr                165                 170                 175Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala            180                 185                 190Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr        195                 200                 205Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala    210                 215                 220Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ser225                 230                 235                 240Gly Ser Gly Gly Gly Ser Ser Ser Gly Ser Ser Gly Gly Glu Ile Val                245                 250                 255Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala            260                 265                 270Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala        275                 280                 285Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp    290                 295                 300Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly305                 310                 315                 320Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp                325                 330                 335Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr Phe            340                 345                 350Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Arg Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>186</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 186Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu        115                 120                 125Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe    130                 135                 140Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys145                 150                 155                 160Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr                165                 170                 175Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala            180                 185                 190Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr        195                 200                 205Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala    210                 215                 220Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Gly225                 230                 235                 240Gly Arg Ser Gly Ser Gly Ser Gly Ser Asn Gly Gly Gly Glu Ile Val                245                 250                 255Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala            260                 265                 270Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu Ala        275                 280                 285Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp    290                 295                 300Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly305                 310                 315                 320Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp                325                 330                 335Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr Phe            340                 345                 350Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>187</s210><s211>718</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 187Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu        115                 120                 125Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe    130                 135                 140Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys145                 150                 155                 160Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr                165                 170                 175Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala            180                 185                 190Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr        195                 200                 205Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala    210                 215                 220Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser225                 230                 235                 240Ser Gly Arg Gly Ser Ser Gly Gly Ser Gly Gly Ser Ser Gly Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Glu Val        355                 360                 365Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu    370                 375                 380Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp Val385                 390                 395                 400Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn Met                405                 410                 415Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Thr            420                 425                 430Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser        435                 440                 445Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr Asn    450                 455                 460Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser465                 470                 475                 480Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr                485                 490                 495Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe            500                 505                 510Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro        515                 520                 525Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val    530                 535                 540Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr545                 550                 555                 560Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val                565                 570                 575Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys            580                 585                 590Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser        595                 600                 605Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro    610                 615                 620Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val625                 630                 635                 640Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly                645                 650                 655Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp            660                 665                 670Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp        675                 680                 685Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His    690                 695                 700Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>188</s210><s211>720</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 188Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Ser Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Gly Ser Gly Gly        355                 360                 365Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly    370                 375                 380Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn385                 390                 395                 400Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile                405                 410                 415Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg            420                 425                 430Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met        435                 440                 445Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu    450                 455                 460Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr465                 470                 475                 480Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr                485                 490                 495His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser            500                 505                 510Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg        515                 520                 525Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro    530                 535                 540Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala545                 550                 555                 560Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val                565                 570                 575Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr            580                 585                 590Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr        595                 600                 605Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu    610                 615                 620Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys625                 630                 635                 640Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser                645                 650                 655Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp            660                 665                 670Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser        675                 680                 685Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala    690                 695                 700Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715                 720</s400><s200><s210>189</s210><s211>721</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 189Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Ser Arg Ser Ser Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Ser Gly Ser Ser Gly Ser Ser Ser Ser Ser Gly Ser Gly Ser Gly Glu                245                 250                 255Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu            260                 265                 270Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile    290                 295                 300Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro                325                 330                 335Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp            340                 345                 350Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Ser Gly Ser Gly        355                 360                 365Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly    370                 375                 380Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met385                 390                 395                 400Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp                405                 410                 415Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly            420                 425                 430Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln        435                 440                 445Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg    450                 455                 460Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val465                 470                 475                 480Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys                485                 490                 495Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro            500                 505                 510Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser        515                 520                 525Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp    530                 535                 540Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn545                 550                 555                 560Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val                565                 570                 575Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu            580                 585                 590Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys        595                 600                 605Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr    610                 615                 620Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr625                 630                 635                 640Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu                645                 650                 655Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu            660                 665                 670Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys        675                 680                 685Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu    690                 695                 700Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly705                 710                 715                 720Lys</s400><s200><s210>190</s210><s211>721</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 190Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Ser Arg Ser Ser Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Ser Gly Ser Ser Gly Ser Ser Ser Ser Ser Gly Ser Gly Ser Gly Glu                245                 250                 255Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu            260                 265                 270Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile    290                 295                 300Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro                325                 330                 335Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp            340                 345                 350Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Ser Gly Ser Gly        355                 360                 365Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly    370                 375                 380Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met385                 390                 395                 400Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp                405                 410                 415Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly            420                 425                 430Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln        435                 440                 445Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg    450                 455                 460Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val465                 470                 475                 480Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys                485                 490                 495Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro            500                 505                 510Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser        515                 520                 525Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp    530                 535                 540Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn545                 550                 555                 560Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val                565                 570                 575Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu            580                 585                 590Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys        595                 600                 605Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr    610                 615                 620Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr625                 630                 635                 640Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu                645                 650                 655Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu            660                 665                 670Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys        675                 680                 685Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu    690                 695                 700Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly705                 710                 715                 720Lys</s400><s200><s210>191</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 191Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu        115                 120                 125Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe    130                 135                 140Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys145                 150                 155                 160Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr                165                 170                 175Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala            180                 185                 190Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr        195                 200                 205Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala    210                 215                 220Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ser225                 230                 235                 240Gly Gly Ser Ser Gly Ser Ser Gly Ser Gly Ser Ser Gly Gly Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Ser Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>192</s210><s211>720</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 192Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu        115                 120                 125Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe    130                 135                 140Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys145                 150                 155                 160Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr                165                 170                 175Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala            180                 185                 190Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr        195                 200                 205Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala    210                 215                 220Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ser225                 230                 235                 240Ser Ser Ser Gly Gly Gly Gly Ser Gly Gly Ser Ser Ser Gly Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Ser Ser Gly Gly Gly        355                 360                 365Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly    370                 375                 380Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn385                 390                 395                 400Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile                405                 410                 415Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg            420                 425                 430Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met        435                 440                 445Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu    450                 455                 460Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr465                 470                 475                 480Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr                485                 490                 495His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser            500                 505                 510Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg        515                 520                 525Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro    530                 535                 540Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala545                 550                 555                 560Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val                565                 570                 575Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr            580                 585                 590Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr        595                 600                 605Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu    610                 615                 620Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys625                 630                 635                 640Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser                645                 650                 655Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp            660                 665                 670Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser        675                 680                 685Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala    690                 695                 700Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715                 720</s400><s200><s210>193</s210><s211>722</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 193Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Ser Gly Ser Ser Ser Ser Ser Arg Ser Ser Ser Gly Ser Gly Gly Gly                245                 250                 255Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly            260                 265                 270Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser        275                 280                 285Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu    290                 295                 300Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser305                 310                 315                 320Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu                325                 330                 335Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro            340                 345                 350Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Ser        355                 360                 365Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro    370                 375                 380Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser385                 390                 395                 400Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala                405                 410                 415Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys            420                 425                 430Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu        435                 440                 445Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    450                 455                 460Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu465                 470                 475                 480Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp                485                 490                 495Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly            500                 505                 510Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile        515                 520                 525Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu    530                 535                 540Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His545                 550                 555                 560Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg                565                 570                 575Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys            580                 585                 590Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu        595                 600                 605Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr    610                 615                 620Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu625                 630                 635                 640Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp                645                 650                 655Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val            660                 665                 670Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp        675                 680                 685Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His    690                 695                 700Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro705                 710                 715                 720Gly Lys</s400><s200><s210>194</s210><s211>721</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 194Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Ser Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu        115                 120                 125Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe    130                 135                 140Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys145                 150                 155                 160Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr                165                 170                 175Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala            180                 185                 190Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr        195                 200                 205Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu Ala    210                 215                 220Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser Ser225                 230                 235                 240Gly Ser Ser Ser Gly Ser Arg Ser Gly Ser Ser Ser Gly Gly Ser Glu                245                 250                 255Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu            260                 265                 270Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr        275                 280                 285Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile    290                 295                 300Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly305                 310                 315                 320Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro                325                 330                 335Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp            340                 345                 350Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly        355                 360                 365Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly    370                 375                 380Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met385                 390                 395                 400Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp                405                 410                 415Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly            420                 425                 430Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln        435                 440                 445Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg    450                 455                 460Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val465                 470                 475                 480Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys                485                 490                 495Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro            500                 505                 510Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser        515                 520                 525Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp    530                 535                 540Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn545                 550                 555                 560Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val                565                 570                 575Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu            580                 585                 590Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys        595                 600                 605Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr    610                 615                 620Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr625                 630                 635                 640Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu                645                 650                 655Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu            660                 665                 670Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys        675                 680                 685Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu    690                 695                 700Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly705                 710                 715                 720Lys</s400><s200><s210>195</s210><s211>720</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 195Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Gly Gly Ser Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Ser Ser Ser Gly Gly Ser Ser Gly Ser Gly Gly Gly Gly Gly Gly Gly                245                 250                 255Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly            260                 265                 270Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser        275                 280                 285Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu    290                 295                 300Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser305                 310                 315                 320Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu                325                 330                 335Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro            340                 345                 350Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Ser        355                 360                 365Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly    370                 375                 380Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn385                 390                 395                 400Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile                405                 410                 415Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg            420                 425                 430Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met        435                 440                 445Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu    450                 455                 460Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr465                 470                 475                 480Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr                485                 490                 495His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser            500                 505                 510Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg        515                 520                 525Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro    530                 535                 540Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala545                 550                 555                 560Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val                565                 570                 575Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr            580                 585                 590Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr        595                 600                 605Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu    610                 615                 620Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys625                 630                 635                 640Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser                645                 650                 655Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp            660                 665                 670Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser        675                 680                 685Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala    690                 695                 700Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715                 720</s400><s200><s210>196</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 196Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Ser Ser Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ser225                 230                 235                 240Gly Gly Gly Ser Ser Gly Ser Gly Gly Gly Arg Ser Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>197</s210><s211>723</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 197Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Gly Ser Gly Gly Gly Gly Ser Ser Gly Ser Ser Gly Ser Gly Gly Ser                245                 250                 255Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro            260                 265                 270Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser        275                 280                 285Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu    290                 295                 300Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu                325                 330                 335Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu            340                 345                 350Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Ser Ser        355                 360                 365Gly Ser Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln    370                 375                 380Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe385                 390                 395                 400Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val                405                 410                 415Ala Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe            420                 425                 430Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr        435                 440                 445Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys    450                 455                 460Ala Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr465                 470                 475                 480Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser                485                 490                 495Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly            500                 505                 510Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met        515                 520                 525Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His    530                 535                 540Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val545                 550                 555                 560His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr                565                 570                 575Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly            580                 585                 590Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile        595                 600                 605Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val    610                 615                 620Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser625                 630                 635                 640Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu                645                 650                 655Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro            660                 665                 670Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val        675                 680                 685Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met    690                 695                 700His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser705                 710                 715                 720Pro Gly Lys</s400><s200><s210>198</s210><s211>722</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 198Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Gly Ser Gly Ser Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly        115                 120                 125Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser    130                 135                 140Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro145                 150                 155                 160Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu                165                 170                 175Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp            180                 185                 190Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu        195                 200                 205Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu    210                 215                 220Leu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser225                 230                 235                 240Gly Gly Gly Gly Ser Ser Gly Ser Gly Ser Ser Ser Arg Ser Ser Gly                245                 250                 255Gly Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro            260                 265                 270Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser        275                 280                 285Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu    290                 295                 300Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe305                 310                 315                 320Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu                325                 330                 335Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu            340                 345                 350Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Gly        355                 360                 365Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro    370                 375                 380Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser385                 390                 395                 400Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala                405                 410                 415Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys            420                 425                 430Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu        435                 440                 445Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala    450                 455                 460Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu465                 470                 475                 480Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp                485                 490                 495Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly            500                 505                 510Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile        515                 520                 525Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu    530                 535                 540Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His545                 550                 555                 560Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg                565                 570                 575Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys            580                 585                 590Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu        595                 600                 605Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr    610                 615                 620Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu625                 630                 635                 640Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp                645                 650                 655Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val            660                 665                 670Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp        675                 680                 685Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His    690                 695                 700Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro705                 710                 715                 720Gly Lys</s400><s200><s210>199</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 199Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Trp Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Val Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Lys Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>200</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 200Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Ile Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Arg Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Arg Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>201</s210><s211>719</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 201Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Trp            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Phe Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Ser Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile                245                 250                 255Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg            260                 265                 270Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser Tyr Leu        275                 280                 285Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr    290                 295                 300Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser305                 310                 315                 320Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu                325                 330                 335Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro Trp Thr            340                 345                 350Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu        355                 360                 365Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser    370                 375                 380Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp385                 390                 395                 400Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn                405                 410                 415Met Tyr Thr Gly Glu Pro Ile Tyr Ala Asp Asp Phe Lys Gly Arg Phe            420                 425                 430Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn        435                 440                 445Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr    450                 455                 460Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val465                 470                 475                 480Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His                485                 490                 495Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            500                 505                 510Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        515                 520                 525Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    530                 535                 540Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys545                 550                 555                 560Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                565                 570                 575Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            580                 585                 590Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        595                 600                 605Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    610                 615                 620Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu625                 630                 635                 640Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                645                 650                 655Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            660                 665                 670Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        675                 680                 685Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    690                 695                 700His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys705                 710                 715</s400><s200><s210>202</s210><s211>476</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 202Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro                245                 250                 255Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe            260                 265                 270Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val        275                 280                 285Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe    290                 295                 300Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro305                 310                 315                 320Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr                325                 330                 335Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val            340                 345                 350Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala        355                 360                 365Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg    370                 375                 380Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly385                 390                 395                 400Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro                405                 410                 415Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser            420                 425                 430Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln        435                 440                 445Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His    450                 455                 460Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400><s200><s210>203</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 203Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser            20                  25                  30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu        35                  40                  45Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65                  70                  75                  80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ser Gly Gly            100                 105                 110Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro        115                 120                 125Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser    130                 135                 140Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala145                 150                 155                 160Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys                165                 170                 175Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu            180                 185                 190Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala        195                 200                 205Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu    210                 215                 220Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp225                 230                 235                 240Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly                245                 250                 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile            260                 265                 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu        275                 280                 285Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His    290                 295                 300Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg305                 310                 315                 320Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys                325                 330                 335Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu            340                 345                 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys        355                 360                 365Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu    370                 375                 380Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp385                 390                 395                 400Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val                405                 410                 415Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp            420                 425                 430Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His        435                 440                 445Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Pro    450                 455                 460Gly Lys465</s400><s200><s210>204</s210><s211>476</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 204Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Asp Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Asp Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro                245                 250                 255Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe            260                 265                 270Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val        275                 280                 285Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe    290                 295                 300Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro305                 310                 315                 320Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr                325                 330                 335Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val            340                 345                 350Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala        355                 360                 365Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg    370                 375                 380Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly385                 390                 395                 400Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro                405                 410                 415Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser            420                 425                 430Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln        435                 440                 445Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His    450                 455                 460Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400><s200><s210>205</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 205Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser            20                  25                  30Tyr Leu Ala Trp Tyr Gln Arg Lys Pro Gly Gln Ala Pro Arg Leu Leu        35                  40                  45Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65                  70                  75                  80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ser Gly Gly            100                 105                 110Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro        115                 120                 125Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser    130                 135                 140Met Asn Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val Ala145                 150                 155                 160Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys                165                 170                 175Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu            180                 185                 190Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala        195                 200                 205Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu    210                 215                 220Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp225                 230                 235                 240Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly                245                 250                 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile            260                 265                 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu        275                 280                 285Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His    290                 295                 300Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg305                 310                 315                 320Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys                325                 330                 335Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu            340                 345                 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys        355                 360                 365Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu    370                 375                 380Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp385                 390                 395                 400Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val                405                 410                 415Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp            420                 425                 430Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His        435                 440                 445Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Pro    450                 455                 460Gly Lys465</s400><s200><s210>206</s210><s211>476</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 206Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Asp Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly        115                 120                 125Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly    130                 135                 140Phe Thr Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Asp Ala Pro Gly145                 150                 155                 160Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys                165                 170                 175Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn            180                 185                 190Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp        195                 200                 205Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Trp Phe Gly Glu Leu    210                 215                 220Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly225                 230                 235                 240Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro                245                 250                 255Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe            260                 265                 270Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val        275                 280                 285Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe    290                 295                 300Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro305                 310                 315                 320Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr                325                 330                 335Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val            340                 345                 350Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala        355                 360                 365Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg    370                 375                 380Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly385                 390                 395                 400Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro                405                 410                 415Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser            420                 425                 430Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln        435                 440                 445Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His    450                 455                 460Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400><s200><s210>207</s210><s211>466</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 207Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser            20                  25                  30Tyr Leu Ala Trp Tyr Gln Lys Lys Pro Gly Gln Ala Pro Arg Leu Leu        35                  40                  45Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser    50                  55                  60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65                  70                  75                  80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Leu Pro                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Ser Gly Gly            100                 105                 110Gly Gly Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro        115                 120                 125Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser    130                 135                 140Met Asn Trp Val Arg Lys Ala Pro Gly Lys Gly Leu Glu Trp Val Ala145                 150                 155                 160Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys                165                 170                 175Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu            180                 185                 190Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala        195                 200                 205Arg Leu Tyr Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu    210                 215                 220Val Thr Val Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp225                 230                 235                 240Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly                245                 250                 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile            260                 265                 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu        275                 280                 285Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His    290                 295                 300Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg305                 310                 315                 320Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys                325                 330                 335Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu            340                 345                 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys        355                 360                 365Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu    370                 375                 380Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp385                 390                 395                 400Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val                405                 410                 415Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp            420                 425                 430Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His        435                 440                 445Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Pro    450                 455                 460Gly Lys465</s400><s200><s210>208</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 208Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>209</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 209Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>210</s210><s211>42</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 210Asp Gln Trp Ser Thr Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val1               5                   10                  15Phe Asn Tyr Gln Gly Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly            20                  25                  30Phe Thr Glu Cys Arg Gly Tyr Phe Thr Leu        35                  40</s400><s200><s210>211</s210><s211>261</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 211Met Ala Val Thr Ala Cys Gln Gly Leu Gly Phe Val Val Ser Leu Ile1               5                   10                  15Gly Ile Ala Gly Ile Ile Ala Ala Thr Cys Met Asp Gln Trp Ser Thr            20                  25                  30Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe Asn Tyr Gln Gly        35                  40                  45Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly Phe Thr Glu Cys Arg    50                  55                  60Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg65                  70                  75                  80Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly Leu Leu Val                85                  90                  95Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Glu Asp Ser            100                 105                 110Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe Ile Val Ser        115                 120                 125Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn Met Leu Val    130                 135                 140Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly Met Gly Gly145                 150                 155                 160Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala Ala Leu Phe                165                 170                 175Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly Val Met Met            180                 185                 190Cys Ile Ala Cys Arg Gly Leu Ala Pro Glu Glu Thr Asn Tyr Lys Ala        195                 200                 205Val Ser Tyr His Ala Ser Gly His Ser Val Ala Tyr Lys Pro Gly Gly    210                 215                 220Phe Lys Ala Ser Thr Gly Phe Gly Ser Asn Thr Lys Asn Lys Lys Ile225                 230                 235                 240Tyr Asp Gly Gly Ala Arg Thr Glu Asp Glu Val Gln Ser Tyr Pro Ser                245                 250                 255Lys His Asp Tyr Val            260</s400><s200><s210>212</s210><s211>200</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 212Met Ala Val Thr Ala Cys Gln Gly Leu Gly Phe Val Val Ser Leu Ile1               5                   10                  15Gly Ile Ala Gly Ile Ile Ala Ala Thr Cys Met Asp Gln Trp Ser Thr            20                  25                  30Gln Asp Leu Tyr Asn Asn Pro Val Thr Ala Val Phe Asn Tyr Gln Gly        35                  40                  45Leu Trp Arg Ser Cys Val Arg Glu Ser Ser Gly Phe Thr Glu Cys Arg    50                  55                  60Gly Tyr Phe Thr Leu Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg65                  70                  75                  80Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly Leu Leu Val                85                  90                  95Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Glu Asp Ser            100                 105                 110Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe Ile Val Ser        115                 120                 125Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn Met Leu Val    130                 135                 140Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly Met Gly Gly145                 150                 155                 160Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala Ala Leu Phe                165                 170                 175Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly Val Met Met            180                 185                 190Cys Ile Ala Cys Arg Gly Leu Ala        195                 200</s400><s200><s210>213</s210><s211>42</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 213Asp Met Trp Ser Thr Gln Asp Leu Tyr Asp Asn Pro Val Thr Ser Val1               5                   10                  15Phe Gln Tyr Glu Gly Leu Trp Arg Ser Cys Val Arg Gln Ser Ser Gly            20                  25                  30Phe Thr Glu Cys Arg Pro Tyr Phe Thr Ile        35                  40</s400><s200><s210>214</s210><s211>261</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 214Met Ser Thr Thr Thr Cys Gln Val Val Ala Phe Leu Leu Ser Ile Leu1               5                   10                  15Gly Leu Ala Gly Cys Ile Ala Ala Thr Gly Met Asp Met Trp Ser Thr            20                  25                  30Gln Asp Leu Tyr Asp Asn Pro Val Thr Ser Val Phe Gln Tyr Glu Gly        35                  40                  45Leu Trp Arg Ser Cys Val Arg Gln Ser Ser Gly Phe Thr Glu Cys Arg    50                  55                  60Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg65                  70                  75                  80Ala Leu Met Ile Val Gly Ile Val Leu Gly Ala Ile Gly Leu Leu Val                85                  90                  95Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Glu Asp Ser            100                 105                 110Ala Lys Ala Asn Met Thr Leu Thr Ser Gly Ile Met Phe Ile Val Ser        115                 120                 125Gly Leu Cys Ala Ile Ala Gly Val Ser Val Phe Ala Asn Met Leu Val    130                 135                 140Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Thr Gly Met Gly Gly145                 150                 155                 160Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala Ala Leu Phe                165                 170                 175Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly Val Met Met            180                 185                 190Cys Ile Ala Cys Arg Gly Leu Ala Pro Glu Glu Thr Asn Tyr Lys Ala        195                 200                 205Val Ser Tyr His Ala Ser Gly His Ser Val Ala Tyr Lys Pro Gly Gly    210                 215                 220Phe Lys Ala Ser Thr Gly Phe Gly Ser Asn Thr Lys Asn Lys Lys Ile225                 230                 235                 240Tyr Asp Gly Gly Ala Arg Thr Glu Asp Glu Val Gln Ser Tyr Pro Ser                245                 250                 255Lys His Asp Tyr Val            260</s400><s200><s210>215</s210><s211>223</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 215Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala1               5                   10                  15Thr Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro            20                  25                  30Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala        35                  40                  45Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly    50                  55                  60Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln65                  70                  75                  80Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu Thr                85                  90                  95Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val            100                 105                 110Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile        115                 120                 125Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly    130                 135                 140Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser145                 150                 155                 160Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe                165                 170                 175Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys            180                 185                 190Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu        195                 200                 205Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn    210                 215                 220</s400><s200><s210>216</s210><s211>288</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 216Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln1               5                   10                  15Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp            20                  25                  30Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp        35                  40                  45Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val    50                  55                  60Ile Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala65                  70                  75                  80Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg                85                  90                  95Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg            100                 105                 110Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu        115                 120                 125Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val    130                 135                 140Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro145                 150                 155                 160Arg Pro Ala Gly Gln Phe Gln Thr Ile Val Val Gly Val Val Gly Gly                165                 170                 175Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu Ala Val Ile Cys            180                 185                 190Ser Arg Ala Ala Arg Gly Thr Ile Gly Ala Arg Arg Thr Gly Gln Pro        195                 200                 205Leu Lys Glu Asp Pro Ser Ala Val Pro Val Phe Ser Val Asp Tyr Gly    210                 215                 220Glu Leu Asp Phe Gln Trp Arg Glu Lys Thr Pro Glu Pro Pro Val Pro225                 230                 235                 240Cys Val Pro Glu Gln Thr Glu Tyr Ala Thr Ile Val Phe Pro Ser Gly                245                 250                 255Met Gly Thr Ser Ser Pro Ala Arg Arg Gly Ser Ala Asp Gly Pro Arg            260                 265                 270Ser Ala Gly Pro Leu Arg Pro Glu Asp Gly His Cys Ser Trp Pro Leu        275                 280                 285</s400><s200><s210>217</s210><s211>177</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 217Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu1               5                   10                  15Asn Ala Pro Tyr Asn Lys Ile Asn Gly Arg Ile Leu Val Val Asp Pro            20                  25                  30Val Thr Ser Glu His Glu Leu Thr Cys Gln Leu Ala Glu Gly Tyr Pro        35                  40                  45Lys Ala Glu Val Ile Trp Thr Ser Ser Asp His Gln Val Leu Ser Gly    50                  55                  60Lys Thr Thr Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn Val65                  70                  75                  80Thr Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr Cys                85                  90                  95Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu Val            100                 105                 110Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr His Leu        115                 120                 125Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly Val Ala Leu Thr Phe    130                 135                 140Ile Phe Arg Leu Arg Lys Gly Arg Met Met Asp Val Lys Lys Cys Gly145                 150                 155                 160Ile Gln Asp Thr Asn Ser Lys Lys Gly Ser Asp Thr His Leu Glu Glu                165                 170                 175Thr</s400><s200><s210>218</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 218Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly1               5                   10                  15Val His Ser</s400><s200><s210>219</s210><s211>87</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 219agggtcacca tcacctgcaa aagcagtcag agtctgctca acagtggcaa ccagaaaagc     60tatctgacct ggtatcaaca gaaacca                                         87</s400><s200><s210>220</s210><s211>60</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 220gctccgaagc ttctgattta ttgggcatct accctcgaaa gcggagtccc ttctcgcttc     60</s400><s200><s210>221</s210><s211>57</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 221gcaacttatt actgtcagaa cgcgtattct tttccgttta cgttcggaca gggtacc        57</s400><s200><s210>222</s210><s211>63</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 222tcctgtgcag cttctggcta cacctttacc aactatggta tgaactgggt gcgtcaggcc     60ccg                                                                   63</s400><s200><s210>223</s210><s211>87</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 223ggcctggaat gggttgcatg gattaacatg tataccggcg aaccgaccta tgccgatgac     60ttcaagggcc gtttcactat aagccgt                                         87</s400><s200><s210>224</s210><s211>57</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 224gtctattatt gtgctcgcct gtataacggc aactctctgg actactgggg tcaagga        57</s400><s200><s210>225</s210><s211>42</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 225gcctatgcat ccgatatcca gmtgacccag tccccgagct cc                        42</s400><s200><s210>226</s210><s211>78</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 226ggtagcggtt ccgggacgga ttwcactctg accatcagca gtctgcagcc ggaagacytc     60gcaacttatt actgtcag                                                   78</s400><s200><s210>227</s210><s211>78</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 227ctccgtttgt cctgtgcary ctctggctac acctttacca actatggtat gaactggrtc     60cgtcaggccc cgggtaag                                                   78</s400><s200><s210>228</s210><s211>72</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(19)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 228gatgacttca agggccgtny cactwtcagc ckcgacrmct ccrmgarcac asygtaccta     60caaatgaaca gc                                                         72</s400><s200><s210>229</s210><s211>45</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 229gacactgccg tctattattg tdygargctg tataacggca actct                     45</s400><s200><s210>230</s210><s211>21</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 230taaggccaag acggcctata a                                               21</s400><s200><s210>231</s210><s211>57</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(36)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 231gtctattatt gtgctcgcnn nnnnnnnnnn nnnnnnwtkg actactgggg tcaagga        57</s400><s200><s210>232</s210><s211>60</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(39)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 232gtctattatt gtgctcgcnn nnnnnnnnnn nnnnnnnnnw tkgactactg gggtcaagga     60</s400><s200><s210>233</s210><s211>63</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(42)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 233gtctattatt gtgctcgcnn nnnnnnnnnn nnnnnnnnnn nnwtkgacta ctggggtcaa     60gga                                                                   63</s400><s200><s210>234</s210><s211>66</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(45)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 234gtctattatt gtgctcgcnn nnnnnnnnnn nnnnnnnnnn nnnnnwtkga ctactggggt     60caagga                                                                66</s400><s200><s210>235</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 235gtctattatt gtgctcgcnn stataacggc aactctctg                            39</s400><s200><s210>236</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 236ctattattgt gctcgcctgn nsaacggcaa ctctctggac                           40</s400><s200><s210>237</s210><s211>43</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(23)..(24)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 237ctattattgt gctcgcctgt atnnsggcaa ctctctggac tac                       43</s400><s200><s210>238</s210><s211>46</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(26)..(27)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 238ctattattgt gctcgcctgt ataacnnsaa ctctctggac tactgg                    46</s400><s200><s210>239</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 239gctcgcctgt ataacggcnn stctctggac tactggggt                            39</s400><s200><s210>240</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 240cgcctgtata acggcaacnn sctggactac tggggtcaa                            39</s400><s200><s210>241</s210><s211>42</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(22)..(23)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 241gcaacttatt actgtcagaa cnnstattct tttccgttta cg                        42</s400><s200><s210>242</s210><s211>41</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(21)..(22)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 242cttattactg tcagaacgcg nnstcttttc cgtttacgtt c                         41</s400><s200><s210>243</s210><s211>44</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(24)..(25)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 243cttattactg tcagaacgcg tatnnstttc cgtttacgtt cgga                      44</s400><s200><s210>244</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 244ctgtcagaac gcgtattctn nsccgtttac gttcggacag                           40</s400><s200><s210>245</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 245cacctgcaaa agcagtcagn nsctgctcaa cagtggcaac                           40</s400><s200><s210>246</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 246ctgcaaaagc agtcagagtn nsctcaacag tggcaaccag                           40</s400><s200><s210>247</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 247caaaagcagt cagagtctgn nsaacagtgg caaccagaaa                           40</s400><s200><s210>248</s210><s211>43</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(23)..(24)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 248caaaagcagt cagagtctgc tcnnsagtgg caaccagaaa agc                       43</s400><s200><s210>249</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 249cagtcagagt ctgctcaacn nsggcaacca gaaaagctat                           40</s400><s200><s210>250</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 250cagagtctgc tcaacagtnn saaccagaaa agctatctg                            39</s400><s200><s210>251</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 251gagtctgctc aacagtggcn nscagaaaag ctatctgacc                           40</s400><s200><s210>252</s210><s211>41</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(21)..(22)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 252gtctgctcaa cagtggcaac nnsaaaagct atctgacctg g                         41</s400><s200><s210>253</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 253ctcaacagtg gcaaccagnn sagctatctg acctggtat                            39</s400><s200><s210>254</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 254caacagtggc aaccagaaan nstatctgac ctggtatcaa                           40</s400><s200><s210>255</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 255cagtggcaac cagaaaagcn nsctgacctg gtatcaacag                           40</s400><s200><s210>256</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 256ggcaaccaga aaagctatnn sacctggtat caacagaaa                            39</s400><s200><s210>257</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 257ccgaagcttc tgatttatnn sgcatctacc ctcgaaagc                            39</s400><s200><s210>258</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 258ctgatttatt gggcatctnn sctcgaaagc ggagtccct                            39</s400><s200><s210>259</s210><s211>43</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(23)..(24)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 259gatttattgg gcatctaccc tcnnsagcgg agtcccttct cgc                       43</s400><s200><s210>260</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 260ggcctggaat gggttgcann sattaacatg tataccggc                            39</s400><s200><s210>261</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 261gaatgggttg catggattnn satgtatacc ggcgaaccg                            39</s400><s200><s210>262</s210><s211>42</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(22)..(23)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 262gaatgggttg catggattaa cnnstatacc ggcgaaccga cc                        42</s400><s200><s210>263</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 263gttgcatgga ttaacatgnn saccggcgaa ccgacctat                            39</s400><s200><s210>264</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(19)..(20)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 264gcatggatta acatgtatnn sggcgaaccg acctatgcc                            39</s400><s200><s210>265</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 265gattaacatg tataccggcn nsccgaccta tgccgatgac                           40</s400><s200><s210>266</s210><s211>43</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(23)..(24)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 266gattaacatg tataccggcg aannsaccta tgccgatgac ttc                       43</s400><s200><s210>267</s210><s211>40</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(20)..(21)</s222><s223>n is a, c, g, or t</s223></s220></s200><s400> 267catgtatacc ggcgaaccgn nstatgccga tgacttcaag                           40</s400><s200><s210>268</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 268Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly Cys1               5                   10</s400><s200><s210>269</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 269Arg Gly Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly Cys1               5                   10                  15</s400><s200><s210>270</s210><s211>18</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 270Arg Gly Cys Arg Gly Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg1               5                   10                  15Gly Cys</s400><s200><s210>271</s210><s211>45</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 271Arg Gly Cys Arg Gly Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg1               5                   10                  15Gly Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly Cys Arg Gly            20                  25                  30Cys Val Gly Cys Arg Gly Cys Arg Gly Cys Arg Gly Cys        35                  40                  45</s400><s200><s210>272</s210><s211>48</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 272Arg Gly Cys Arg Gly Cys Arg Gly Cys Arg Gly Cys Val Gly Cys Arg1               5                   10                  15Gly Cys Arg Gly Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly            20                  25                  30Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly Cys Arg Gly Cys        35                  40                  45</s400><s200><s210>273</s210><s211>51</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 273Arg Gly Cys Arg Gly Cys Arg Gly Cys Arg Gly Cys Val Gly Cys Arg1               5                   10                  15Gly Cys Arg Gly Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly            20                  25                  30Cys Arg Gly Cys Val Gly Cys Arg Gly Cys Arg Gly Cys Arg Gly Cys        35                  40                  45Arg Gly Cys    50</s400><s200><s210>274</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Ser, Thr, Tyr, Phe, or Trp</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(12)..(12)</s222><s223>Xaa is Gln, Asn, Trp, Phe, Tyr, Ile, Met, or      Val</s223></s220></s200><s400> 274Lys Ser Ser Gln Ser Leu Leu Asn Xaa Gly Asn Xaa Lys Ser Tyr Leu1               5                   10                  15Thr</s400><s200><s210>275</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>misc_feature</s221><s222>(6)..(6)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220></s200><s400> 275Trp Ala Ser Thr Leu Xaa Ser1               5</s400><s200><s210>276</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Ser, Thr, Phe, Tyr, or Trp</s223></s220></s200><s400> 276Gln Asn Ala Tyr Xaa Phe Pro Phe Thr1               5</s400><s200><s210>277</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(8)..(8)</s222><s223>Xaa is Glu, Asp, Lys, His, or Arg</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(9)..(9)</s222><s223>Xaa is Pro, Lys, Arg, His, Thr, or Ser</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is Ser, Thr, Val, Ile, or Leu</s223></s220></s200><s400> 277Trp Ile Asn Met Tyr Thr Gly Xaa Xaa Xaa Tyr Ala Asp Asp Phe Lys1               5                   10                  15Gly</s400><s200><s210>278</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is Asn, Gln, Lys, Arg, or His</s223></s220></s200><s400> 278Leu Tyr Xaa Gly Asn Ser Leu Asp Tyr1               5</s400><s200><s210>279</s210><s211>478</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 279Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu        115                 120                 125Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Thr Ser Gly    130                 135                 140Asp Thr Phe Ser Thr Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala                165                 170                 175His Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu            180                 185                 190Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp        195                 200                 205Thr Ala Val Tyr Phe Cys Ala Arg Lys Phe His Phe Val Ser Gly Ser    210                 215                 220Pro Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser225                 230                 235                 240Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr                245                 250                 255Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe            260                 265                 270Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro        275                 280                 285Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val    290                 295                 300Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr305                 310                 315                 320Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val                325                 330                 335Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys            340                 345                 350Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser        355                 360                 365Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro    370                 375                 380Cys Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val385                 390                 395                 400Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly                405                 410                 415Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp            420                 425                 430Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp        435                 440                 445Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His    450                 455                 460Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400><s200><s210>280</s210><s211>463</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 280Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu            100                 105                 110Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser        115                 120                 125Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp    130                 135                 140Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn145                 150                 155                 160Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe                165                 170                 175Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn            180                 185                 190Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr        195                 200                 205Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val    210                 215                 220Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His225                 230                 235                 240Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val                245                 250                 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr            260                 265                 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu        275                 280                 285Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys    290                 295                 300Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser305                 310                 315                 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys                325                 330                 335Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile            340                 345                 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro        355                 360                 365Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Ser Cys Ala    370                 375                 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385                 390                 395                 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser                405                 410                 415Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg            420                 425                 430Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu        435                 440                 445His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455                 460</s400><s200><s210>281</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 281Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>282</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 282Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala1               5                   10</s400><s200><s210>283</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 283Asp Ala Ser Asn Arg Ala Thr1               5</s400><s200><s210>284</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 284Gln Gln Arg Ser Asn Trp Pro Thr1               5</s400><s200><s210>285</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 285Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>286</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 286Gly Asp Thr Phe Ser Thr Tyr Ala Ile Ser1               5                   10</s400><s200><s210>287</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 287Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>288</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 288Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val1               5                   10</s400><s200><s210>289</s210><s211>478</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 289Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser            20                  25                  30Gly Asn Gln Lys Ser Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys        35                  40                  45Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Leu Glu Ser Gly Val    50                  55                  60Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Asn                85                  90                  95Ala Tyr Phe Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile            100                 105                 110Lys Ser Gly Gly Gly Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu        115                 120                 125Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Thr Ser Gly    130                 135                 140Asp Thr Phe Ser Thr Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly145                 150                 155                 160Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Gly Lys Ala                165                 170                 175His Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu            180                 185                 190Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp        195                 200                 205Thr Ala Val Tyr Phe Cys Ala Arg Lys Phe His Phe Val Arg Gly Ser    210                 215                 220Pro Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser225                 230                 235                 240Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr                245                 250                 255Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe            260                 265                 270Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro        275                 280                 285Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val    290                 295                 300Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr305                 310                 315                 320Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val                325                 330                 335Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys            340                 345                 350Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser        355                 360                 365Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro    370                 375                 380Cys Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val385                 390                 395                 400Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly                405                 410                 415Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp            420                 425                 430Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp        435                 440                 445Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His    450                 455                 460Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400><s200><s210>290</s210><s211>463</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 290Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Gly Gly Glu            100                 105                 110Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser        115                 120                 125Leu Arg Leu Ser Cys Ala Val Ser Gly Tyr Thr Phe Ser Met Asn Trp    130                 135                 140Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Trp Ile Asn145                 150                 155                 160Met Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe                165                 170                 175Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn            180                 185                 190Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Tyr        195                 200                 205Asn Gly Asn Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val    210                 215                 220Ser Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Ser Asp Lys Thr His225                 230                 235                 240Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val                245                 250                 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr            260                 265                 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu        275                 280                 285Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys    290                 295                 300Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser305                 310                 315                 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys                325                 330                 335Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile            340                 345                 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro        355                 360                 365Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Ser Cys Ala    370                 375                 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385                 390                 395                 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser                405                 410                 415Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg            420                 425                 430Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu        435                 440                 445His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455                 460</s400><s200><s210>291</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 291Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>292</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 292Asp Ala Ser Asn Arg Ala Pro1               5</s400><s200><s210>293</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 293Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Leu Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Arg Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>294</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 294Gly Ile Ile Pro Leu Phe Gly Lys Ala His Tyr Ala Gln Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>295</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 295Lys Phe His Phe Val Arg Gly Ser Pro Phe Gly Met Asp Val1               5                   10</s400><s200><s210>296</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(5)..(5)</s222><s223>Xaa is Ile or Leu</s223></s220></s200><s400> 296Gly Ile Ile Pro Xaa Phe Gly Lys Ala His1               5                   10</s400><s200><s210>297</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(3)..(3)</s222><s223>Xaa is His or Arg</s223></s220><s220><s221>misc_feature</s221><s222>(6)..(6)</s222><s223>Xaa is Ser or Arg</s223></s220></s200><s400> 297Lys Phe Xaa Phe Val Xaa Gly Ser Pro Phe Gly Met Asp Val1               5                   10</s400><s200><s210>298</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 298Lys Phe Arg Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val1               5                   10</s400><s200><s210>299</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(10)..(10)</s222><s223>Xaa is Leu or Met</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(11)..(11)</s222><s223>Xaa is Ala, Ser, or Glu</s223></s220></s200><s400> 299Arg Ala Ser Gln Ser Val Ser Ser Tyr Xaa Xaa1               5                   10</s400><s200><s210>300</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 300Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ser1               5                   10</s400><s200><s210>301</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 301Arg Ala Ser Gln Ser Val Ser Ser Tyr Met Ala1               5                   10</s400><s200><s210>302</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 302Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Glu1               5                   10</s400><s200><s210>303</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(7)..(7)</s222><s223>Xaa is Thr, Pro, Met, or Glu</s223></s220></s200><s400> 303Asp Ala Ser Asn Arg Ala Xaa1               5</s400><s200><s210>304</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 304Asp Ala Ser Asn Arg Ala Met1               5</s400><s200><s210>305</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 305Asp Ala Ser Asn Arg Ala Glu1               5</s400><s200><s210>306</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(4)..(4)</s222><s223>Xaa is Ser or Ala</s223></s220></s200><s400> 306Gln Gln Arg Xaa Asn Trp Pro Thr1               5</s400><s200><s210>307</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 307Gln Gln Arg Ala Asn Trp Pro Thr1               5</s400><s200><s210>308</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 308Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>309</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 309Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>310</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 310Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Arg Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>311</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 311Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>312</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 312Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe Arg Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>313</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 313Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>314</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 314Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Leu Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>315</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 315Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>316</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 316Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>317</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 317Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ala Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>318</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 318Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>319</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 319Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Met Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>320</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 320Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>321</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 321Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>322</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 322Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>323</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 323Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Met Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Glu Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ala Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>324</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 324Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>325</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 325Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Glu Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>326</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 326Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Leu Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Ser Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>327</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 327Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>328</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 328Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Ile Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Arg Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>329</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 329Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Pro Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400><s200><s210>330</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 330Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1               5                   10                  15Ser Val Lys Val Ser Cys Lys Thr Ser Gly Asp Thr Phe Ser Thr Tyr            20                  25                  30Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met        35                  40                  45Gly Gly Ile Ile Pro Leu Phe Gly Lys Ala His Tyr Ala Gln Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Ala Arg Lys Phe His Phe Val Arg Gly Ser Pro Phe Gly Met Asp Val            100                 105                 110Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>331</s210><s211>106</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 331Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1               5                   10                  15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro65                  70                  75                  80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Thr                85                  90                  95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys            100                 105</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002487A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002487</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17617046</doc-number><date>20200608</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2809</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>92</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>31</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>2317</main-group><subgroup>622</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">HIGH AFFINITY ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62858949</doc-number><date>20190607</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>ADIMAB, LLC</orgname><address><city>Lebanon</city><state>NH</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>PEJCHAL</last-name><first-name>Robert</first-name><address><city>Lebanon</city><state>NH</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>STEIN</last-name><first-name>Caitlin</first-name><address><city>Lebanon</city><state>NH</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>McCREARY</last-name><first-name>Julia</first-name><address><city>Lebanon</city><state>NH</state><country>US</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/036653</doc-number><date>20200608</date></document-id><us-371c12-date><date>20211207</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.</p></abstract><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a U.S. Nat'l Phase Appl. submitted under 35 U.S.C. 371 based on Int'l Appl. No. PCT/US2020/036653, filed Jun. 8, 2020, which claims priority to U.S. Provisional Appl. No. 62/858,949, filed Jun. 7, 2019, all of which are hereby incorporated by reference in their entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">SEQUENCE LISTING</heading><p id="p-0003" num="0002">The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 6, 2021, is named &#x201c;1160430o001801&#x201d;, and is 92,369 bytes in size.</p><heading id="h-0003" level="1">FIELD OF THE INVENTION</heading><p id="p-0004" num="0003">The invention relates, inter alia, to anti-Cluster of Differentiation 3 (CD3) antibodies, including multispecific antibodies, and functional fragments thereof, and methods and reagents for their identification, isolation, preparation, and use.</p><heading id="h-0004" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0005" num="0004">Cell proliferative disorders, such as cancer, are characterized by the uncontrolled growth of cell subpopulations. They are the leading cause of death in the developed world and the second leading cause of death in developing countries, with a total number of new cancer cases per year expected to rise to 23.6 million by 2030. The National Cancer Institute estimates that almost 2 million new cases of cancer will be diagnosed in the U.S. and greater than 600,000 Americans will die of cancer in 2018. Cancer care thus represents a significant and ever-increasing societal burden.</p><p id="p-0006" num="0005">The idea of using the cytotoxic capacity of T cells to kill tumor cells through use of CD3 targeting bispecific antibodies dates back to the mid-1980s. (Staerz et al. Nature 1985 314: 628-32). Many bispecific antibodies developed to date contain a first binding site specific to CD3 for T-cell recruitment and activation, and a second binding site for a targeted disease-associated antigen, such as an antigen produced by a tumor cell. CD3 bispecific antibodies trigger the CD3 surface receptor on T cells by binding to their second target protein expressed on tumors such that available T cells can bind to target-expressing cells via bridging by the CD3 bispecific antibody, irrespective of the peptide/MHC specificity of their T-cell receptor. (See, e.g., Bassan, 2012, Blood 120:5094-95). Bridging of T cells and tumor cells using CD3 bispecific antibodies can induce dramatic regression of advanced-stage malignancies and, in some cases, lead to complete remission. Currently, more than 25 different CD3 bispecific antibodies are in clinical development for treatment of hematologic malignancies or solid cancers by targeting CD19, CD20, CD33, and CD123, or EpCAM, HER2, PSMA, and CEA, respectively. (See e.g., Liu et al. Front Immunol 2017 8:38).</p><p id="p-0007" num="0006">While bispecific antibodies have shown considerable benefits over monospecific antibodies for the treatment and the detection of cancer, broad commercial application of bispecific antibodies has been hampered by the lack of efficient/low-cost production methods, the lack of stability of bispecific polypeptides and the lack of long half-lives in humans. A large variety of methods have been developed over the last few decades to produce bispecific monoclonal antibodies. However, many candidate bispecific antibodies with exquisite selectivity and high potency toward the target of interest often have problems in downstream development and clinical efficacy activities, including polyspecific binding (or &#x201c;polyspecificity&#x201d;); off-target binding; nonspecific binding; poor expression levels or profiles in eukaryotic host cells, such as mammalian host cells and yeast cells; poor chemical and physical properties, such as poor stability during storage (e.g., poor/low &#x201c;shelf-life&#x201d; stability), poor (low) solubility, poor (high) viscosity, propensity to aggregate, and the like; and poor clinical and biophysical profiles, such as poor pharmacokinetic profiles, poor pharmacodynamic profiles, fast or poor in vivo clearance rates, short circulation half-life, some of which result in termination of their development.</p><p id="p-0008" num="0007">Certain techniques and assays exist to assess many of the aforementioned developability characteristics for discovered antibodies in the context of downstream development activities (&#x201c;post-discovery antibodies&#x201d;), such as CIC, SIC, BVP-ELISA, TMA, and other assays; however, such assays are typically not amenable to high-throughput formats in early antibody discovery platforms. Furthermore, assessment of these attributes typically requires milligram to gram quantities of protein, thus often imposing a de facto limitation on the number of leads that can be pragmatically considered for development, and consequently reducing the likelihood of program success. Consequently, significant resources are often expended attempting to fix poorly behaving lead candidates with few backups available in later stages of development.</p><p id="p-0009" num="0008">A variety of CD3 antibodies are known in the art, including monoclonal and bispecific antibody formats. See, e.g., U.S. Pat. Nos. 7,262,276; 7,635,472; 7,862,813; 9,587,021; and 10,174,124. However, many of these CD3 antibodies possess developability issues, such as those outlined above, and/or possess insufficiently high binding affinity to CD3 for a particular multispecific format or chimeric antigen receptor (CAR) format or delivery approach or the like. Accordingly, there is an unmet need in the field of bispecific antibodies for anti-CD3 antibodies that display desirable developability profiles and possess high affinity for CD3 for use in cancer treatment.</p><heading id="h-0005" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0010" num="0009">The present disclosure relates to anti-CD3 antibodies and methods of using them, which antibodies have particularly high affinity for CD3, e.g., a monovalent K<sub>D </sub>of about 250 picomolar or less.</p><p id="p-0011" num="0010">The present disclosure provides an anti-CD3 antibody and/or antigen-binding fragment comprising a complementarity determining region (CDR) in a light chain variable region, CDRL3, wherein the CDRL3 comprises an amino acid sequence of X<sub>1</sub>QSYFRRT (SEQ ID NO: 1), wherein X<sub>1 </sub>is K, A, T, or V. In some embodiments, X<sub>1 </sub>is A, T or V. In certain embodiments, CDRL3 comprises AQSYFRRT (SEQ ID NO: 2); TQSYFRRT (SEQ ID NO: 3); VQSYFRRT (SEQ ID NO: 4); or KQSYFRRT (SEQ ID NO: 5).</p><p id="p-0012" num="0011">In some embodiments, an anti-CD3 antibody and/or antigen-binding fragment further comprises a complementarity determining region (CDR) in a heavy chain variable region, CDRH3, wherein the CDRH3 comprises an amino acid sequence of X<sub>3</sub>RDAYGX<sub>4</sub>YFYDV (SEQ ID NO: 6), wherein X<sub>3 </sub>is A or V and X<sub>4 </sub>is R or Q. In certain embodiments, X<sub>3 </sub>is A.</p><p id="p-0013" num="0012">In other embodiments, an anti-CD3 antibody and/or antigen-binding fragment further comprise a complementarity determining region (CDR) in a light chain variable region, CDRL1, wherein the CDRL1 comprises an amino acid sequence of KSSQSLLNARTX<sub>5</sub>KNYLA (SEQ ID NO: 7), wherein X<sub>5 </sub>is G, M, N, or R. In certain embodiments, X<sub>5 </sub>is G or R. In some embodiments, CDRL1 may comprise KSSQSLLNARTGKNYLA (SEQ ID NO: 8) or KSSQSLLNARTRKNYLA (SEQ ID NO: 9).</p><p id="p-0014" num="0013">In some embodiments, an anti-CD3 antibody and/or antigen-binding fragment further comprises a complementarity determining region (CDR) in a light chain variable region, CDRL2, wherein the CDRL2 comprises an amino acid sequence of WASTRES (SEQ ID NO: 10) or WASTRSS (SEQ ID NO: 11).</p><p id="p-0015" num="0014">In some embodiments, an anti-CD3 antibody and/or antigen-binding fragment further comprises a complementarity determining region (CDR) in a heavy chain variable region, CDRH1, wherein the CDRH1 comprises an amino acid sequence of FNX<sub>6</sub>KDYYX<sub>7</sub>H (SEQ ID NO: 12), wherein X<sub>6 </sub>is I, N or V and X<sub>7 </sub>is M or 1. In certain embodiments, X<sub>6 </sub>is I and/or X<sub>7 </sub>is M. In certain embodiments, CDRH1 comprises FNIKDYYMH (SEQ ID NO: 13).</p><p id="p-0016" num="0015">In some embodiments, an anti-CD3 antibody and/or antigen-binding fragment further comprises a complementarity determining region (CDR) in a heavy chain variable region, CDRH2, wherein CDRH2 comprises an amino acid sequence of WIDLX<sub>8</sub>NANTVYDX<sub>9</sub>KX<sub>10</sub>QG (SEQ ID NO: 14), wherein X<sub>8 </sub>is E or N, X<sub>9 </sub>is A, H, or T, and X<sub>10 </sub>is F or L. In certain embodiments, X<sub>8 </sub>is E and/or X<sub>9 </sub>is A and/or X<sub>10 </sub>is F. In certain embodiments, CDRH2 comprises WIDLENANTVYDAKFQG (SEQ ID NO: 15) or WIDLENANTIYDAKFQG (SEQ ID NO: 16).</p><p id="p-0017" num="0016">In some embodiments, the disclosure provides an anti-CD3 antibody and/or antigen-binding fragment thereof comprising one or more of a CDRL1, a CDRL2, and a CDRL3. Such an antibody, in some embodiments, further comprises a CDRH1, a CDRH2, and a CDRH3.</p><p id="p-0018" num="0017">In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein comprise a binding affinity (K<sub>D</sub>) of about 500 pM or less. In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof comprise a binding affinity (K<sub>D</sub>) of about 250 pM or less. In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof comprise a binding affinity (K<sub>D</sub>) of about 100 pM or less.</p><p id="p-0019" num="0018">Moreover, the present disclosure generally relates to an anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antigen-binding antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises: a. a variable heavy (V<sub>H</sub>) chain polypeptide comprising: i. a VH CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13); ii. a V<sub>H </sub>CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15); iii. a V<sub>H </sub>CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or b. a variable light (V<sub>L</sub>) chain polypeptide comprising: i. a V<sub>L </sub>CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8); ii. a V<sub>L </sub>CDR2 (CDRL2) of WASTRX<sub>1</sub>S (SEQ ID NO: 133); and iii. a V<sub>L </sub>CDR3 (CDRL3) of X<sub>2</sub>QSYFRRT (SEQ ID NO: 134); X<sub>1 </sub>and X<sub>2 </sub>are each independently any amino acid. In some embodiments, X<sub>1 </sub>is E or S; and/or X<sub>2 </sub>is K or V. In some embodiments, said antibody or antigen-binding antibody fragment comprises a CDRL2 of SEQ ID NO: 10 or SEQ ID NO: 11; and/or a CDRL3 of SEQ ID NO: 5 or SEQ ID NO: 4. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment is selected from the group consisting of: a. one which comprises a V<sub>H </sub>chain CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13), a V<sub>H </sub>chain CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15), and a V<sub>H </sub>chain CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or a V<sub>L </sub>chain CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8), a V<sub>L </sub>chain CDR2 (CDRL2) of WASTRES (SEQ ID NO: 10), and a V<sub>L </sub>chain CDR3 (CDRL3) of KQSYFRRT (SEQ ID NO: 5); and b. one which comprises a V<sub>H </sub>chain CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13), a V<sub>H </sub>chain CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15), and a V<sub>H </sub>chain CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or a V<sub>L </sub>chain CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8), a V<sub>L </sub>chain CDR2 (CDRL2) of WASTRSS (SEQ ID NO: 11), and a V<sub>L </sub>chain CDR3 (CDRL3) of VQSYFRRT (SEQ ID NO: 4).</p><p id="p-0020" num="0019">In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 34; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17.</p><p id="p-0021" num="0020">In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 500 pM or less, about 450 pM or less, about 400 pM or less, about 350 pM or less, about 300 pM or less, about 250 pM or less, about 200 pM or less, about 150 pM or less, or about 100 pM or less, optionally wherein said CD3 is human and/or cynomolgus, further optionally wherein said binding affinity is measured by surface plasmon resonance. In some embodiments, wherein said K<sub>D </sub>is a monovalent K<sub>D </sub>and/or wherein said K<sub>D </sub>is measured using an scFv fragment of said anti-CD3 antibody or antibody fragment.</p><p id="p-0022" num="0021">In some embodiments, said antibody or antigen-binding antibody fragment elicits T cell activation or T cell killing while displaying a decreased propensity to elicit cytokine production to levels capable of inducing cytokine release syndrome. In some embodiments, the antibody or antigen-binding antibody fragment comprises a multispecific antibody. In some embodiments, the antibody or antigen-binding antibody fragment comprises a bispecific antibody. In some embodiments, the antibody or antigen-binding antibody fragment comprises an scFv. In some embodiments, the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an oncology target; an immune-oncology target; a neurodegenerative disease targets; an autoimmune disorder target; an infectious disease target; a metabolic disease target; a cognitive disorder target; a blood-brain barrier target; or a blood disease target. In some embodiments, the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen selected from the group consisting of: 17-IA, 4-1BB, 4Dc, 6- keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, A1 Adenosine Receptor, A33, ACE, ACE-2, Activin, Activin A, Activin AB, Activin B, Activin C, Activin RIA, Activin RIA ALK-2, Activin RIB ALK-4, Activin RIIA, Activin RUB, ADAM, ADAM10, ADAM12, ADAM 15, ADAM 17/T ACE, ADAM8, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, Addressins, aFGF, ALCAM, ALK, ALK-1, ALK-7, alpha-l-antitrypsin, alpha-V/beta-I antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, ARC, ART, Artemin, anti-Id, ASPARTIC, Atrial natriuretic factor, av/b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B-lymphocyte Stimulator (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bel, BCMA, BDNF, b-ECGF, bFGF, BID, Bik, BFM, BLC, BL-CAM, BLK, BMP, BMP-2 BMP-2a, BMP-3 Osteogenin, BMP-4 BMP-2b, BMP-5, BMP-6 Vgr-1, BMP-7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1, BMPR-II (BRK-3), BMPs, b-NGF, BOK, Bombesin, Bone-derived neurotrophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, CIO, CA125, CAD-8, Calcitonin, cAMP, carcinoembryonic antigen (CEA), carcinoma-associated antigen, Cathepsin A, Cathepsin B, Cathepsin C/DPPI, Cathepsin D, Cathepsin E, Cathepsin H, Cathepsin L, Cathepsin O, Cathepsin S, Cathepsin V, Cathepsin X/Z/P, CBL, CCI, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL 14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/10, CCR, CCR1, CCR10, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD4, CD5, CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, CD32, CD33 (p67 proteins), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80 (B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, <i>Clostridium botulinum </i>toxin, <i>Clostridium perfringens </i>toxin, CKb8-1, CLC, CMV, CMV UL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-associated antigen, DAN, DCC, DcR3, DC-SIGN, Decay accelerating factor, des(1-3)-IGF-I (brain IGF-1), Dhh, digoxin, DNAM-1, Dnase, Dpp, DPPIV/CD26, Dtk, ECAD, EDA, EDA-A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, EN A, endothelin receptor, Enkephalinase, eNOS, Eot, eotaxinl, EpCAM, Ephrin B2/EphB4, EPO, ERCC, E-selectin, ET-1, Factor IIa, Factor VII, Factor VIIIc, Factor IX, fibroblast activation protein (FAP), Fas, FcRI, FEN-1, Ferritin, FGF, FGF-19, FGF-2, FGF3, FGF-8, FGFR, FGFR-3, Fibrin, FL, FLIP, Flt-3, Flt-4, Follicle stimulating hormone, Fractalkine, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas 6, GCP-2, GCSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr-2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-2), GDF-7 (BMP-12, CDMP-3), GDF-8 (Myostatin), GDF-9, GDF-15 (MIC-1), GDNF, GFAP, GFRa-1, GFR-alpha1, GFR-alpha2, GFR-alpha3, GITR, Glucagon, Glut 4, glycoprotein IIb/IIIa (GP IIb/IIIa), GM-CSF, gp130, gp72, GRO, Growth horn-one releasing factor, Hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMV gB envelope glycoprotein, HCMV) gH envelope glycoprotein, HCMV UL, Hemopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2/neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV) gB glycoprotein, HSV gD glycoprotein, HGFA, High molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp 120 V3 loop, HLA, HLA-DR, HM1.24, HMFG PEM, HRG, Hrk, human cardiac myosin, human cytomegalovirus (HCMV), human growth hormone (HGH), HVEM, 1-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF binding proteins, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-18R, IL-23, interferon (INF)-alpha, INF-beta, INF-gamma, Inhibin, iNOS, Insulin A-chain, Insulin B-chain, Insulin-like growth factor 1, integrin alpha2, integrin alpha3, integrin alpha4, integrin alpha4/beta1, integrin, alpha4/beta7, integrin alpha5 (alphaV), integrin alpha5/beta1, integrin alpha5/beta3, integrin alpha6, integrin beta1, integrin beta2, interferon gamma, IP-10, 1-TAC, JE, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 15, Kallikrein LI, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), lanminin 5, LAMP, LAP, LAP (TGF-1), Latent TGF-1, Latent TGF-1 bpl, LBP, LDGF, LECT2, Lefty, Lewis-Y antigen, Lewis-Y related antigen, LFA-1, LFA-3, Lfo, LIF, LIGHT, lipoproteins, LIX, LKN, Lptn, L-Selectin, LT-a, LT-b, LTB4, LTBP-1, Lung surfactant, Luteinizing hormone, Lymphotoxin Beta Receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCAM, MCK-2, MCP, M-CSF, MDC, Mer, a metalloprotease, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP-1-alpha, MK, MMAC1, MMP, MMP-1, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3, MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Mucl), MUC18, Muellerian-inhibiting substance, Mug, MuSK, NAIP, NAP, NCAD, N-Cadherin, NCA 90, NCAM, NCAM, Neprilysin, Neurotrophin-3, -4, or -6, Neurturin, Neuronal growth factor (NGF), NGFR, NGF-beta, nNOS, NO, NOS, Npn, NRG-3, NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, Parathyroid hormone, PARC, PARP, PBR, PBSF, PCAD, P-Cadherin, PCNA, PDGF, PDGF, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), PIGF, PLP, PP14, Proinsulin, Prorelaxin, Protein C, PS, PSA, PSCA, prostate specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK, RANKL, RANTES, Relaxin A-chain, Relaxin B-chain, renin, respiratory syncytial virus (RSV) F, RSV Fgp, Ret, Rheumatoid factors, RLIP76, RPA2, RSK, Si00, SCF/KL, SDF-1, SERINE, Serum albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (tumor-associated glycoprotein-72), TARC, TCA-3, T-cell receptors (e.g., T-cell receptor alpha/beta), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, testicular PLAP-like alkaline phosphatase, TfR, TGF, TGF-alpha, TGF-beta, TGF-beta Pan Specific, TGF-beta RI (ALK-5), TGF-beta RII, TGF-beta RIIb, TGF-beta RIII, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta4, TGF-beta5, Thrombin, Thymus Ck-1, Thyroid stimulating hormone, Tie, TIMP, TIQ, Tissue Factor, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-alpha, TNF-alpha beta, TNF-beta2, TNFc, TNF-RI, TNF-RII, TNFRSF10A (TRAIL RI Apo-2, DR4), TNFRSFIOB (TRAIL R2 DR5, KILLER, TRICK-2A, TRICK-B), TNFRSF10C (TRAIL R3 DcR1, LIT, TRID), TNFRSF10D (TRAIL R4 DcR2, TRUNDD), TNFRSF11A (RANK ODF R, TRANCE R), TNFRSF11B (OPG OCIF, TR1), TNFRSF12 (TWEAK R FN14), TNFRSF13B (TACI), TNFRSF13C (BAFF R), TNFRSF14 (HVEM ATAR, HveA, LIGHT R, TR2), TNFRSF16 (NGFR p75NTR), TNFRSF17 (BCMA), TNFRSF 18 (GITR AITR), TNFRSF19 (TROY TAJ, TRADE), TNFRSF19L (RELT), TNFRSFIA (TNF RI CD120a, p55-60), TNFRSFIB (TNF RII CD120b, p75-80), TNFRSF26 (TNFRH3), TNFRSF3 (LTbR TNF RIII, TNFC R), TNFRSF4 (OX40 ACT35, TXGP1 R), TNFRSF 5 (CD40 p50), TNFRSF6 (Fas Apo-1, APT1, CD95), TNFRSF6B (DcR3 M68, TR6), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB CD137, ILA), TNFRSF21 (DR6), TNFRSF22 (DcTRAIL R2 TNFRH2), TNFRST23 (DcTRAIL RI TNFRH1), TNFRSF25 (DR3 Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10 (TRAIL Apo-2 Ligand, TL2), TNFSF 11 (TRANCE/RANK Ligand ODF, OPG Ligand), TNFSF12 (TWEAK Apo-3 Ligand, DR3 Ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM Ligand, LTg), TNFSF15 (TLIA/VEGI), TNFSF18 (GITR Ligand AITR Ligand, TL6), TNFSFIA (TNF-a Conectin, DIF, TNFSF2), TNFSF1B (TNF-b LTa, TNFSF1), TNFSF3 (LTb TNFC, p33), TNFSF4 (OX40 Ligand gp34, TXGP1), TNFSF5 (CD40 Ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas Ligand Apo-1 Ligand, APT1 Ligand), TNFSF7 (CD27 Ligand CD70), TNFSF8 (CD30 Ligand CD153), TNFSF9 (4-1BB Ligand CD137 Ligand), TP-1, t-PA, Tpo, TRAIL, TRAIL R, TRAIL-R1, TRAIL-R2, TRANCE, transferring receptor, TRF, Trk, TROP-2, TSG, TSLP, tumor-associated antigen CA 125, tumor-associated antigen expressing Lewis Y related carbohydrate, TWEAK, TXB2, Ung, uPAR, uPAR-1, Urokinase, VCAM, VCAM-1, VECAD, VE-Cadherin, VE-cadherin-2, VEFGR-1 (fit-1), VEGF, VEGFR, VEGFR-3 (flt-4), VEGI, VFM, Viral antigens, VLA, VLA-1, VLA-4, VNR integrin, von Willebrands factor, WIF-1, WNT1, WNT2, WNT2B/13, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, XCL1, XCL2, XCR1, XCR1, XEDAR, XIAP, XPD, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3 (T cell immunoglobulin and mucin protein-3), hormone receptors and growth factors.</p><p id="p-0023" num="0022">In some embodiments, the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen selected from the group consisting of BCMA, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3, CD20, CD2, CD19, Her2, EGFR, EpCAM, Fc&#x3b3;RIIIa (CD16), Fc&#x3b3;RIIa (CD32a), Fc&#x3b3;RIIb (CD32b), Fc&#x3b3;RI (CD64), Toll-like receptors (TLRs), TLR4, TLR9, cytokines, IL-2, IL-5, IL-13, IL-6, IL-17, IL-12, IL-23, TNFa, TGFb, cytokine receptors, IL-2R, chemokines, chemokine receptors, growth factors, VEGF, and HGF. In some embodiments, the antibody or antigen-binding antibody fragment is comprised in a chimeric antigen receptor (CAR), which optionally comprises at least one transmembrane domain, and at least one intracellular domain from a T-cell receptor, optionally a CD3&#x3b6; subunit, and at least one co-stimulatory domain. In some embodiments, the antibody or antigen-binding antibody fragment comprises an scFv2-Fc2 and/or scFv-IgG. In some embodiments, the antibody or antigen-binding antibody fragment comprises an IgG constant domain. In some embodiments, k. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen, wherein said antibody comprises a multispecific format selected from the group consisting of: Fab-Fc-scFv, &#x201c;bottle-opener, Mab-scFv, Mab-Fv, Dual scFv, central Fv, central scFv, one-arm central scFv, Fab-Fab, Fab-Fv, mAb-Fv, mAb-Fab, DART, BiTE, common light chain-IgG, TandAb, Cross-Mab, SEED, BEAT, TrioMab, and DuetMab. Moreover, the present disclosure generally relates to an isolated or recombinant nucleic acid sequence encoding an antibody or antigen-binding antibody fragment as described herein. Furthermore, the present disclosure generally relates to an expression vector comprising an isolated or recombinant nucleic acid sequence as described herein. Furthermore, the present disclosure generally relates to a host cell transfected, transformed, or transduced with a nucleic acid sequence, optionally a mammalian or yeast cell, or a vector containing said nucleic acid sequence as described herein.</p><p id="p-0024" num="0023">Moreover, the present disclosure generally relates to a pharmaceutical composition comprising an antibody or antigen-binding antibody fragment as described herein; and a pharmaceutically acceptable carrier and/or excipient.</p><p id="p-0025" num="0024">Furthermore, the present disclosure generally relates to a method of treating a disorder in a mammal in need of such treatment, wherein the disorder comprises a proliferative disorder, an oncological disorder, an immuno-oncological disorder, a neurological disorder, a neurodegenerative disorder, or an autoimmune disorder, comprising administering an effective amount of one or more antibodies or antibody fragments as described herein, or a host cell which expresses one of said antibodies or antibody fragments as described herein, optionally an immune cell, further optionally a T or NK cell. In some embodiments, the method further comprises administering to the mammal an additional therapeutic agent, optionally wherein the mammal is a human.</p><p id="p-0026" num="0025">Moreover, the present disclosure generally relates to an anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises one or more CDRs of any one or more of Ab1-Ab50. Furthermore, the present disclosure generally relates to an anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises one or more V<sub>H </sub>and/or V<sub>L </sub>chains comprising an amino acid sequence selected from those in Table 4.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0006" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0027" num="0026">Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term &#x201c;about,&#x201d; when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression &#x201c;about 100&#x201d; includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).</p><p id="p-0028" num="0027">It is understood that aspects and embodiments of the invention described herein include &#x201c;comprising,&#x201d; &#x201c;consisting,&#x201d; and &#x201c;consisting essentially of&#x201d; aspects and embodiments.</p><p id="p-0029" num="0028">Provided herein are anti-CD3 antibodies and/or antigen-binding fragments thereof having high affinity (K<sub>D</sub>) for CD3. In some embodiments, the K<sub>D </sub>of the anti-CD3 is about 500 pM or less. In some embodiments, the K<sub>D </sub>is about 250 pM or less. In some embodiments, the K<sub>D </sub>is about 100 pM or less. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 500 pM or more, about 500 pM or less, about 470 pM or less, about 450 pM or less, about 400 pM or less, about 350 pM or less, about 300 pM or less, about 250 pM or less, about 200 pM or less, about 150 pM or less, or about 100 pM or less, optionally wherein said CD3 is human and/or cynomolgus, further optionally wherein said binding affinity is measured by surface plasmon resonance. In some embodiments, said K<sub>D </sub>is a monovalent K<sub>D </sub>and/or wherein said K<sub>D </sub>is measured using an scFv fragment of said anti-CD3 antibody or antibody fragment. In some embodiments, the anti-CD3 antibodies and/or antigen binding fragments thereof comprise certain CDR sequence motifs. In some embodiments, a CDR sequence motif comprises CDRL3 comprising SEQ ID NO: 1. In some embodiments, the anti-CD3 antibodies have favorable developability profiles.</p><heading id="h-0007" level="2">Exemplary High Affinity Anti-CD3 Antibodies and Antigen-Binding Fragments Thereof</heading><p id="p-0030" num="0029">&#x201c;Cluster of Differentiation 3&#x201d; or &#x201c;CD3&#x201d;, generally refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated, including, for example, CD3&#x3b5;, CD3&#x3b3;, CD3&#x3b1;, and CD3&#x3b2; chains. The term encompasses &#x201c;full-length,&#x201d; unprocessed CD3 (e.g., unprocessed or unmodified CD3&#x3b5; or CD3&#x3b3;), as well as any form of CD3 that results from processing in the cell. The term also encompasses naturally occurring variants of CD3, including, for example, splice variants or allelic variants. CD3 includes, for example, human CD3&#x3b5; protein (NCBI Ref Seq No. NP 000724), which is 207 amino acids in length, and human CD3&#x3b3; protein (NCBI Ref Seq No. NP 000064), which is 182 amino acids in length. The term also refers to either the human or cynomolgus CD3epsilon protein, the amino acid sequence for which is SEQ ID NOs: 131 and 132, respectively (Table 7). &#x201c;CD3&#x3b5;N27&#x201d; and &#x201c;CD3&#x3b5;N13&#x201d; refer to the N-terminal 27 amino acids and the N-terminal 13 amino acids, respectively, of CD3, and optionally containing chemical modifications or conjugations made thereto.</p><p id="p-0031" num="0030">An &#x201c;anti-CD3 antibody&#x201d; refers to an antibody or an antigen-binding fragment thereof capable of binding to CD3, e.g., CD3&#x3b5; and/or CD3&#x3b3;, e.g., human CD3&#x3b5; and/or CD3&#x3b3;, with sufficient affinity and/or specificity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD3. The anti-CD3 antibodies and antigen-binding fragments thereof described herein have particularly high affinity for CD3.</p><p id="p-0032" num="0031">The term &#x201c;high affinity&#x201d; refers to those antibodies having a binding affinity to CD3, expressed as K<sub>D</sub>. In some embodiments, the K<sub>D </sub>is about 5&#xd7;10<sup>&#x2212;10 </sup>M or less. In some embodiments, the K<sub>D </sub>is about 2.5&#xd7;10<sup>&#x2212;10 </sup>M or less. In some embodiments, the K<sub>D </sub>is about 1&#xd7;10<sup>&#x2212;1 </sup>M or less. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 500 pM or more, about 500 pM or less, about 470 pM or less, about 450 pM or less, about 400 pM or less, about 350 pM or less, about 300 pM or less, about 250 pM or less, about 200 pM or less, about 150 pM or less, or about 100 pM or less, optionally wherein said CD3 is human and/or cynomolgus, further optionally wherein said binding affinity is measured by surface plasmon resonance. In some embodiments, the K<sub>D </sub>is measured by surface plasmon resonance, e.g., BIACORE, biolayer interferometry measurements using, e.g., a FORTEBIO Octet HTX instrument (Pall Life Sciences), or solution-affinity ELISA. In some embodiments, the K<sub>D </sub>is measured using an scFv fragment of the anti-CD3 antibody. In some embodiments, the monovalent K<sub>D </sub>is measured.</p><p id="p-0033" num="0032">In some embodiments, an anti-CD3 antibody binds to CD3 with a dissociation constant (K<sub>D</sub>) of less than about 500 pM (5&#xd7;10<sup>&#x2212;10 </sup>M). In some embodiments, an anti-CD3 antibody binds to CD3 with a dissociation constant (K<sub>D</sub>) of less than about 250 pM. In some embodiments, an anti-CD3 antibody binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 100 pM. In certain embodiments, the anti-CD3 antibody binds to an epitope of CD3 that is conserved among CD3 from different species, e.g., human and cyno cross-reactive.</p><p id="p-0034" num="0033">The K<sub>D </sub>can be measured using assays well-known to a skilled artisan, including, but not limited to: biolayer interferometry (BLI), surface plasmon resonance (SPR), solution equilibrium based kinetic exclusion assays, KinExA direct association, assays using FORTEBIO instruments and reagents, such as Octet RED 384 and HTX BLI-based instruments, enzyme-linked immunosorbent assays (ELISA), or radioimmunoassay (RIA). The K<sub>D </sub>measurement may be performed with an intact anti-CD3 antibody or an antigen-binding fragment thereof, e.g., scFv, using a BIACORE&#xae; surface plasmon resonance assay.</p><p id="p-0035" num="0034">While high affinity CD3 binders have been associated with triggering or contributing to cytokine release syndrome (CRS) in patients, the binding affinity of an antibody for CD3 is not the sole determinant of CRS. For example, a high affinity anti-CD3 antibody (&#x2dc;low single digit nM K<sub>D</sub>) used in a bispecific format, successfully demonstrated potent T-cell cytotoxicity for target tumor cells with limited cytokine (IFN&#x3b3;, IL-6, TNF&#x3b1;) release (See, e.g., <i>Mol Cancer Ther. </i>2016 September; 15(9); 2155-65 and APTEVO AACR Poster regarding preclinical studies of APOV436, presented Apr. 16, 2018). Without being bound by theory, a high affinity anti-CD3 antibody may be particularly beneficial for providing specific targeting and minimal CRS risk in multispecific antibodies with certain formats, e.g., scFv2-Fc2 or scFv-IgG or other like polymeric formats) or chimeric antigen receptors with various components assembled in different orders.</p><p id="p-0036" num="0035">The term &#x201c;cytokine release syndrome&#x201d; (or &#x201c;CRS&#x201d;) refers to a pro-inflammatory, positive feedback loop between cytokines and immune cells leading to excessive or uncontrolled release of pro-inflammatory cytokines by cells within the immune system (see, e.g., Lee et al., Blood, Vol. 124, pages 188-195 (2014) and Tisoncik et al., Microbiol Mol Biol Rev, Vol. 76, pages 16-32 (2012). Upon stimulation and activation, T cells release a series of cytokines to a level and degree that generates untoward biological/physiological effects of varying degree and severity, including acute inflammation characterized by, e.g., rubor (redness), swelling or edema, calor (heat), dolor (pain), and &#x201c;functio laesa&#x201d; (loss of function). When localized in skin or other tissue, biological/physiological effects comprise increased blood flow, enabling vascular leukocytes and plasma proteins to reach extravascular sites of injury, increasing local temperatures and generation of pain, tissue edema and extravascular pressure and a reduction in tissue perfusion. Other biological/physiological effects comprise organ and system dysfunction, such as cardiac dysfunction, adult respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation. Elevated levels of IFN&#x3b3;, IL-6, TNF&#x3b1;, TGFbeta, IL-2, granulocyte macrophage-colony-stimulating factor (GM-CSF), IL-10, IL-8, IL-5, and/or fractalkine are implicated as predictive and/or causative of CRS or the propensity to elicit CRS upon T-cell stimulation.</p><p id="p-0037" num="0036">In certain embodiments, the anti-CD3 antibodies and/or antigen-binding fragments thereof described herein are detuned and/or modified to reduce the likelihood or severity of CRS induced by the antibody. Non-limiting exemplary modifications may include silent Fc regions (e.g., removing the Fc completely or modifying the Fc region to reduce or eliminate effector function), and/or masking (e.g., a polypeptide mask that is positioned such that it reduces or inhibits the ability of the antibody or antigen-binding fragment thereof to specifically bind CD3).</p><p id="p-0038" num="0037">The term &#x201c;antibody&#x201d; is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and/or antibody fragments (preferably those fragments that exhibit the desired antigen-binding activity).</p><p id="p-0039" num="0038">A &#x201c;monoclonal antibody&#x201d; or &#x201c;mAb&#x201d; refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies (e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation), such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.</p><p id="p-0040" num="0039">With regard to multispecific antibodies, such antibodies comprise at least two different antigen binding domains which recognize and specifically bind to at least two different antigens. With regard to bispecific antibodies, such antibodies comprise two different antigen binding domains which recognize and specifically bind to at least two different antigens. A &#x201c;different antigen&#x201d; may refer to different and/or distinct proteins, polypeptides, or molecules; as well as different and/or distinct epitopes, which epitopes may be contained within one protein, polypeptide, or other molecule.</p><p id="p-0041" num="0040">The term &#x201c;epitope&#x201d; refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. The term &#x201c;epitope&#x201d; also refers to a site on an antigen to which B and/or T cells respond. It also refers to a region of an antigen that is bound by an antibody. Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of the structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes may also be conformational, that is, composed of non-linear amino acids. In certain embodiments, epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics, and/or specific charge characteristics.</p><p id="p-0042" num="0041">In some instances, an antibody comprises four polypeptide chains: two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, IgG<sub>4</sub>, IgA<sub>1</sub>, and IgA<sub>2</sub>. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called &#x3b1;, &#x3b4;, &#x3b5;, &#x3b3;, and &#x3bc;, respectively.</p><p id="p-0043" num="0042">In other instances, an antibody may instead comprise multimers thereof (e.g., IgM) or antigen-binding fragments thereof. Each heavy chain is comprised of a heavy chain variable region (&#x201c;VH&#x201d;) and a heavy chain constant region (&#x201c;CH&#x201d;), which is comprised of domains C<sub>H</sub>1, C<sub>H</sub>2 and C<sub>H</sub>3. Each light chain is comprised of a light chain variable region (&#x201c;V<sub>L</sub>&#x201d;) and a light chain constant region (&#x201c;CL&#x201d;). The V<sub>H </sub>and V<sub>L </sub>regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). Each V<sub>H </sub>and V<sub>L </sub>is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the invention, the FRs of the antibody (or antigen-binding fragment thereof) may be identical to the human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs. Accordingly, the CDRs in a heavy chain are designated &#x201c;CDRH1&#x201d;, &#x201c;CDRH2&#x201d;, and &#x201c;CDRH3&#x201d;, respectively, and the CDRs in a light chain are designated &#x201c;CDRL1&#x201d;, &#x201c;CDRL2&#x201d;, and &#x201c;CDRL3&#x201d;.</p><p id="p-0044" num="0043">Unless specifically indicated otherwise, the term &#x201c;antibody&#x201d; as used herein encompasses molecules comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., &#x201c;full antibody molecules&#x201d; or &#x201c;intact antibodies&#x201d;) as well as antigen-binding fragments thereof.</p><p id="p-0045" num="0044">An &#x201c;antigen-binding fragment&#x201d; refers to a portion of an intact antibody that binds the antigen to which the intact antibody binds (in this case, CD3). The terms &#x201c;full-length antibody,&#x201d; &#x201c;intact antibody,&#x201d; and &#x201c;whole antibody&#x201d; or the like are used herein interchangeably and refer to an antibody having a structure substantially similar to a native antibody.</p><p id="p-0046" num="0045">An antigen-binding fragment of an antibody includes any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. Exemplary antibody fragments include, but are not limited to, Fv, Fab, Fab&#x2032;, Fab&#x2032;-SH, F(ab&#x2032;)<sub>2</sub>; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv or VH or VL domains only); and multispecific antibodies formed from antibody fragments. In some embodiments, the antigen-binding fragments of the anti-CD3 antibodies described herein are scFvs.</p><p id="p-0047" num="0046">As with full antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). A multi-specific antigen-binding fragment of an antibody may comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. A variety of multi-specific antibody formats may be used in the context of an antigen-binding fragment of anti-CD3 antibody described herein. Non-limiting examples of multispecific and bispecific formats include, e.g., Fab-Fc-scFv (&#x201c;bottle-opener&#x201d;) (XENCOR), Mab-scFv (XENCOR), Mab-Fv (XENCOR), Dual scFv (XENCOR), central Fv (XENCOR), central scFv(XENCOR), one-arm central scFv (XENCOR), Fab-Fab (XENCOR), Fab-Fv (XENCOR), mAb-Fv (XENCOR), mAb-Fab (XENCOR), DART (MACROGENICS), BiTE (AMGEN/MICROMET), KiTE, common light chain-IgG (Genentech), TandAb (SFFIMED) Cross-Mab (ROCHE), SEED (EMD SERONO), BEAT (GLENMARK), TrioMab (TRION PHARMA/FRESENIUS BIOTECH), DuetMab (MEDIMMUNE), and others, as disclosed, e.g., in (WO 95/09917; WO 2008/119566; WO 2008/119567; WO2011/121110; WO 2010/037835; WO 2007/042261; WO 2007/110205; WO 2011/121110; WO 2012/055961; WO 2012/16067; WO 2016/086189; WO 2016/182751; WO 2015/006749; WO 2014/049003; WO 2013/177101; WO 2015/128509; U.S. Pat. No. 7,951,917; US 2009/0252729; US 2014/0348839; U.S. Pat. No. 7,183,076; Mazor et al., <i>Mabs</i>, Vol. 7, pages 377-389 (2015); Muda et al., <i>Protein Engineering, Design</i>, &#x26; <i>Selection</i>, Vol. 24, pages 447-454 (2011); and Del Bano et al., Antibodies, Vol. 5, pages 1-23 (2016). In some embodiments, the anti-CD3 scFv fragments described herein comprise one or more variable domains of a multispecific (e.g., bispecific) antibody.</p><p id="p-0048" num="0047">In certain embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein are contained in a multispecific antibody, in particular, a bispecific antibody that has binding specificity for a second antigen. Such a second antigen may be a different target altogether than the first target, or a different epitope present on the same target. In some embodiments, the binding specificities are to two different epitopes of CD3 (e.g., CD3&#x3b5; or CD3&#x3b3;). In other embodiments, one of the binding specificities is for CD3 (e.g., CD3&#x3b5; or CD3&#x3b3;) and the other is for a different biological molecule (e.g., a cell surface antigen, e.g., a tumor antigen).</p><p id="p-0049" num="0048">Non-limiting examples of a second antigen, toward which a bispecific antibody comprising anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein, comprises targets selected from the group consisting of: 17-IA, 4-1BB, 4Dc, 6- keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, A1 Adenosine Receptor, A33, ACE, ACE-2, Activin, Activin A, Activin AB, Activin B, Activin C, Activin RIA, Activin RIA ALK-2, Activin RIB ALK-4, Activin RIIA, Activin RUB, ADAM, ADAM10, ADAM12, ADAM15, ADAM17/TACE, ADAM8, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, Addressins, aFGF, ALCAM, ALK, ALK-1, ALK-7, alpha-l-antitrypsin, alpha-V/beta-1 antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, ARC, ART, Artemin, anti-Id, ASPARTIC, Atrial natriuretic factor, av/b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B-lymphocyte Stimulator (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bel, BCMA, BDNF, b-ECGF, bFGF, BID, Bik, BIM, BLC, BL-CAM, BLK, BMP, BMP-2 BMP-2a, BMP-3 Osteogenin, BMP-4 BMP-2b, BMP-5, BMP-6 Vgr-1, BMP-7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1, BMPR-II (BRK-3), BMPs, b-NGF, BOK, Bombesin, Bone-derived neurotrophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, CIO, CA125, CAD-8, Calcitonin, cAMP, carcinoembryonic antigen (CEA), carcinoma-associated antigen, Cathepsin A, Cathepsin B, Cathepsin C/DPPI, Cathepsin D, Cathepsin E, Cathepsin H, Cathepsin L, Cathepsin O, Cathepsin S, Cathepsin V, Cathepsin X/Z/P, CBL, CCI, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL 14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/10, CCR, CCR1, CCR10, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD4, CD5, CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, CD32, CD33 (p67 proteins), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80 (B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, <i>Clostridium botulinum </i>toxin, <i>Clostridium perfringens </i>toxin, CKb8-1, CLC, CMV, CMV UL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-associated antigen, DAN, DCC, DcR3, DC-SIGN, Decay accelerating factor, des(1-3)-IGF-I (brain IGF-1), Dhh, digoxin, DNAM-1, Dnase, Dpp, DPPIV/CD26, Dtk, ECAD, EDA, EDA-A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, EN A, endothelin receptor, Enkephalinase, eNOS, Eot, eotaxinl, EpCAM, Ephrin B2/EphB4, EPO, ERCC, E-selectin, ET-1, Factor IIa, Factor VII, Factor VIIIc, Factor IX, fibroblast activation protein (FAP), Fas, FcR1, FEN-1, Ferritin, FGF, FGF-19, FGF-2, FGF3, FGF-8, FGFR, FGFR-3, Fibrin, FL, FLIP, Flt-3, Flt-4, Follicle stimulating hormone, Fractalkine, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas 6, GCP-2, GCSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr-2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-2), GDF-7 (BMP-12, CDMP-3), GDF-8 (Myostatin), GDF-9, GDF-15 (MIC-1), GDNF, GDNF, GFAP, GFRa-1, GFR-alpha1, GFR-alpha2, GFR-alpha3, GITR, Glucagon, Glut 4, glycoprotein IIb/IIIa (GP IIb/IIIa), GM-CSF, gp130, gp72, GRO, Growth hormone releasing factor, Hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMV gB envelope glycoprotein, HCMV) gH envelope glycoprotein, HCMV UL, Hemopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2/neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV) gB glycoprotein, HSV gD glycoprotein, HGFA, High molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp 120 V3 loop, HLA, HLA-DR, HM1.24, HMFG PEM, HRG, Hrk, human cardiac myosin, human cytomegalovirus (HCMV), human growth hormone (HGH), HVEM, 1-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF binding proteins, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-18R, IL-23, interferon (INF)-alpha, INF-beta, INF-gamma, Inhibin, iNOS, Insulin A-chain, Insulin B-chain, Insulin-like growth factor 1, integrin alpha2, integrin alpha3, integrin alpha4, integrin alpha4/beta1, integrin, alpha4/beta7, integrin alpha5 (alphaV), integrin alpha5/beta1, integrin alpha5/beta3, integrin alpha6, integrin beta1, integrin beta2, interferon gamma, IP-10, 1-TAC, JE, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 15, Kallikrein LI, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), laminin 5, LAMP, LAP, LAP (TGF-1), Latent TGF-1, Latent TGF-1 bpl, LBP, LDGF, LECT2, Lefty, Lewis-Y antigen, Lewis-Y related antigen, LFA-1, LFA-3, Lfo, LIF, LIGHT, lipoproteins, LIX, LKN, Lptn, L-Selectin, LT-a, LT-b, LTB4, LTBP-1, Lung surfactant, Luteinizing hormone, Lymphotoxin Beta Receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCAM, MCK-2, MCP, M-CSF, MDC, Mer, METALLOPROTEASES, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP-1-alpha, MK, MMAC1, MMP, MMP-1, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3, MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Mucl), MUC18, Muellerian-inhibitin substance, Mug, MuSK, NAIP, NAP, NCAD, N-Cadherin, NCA 90, NCAM, NCAM, Neprilysin, Neurotrophin-3, -4, or -6, Neurturin, Neuronal growth factor (NGF), NGFR, NGF-beta, nNOS, NO, NOS, Npn, NRG-3, NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, Parathyroid hormone, PARC, PARP, PBR, PBSF, PCAD, P-Cadherin, PCNA, PDGF, PDGF, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), P1GF, PLP, PP14, Proinsulin, Prorelaxin, Protein C, PS, PSA, PSCA, prostate specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK, RANKL, RANTES, RANTES, Relaxin A-chain, Relaxin B-chain, renin, respiratory syncytial virus (RSV) F, RSV Fgp, Ret, Rheumatoid factors, RLIP76, RPA2, RSK, S100, SCF/KL, SDF-1, SERINE, Serum albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (tumor-associated glycoprotein-72), TARC, TCA-3, T-cell receptors (e.g., T-cell receptor alpha/beta), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, testicular PLAP-like alkaline phosphatase, TfR, TGF, TGF-alpha, TGF-beta, TGF-beta Pan Specific, TGF-beta RI (ALK-5), TGF-beta RII, TGF-beta RIIb, TGF-beta RIII, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta4, TGF-beta5, Thrombin, Thymus Ck-1, Thyroid stimulating hormone, Tie, TIMP, TIQ, Tissue Factor, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-alpha, TNF-alpha beta, TNF-beta2, TNFc, TNF-RI, TNF-RII, TNFRSF10A (TRAIL RI Apo-2, DR4), TNFRSFIOB (TRAIL R2 DR5, KILLER, TRICK-2A, TRICK-B), TNFRSF10C (TRAIL R3 DcR1, LIT, TRID), TNFRSF10D (TRAIL R4 DcR2, TRUNDD), TNFRSF11A (RANK ODF R, TRANCE R), TNFRSF11B (OPG OCIF, TR1), TNFRSF12 (TWEAK R FN14), TNFRSF13B (TACI), TNFRSF13C (BAFF R), TNFRSF14 (HVEM ATAR, HveA, LIGHT R, TR2), TNFRSF16 (NGFR p75NTR), TNFRSF17 (BCMA), TNFRSF18 (GITR AITR), TNFRSF19 (TROY TAJ, TRADE), TNFRSF19L (RELT), TNFRSFIA (TNF RI CD120a, p55-60), TNFRSFIB (TNF RII CD120b, p75-80), TNFRSF26 (TNFRH3), TNFRSF3 (LTbR TNF RIII, TNFC R), TNFRSF4 (OX40 ACT35, TXGP1 R), TNFRSF5 (CD40 p50), TNFRSF6 (Fas Apo-1, APT1, CD95), TNFRSF6B (DcR3 M68, TR6), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB CD137, ILA), TNFRSF21 (DR6), TNFRSF22 (DcTRAIL R2 TNFRH2), TNFRST23 (DcTRAIL RI TNFRH1), TNFRSF25 (DR3 Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10 (TRAIL Apo-2 Ligand, TL2), TNFSF11 (TRANCE/RANK Ligand ODF, OPG Ligand), TNFSF12 (TWEAK Apo-3 Ligand, DR3 Ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM Ligand, LTg), TNFSF15 (TL1A/VEGI), TNFSF18 (GITR Ligand AITR Ligand, TL6), TNFSFIA (TNF-a Conectin, DIF, TNFSF2), TNFSF1B (TNF-b LTa, TNFSF1), TNFSF3 (LTb TNFC, p33), TNFSF4 (OX40 Ligand gp34, TXGP1), TNFSF5 (CD40 Ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas Ligand Apo-1 Ligand, APT1 Ligand), TNFSF7 (CD27 Ligand CD70), TNFSF8 (CD30 Ligand CD153), TNFSF9 (4-1BB Ligand CD137 Ligand), TP-1, t-PA, Tpo, TRAIL, TRAIL R, TRAIL-R1, TRAIL-R2, TRANCE, transferring receptor, TRF, Trk, TROP-2, TSG, TSLP, tumor-associated antigen CA 125, tumor-associated antigen expressing Lewis Y related carbohydrate, TWEAK, TXB2, Ung, uPAR, uPAR-1, Urokinase, VCAM, VCAM-1, VECAD, VE-Cadherin, VE-cadherin-2, VEFGR-1 (fit-1), VEGF, VEGFR, VEGFR-3 (flt-4), VEGI, VIM, Viral antigens, VLA, VLA-1, VLA-4, VNR integrin, von Willebrands factor, WIF-1, WNT1, WNT2, WNT2B/13, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, XCL1, XCL2, XCR1, XCR1, XEDAR, XIAP, XPD, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3 (T cell immunoglobulin and mucin protein-3), receptors for hormones, and growth factors.</p><p id="p-0050" num="0049">Multispecifics comprising anti-CD3 antibodies and antigen-binding fragments disclosed herein may be prepared according to a variety of techniques including, but not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO J. 10: 3655 (1991)) &#x201c;knob-in-hole&#x201d; engineering (see, e.g., U.S. Pat. No. 5,731,168); immunoglobulin crossover (also known as Fab domain exchange or CrossMab format) technology (see e.g., WO2009/080253; Schaefer et al., Proc. Natl. Acad. Sci. USA, 108:11187-11192 (2011)); engineering electrostatic steering effects for antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); leucine zippers (see, e.g., Kostelny et al., J. Immunol, 148(5):1547-1553 (1992)); &#x201c;diabody&#x201d; technology (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); single-chain Fv (sFv) dimers (see, e.g. Gruber et al., J. Immunol, 152:5368 (1994)); and trispecific antibodies as described, e.g., in Tutt et al. J. Immunol 147: 60 (1991).</p><p id="p-0051" num="0050">The present disclosure also contemplates modification of anti-CD3 antibodies disclosed herein, such modifications comprising one or more amino acid substitutions, insertions and/or deletions in the FR and/or CDR regions of the heavy and light chain variable domains. Once obtained, such derivative antibodies and/or antigen-binding fragments can be tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved developability, etc.</p><p id="p-0052" num="0051">In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof comprise a heavy chain (HC) sequence, light chain (LC) sequence, CDRH3 sequence, CDRH2 sequence, CHRH1 sequence, CDRL3 sequence, CDRL2 sequence, CDRL1 sequence, and/or framework sequence. In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof have amino acid sequence identity to corresponding sequences of anti-CD3 antibodies disclosed in Table 4 (Ab1-Ab50) by at least about 100%, at least about 99%, at least about 98%, at least about 97%, at least about 96%, at least about 95%, at least about 94%, at least about 93%, at least about 92%, at least about 91%, at least about 90%, at least about 89%, at least about 88%, at least about 87%, at least about 86%, at about 85%, at least about 84%, at least about 83%, at least about 82%, at least about 80%; and/or all percentages of identity in between. In some embodiments, percent identity is measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or GAP.</p><p id="p-0053" num="0052">In some embodiments, residue positions that are not identical differ by conservative amino acid substitutions. A &#x201c;conservative amino acid substitution&#x201d; is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. (See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331). Examples of groups of amino acids that have side chains with similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate, and 7) sulfur-containing side chains: cysteine and methionine. In some embodiments, conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, in some embodiments, a conservative replacement comprises any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256: 1443 45. In some embodiments, a &#x201c;moderately conservative&#x201d; replacement comprises any change having a nonnegative value in a PAM250 log-likelihood matrix.</p><p id="p-0054" num="0053">Substitution of one or more CDR residues or omission of one or more CDRs is also possible. Antibodies have been described in which one or two CDRs can be dispensed to alter binding in the scientific literature. Padlan et al. (1995 FASEB J. 9:133-139) analyzed contact regions between antibodies and their antigens based on published crystal structures, and concluded that only about one fifth to one third of CDR residues actually contact their associated antigen. Padlan also found many antibodies in which one or two CDRs had zero amino acids in contact with an antigen (see also, Vajdos et al. 2002 <i>J Mol Biol </i>320:415-428). CDR residues not contacting an antigen can be identified based on previous studies (for example residues H60-H65 in CDRH2 are often not required), from regions of Kabat CDRs lying outside Chothia CDRs, by molecular modeling and/or empirically. If a CDR or residue(s) thereof is omitted, it is usually substituted with an amino acid occupying the corresponding position in another human antibody sequence or a consensus of such sequences. Positions for substitution within CDRs and amino acids to substitute can also be selected empirically.</p><p id="p-0055" num="0054">In certain embodiments, substitutions, insertions, or deletions may occur within one or more CDRs of anti-CD3 antibodies described herein so long as such alterations do not substantially reduce the ability of the antibody to bind its antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in CDRs. Such alterations may, for example, be outside of antigen contacting residues in the CDRs. In certain embodiments of the variant VH and VL sequences provided above, each CDR either is unaltered, or contains no more than one, two or three amino acid substitutions.</p><p id="p-0056" num="0055">A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called &#x201c;alanine scanning mutagenesis&#x201d; as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.</p><p id="p-0057" num="0056">Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of an antibody molecule include fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases serum half-life of the antibody.</p><p id="p-0058" num="0057">As described throughout, anti-CD3 antibodies and/or antigen-binding fragments thereof as provided herein possess favorable developability and are, thus, relatively developable.</p><p id="p-0059" num="0058">The term &#x201c;developable&#x201d; refers to the extent to which one or more polypeptides in a plurality of polypeptides possess desirable characteristics, such as, e.g., desirable expression, for example, in mammalian cells; solubility; viscosity; aggregation; chemical and/or physical stability; desirable shelf-life; melting temperature; pharmacokinetic profiles; circulation half-life; and clearance characteristics. Such characteristics may serve as indicia, independently, as combinations of sub-sets of such indicia, or in totality, for the likelihood that such one or more polypeptides may be successfully developed as a therapeutic candidate, and ultimately an approved drug. Accordingly, as understood in the art, generally, polypeptides with desirable developability characteristics possess, e.g., relatively high solubility, relatively low viscosity, relatively low propensity for aggregation, relatively high chemical stability, relatively high physical stability, relatively long shelf life, relatively high melting temperature, relatively long circulation half-life, relatively long clearance time, and the like. Polypeptides with undesirable developability characteristics possess, e.g., relatively low solubility, relatively high viscosity, relatively high propensity for aggregation, relatively poor chemical stability, relatively poor physical stability, relatively short shelf life, relatively low melting temperature, relatively short circulation half-life, relatively short clearance time, and the like.</p><p id="p-0060" num="0059">Methods and assays that may be employed to ascertain the degree to which polypeptides, such as anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein, possess desirable developability characteristics are available in the art, and include, for example; PSR assays (WO 2014/179363 and Xu et al., <i>Protein Eng Des Sol</i>, Vol. 26, pages 663-670 (2013)); SMP and SCP assays and the like; cross interaction chromatography (CIC); self-interaction chromatography (SIC); dynamic light scattering; size exclusion chromatography (SEC), dynamic light scattering (DLS) spectroscopy; photon correlation spectroscopy; quasi-elastic light scattering, circular dichroism (CD), viscosity measurements; whole cell binding; tissue micro array methodologies; BVP ELISA assays; AC-SINS assays (Liu et al; <i>MAbs</i>, Vol. 6, pages 483-492 (2014); differential scanning calorimetry; and the like (see, e.g., He et al., <i>J. Pharm. Sci., Vol. </i>100(4), pp. 1330-1340 (2011); Wagner et al., <i>Pharm. Develop</i>. &#x26; <i>Technol </i>(posted online 2012; hyper-text transfer protocol: informahealthcare.com/doi/abs/10.3109/10837450.2011.649851); Hotzel et al., <i>mAbs</i>, Vol. 4(6), pages 753-7601 (2012); Weiqiang et al., <i>J Pharm. Sci., Vol. </i>101(5), pp. 1701-1720 (2012); Banks et al., <i>J. Pharm. Sci</i>., Vol. 101(8), pp. 2720-2732 (2012); Lie et al., <i>J. Pharm. Sci</i>., Vol. 94(9), pp. 1928-1948 (2005); and Payne et al., <i>Biopolymers</i>, Vol. 85(5), pp. 527-533 (2006)).</p><p id="p-0061" num="0060">In some embodiments, antibodies that are identified as possessing decreased developability are so detected by virtue of their interaction with a polyspecificity reagent (&#x201c;PSR&#x201d;) and, as such, are referred to as &#x201c;polyspecific&#x201d; polypeptides. Such polyspecific antibodies may be referred to as relatively &#x201c;undevelopable&#x201d; or relatively &#x201c;non-developable&#x201d;.</p><p id="p-0062" num="0061">A &#x201c;developability profile&#x201d; refers to an index that may be assigned to antibodies upon assessing their developability. A developability profile is a measure or metric by which developability of anti-CD3 antibodies may be assessed, compared, and/or ranked. Such developability profiles serve as a measure of the degree of interaction of CD3 binders and antibodies comprising them. The degree of interaction may be assessed by any number of means available in the art that provides an output value that correlates with a strength or affinity of a polypeptide for a moiety to which it is bound. Exemplary means include flow cytometry means, such as FACS; ELISA; quantitative immunoaffinity assays or immunoprecipitation assays; mammalian two-hybrid or yeast two-hybrid assays, and the like. In the context of FACS, as demonstrated in the Examples, a degree of interaction between polypeptides in the plurality and the PSR may be ascertained by generating a mean fluorescence intensity (MFI) for each polypeptide-PSR interaction that is detected, and then ordering the MFI in either ascending or descending order, thereby ranking the polypeptides in the plurality according to the relative degree of interaction between each detected polypeptide and the PSR. Such a ranking provides for a ranking of polypeptides of the plurality such that those polypeptides possessing enhanced developability are readily ascertained, as are those polypeptides possessing decreased developability.</p><p id="p-0063" num="0062">A developability profile may also take the form of a normalized score, for example, by normalizing developability of anti-CD3 antibodies described herein to the developability of a standard (or control) antibody, e.g., anti-HEL antibody.</p><p id="p-0064" num="0063">In certain embodiments, inventive CD3 binding domains and antibodies comprising them may be further modified to contain additional nonproteinaceous moieties that are known in the art and are readily available. Moieties suitable for derivatization of an antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, polypropylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.</p><p id="p-0065" num="0064">In certain embodiments, the inventive CD3 binding domains and antibodies comprising them are provided which display an enhanced developability profile. The developability profile for anti-CD3 antibodies is obtained by performing one or more of a PSR assay; an SCP assay; AC-SINS; an ELISA; a DSF assay; a Tm assay; a HIC assay; a CIC assay; or combinations thereof.</p><p id="p-0066" num="0065">In other embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein display a poly-specificity reagent (PSR) score of between about 0.0 and about 0.45; between about 0.0 and about 0.4; between about 0.0 and about 0.35; between about 0.0 and about 0.3; between about 0.0 and about 0.25; between about 0.0 and about 0.2; between about 0.0 and about 0.15; or between about 0.0 and about 0.1. A score of 0.0-0.1 is &#x201c;clean PSR&#x201d;. A score of 0.1 to 0.33 is &#x201c;low PSR&#x201d;. A score of 0.33 to 0.66 is &#x201c;medium PSR&#x201d;. A score of 0.66-1.00 is &#x201c;high PSR&#x201d;. A high PSR score is indicative of decreased (or poor) developability. Generally, the lower the PSR score the more favorable the developability of the antibody.</p><p id="p-0067" num="0066">In still other embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein display a HIC score of less than about 10.5 minutes (a clean to low HIC score); between about 10.5 minutes and 11.5 minutes (a medium HIC score); or greater than about 11.5 minutes (a high HIC score). Generally, the lower the HIC score the more favorable the developability of the antibody.</p><p id="p-0068" num="0067">In yet other embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein display an SEC score of less than about 95%, which indicates that the antibody is a monomer, i.e., not aggregating.</p><p id="p-0069" num="0068">In still other embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein display a Tm of less than about 65&#xb0; C.</p><p id="p-0070" num="0069">In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein may be further modified to minimize effector function, e.g., a silent Fc.</p><p id="p-0071" num="0070">&#x201c;Effector function&#x201d; refers to biological activities attributable to the Fc region of an antibody, which varies by antibody isotype. Exemplary effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.</p><p id="p-0072" num="0071">&#x201c;Fc region&#x201d; is a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region, including native sequence Fc regions and variant Fc regions. A human IgG heavy chain Fc region can extend from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.</p><p id="p-0073" num="0072">In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an anti-CD3 antibody of the disclosure, thereby generating an Fc region variant (see e.g., US 2012/0251531). An Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.</p><p id="p-0074" num="0073">In certain embodiments, the disclosure contemplates an anti-CD3 antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half-life of an antibody in vivo is important, yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that an antibody lacks Fc&#x3b3;R binding (hence likely lacking ADCC activity) but retains FcRn binding ability. The primary cells for mediating ADCC (e.g. NK cells) express Fc&#x3b3;RIII only, whereas monocytes express Fc&#x3b3;RI, Fc&#x3b3;RII and Fc&#x3b3;RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be employed (see, for example, ACTI&#x2122; non-radioactive cytotoxicity assay for flow cytometry (Cell Technology, Inc. Mountain View, Calif.); and CytoTox 96&#xae; non-radioactive cytotoxicity assay (Promega, Madison, Wis.)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). C1q binding assays may also be carried out to confirm that an antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al. J. Immunol Methods 202:163 (1996); Cragg, M. S. et al. Blood. 101:1045-1052 (2003); and Cragg, M. S. and M. J. Glennie Blood. 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al. Int'l. Immunol 18(12):1759-1769 (2006)).</p><p id="p-0075" num="0074">In some embodiments, antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. Nos. 6,737,056 and 8,219,149). In some embodiments, Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called &#x201c;DANA&#x201d; Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. Nos. 7,332,581 and 8,219,149).</p><p id="p-0076" num="0075">In other embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein are further modified to include a masking agent, e.g., a polypeptide mask, attached via a cleavable linker.</p><p id="p-0077" num="0076">In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein are conjugated to a therapeutic moiety thereby forming an immunoconjugate. An &#x201c;immunoconjugate&#x201d; is an antibody conjugated to one or more heterologous molecule(s) such as, e.g., an antibiotic, a second anti-CD3 antibody, a vaccine, or a toxoid, or any other therapeutic moiety.</p><p id="p-0078" num="0077">In certain embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an anti-CD3 antibody of the disclosure may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.</p><p id="p-0079" num="0078">Moreover, the present disclosure generally relates to an anti-CD3 antibody or antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises: a. a variable heavy (VH) chain polypeptide comprising: i. a V<sub>H </sub>CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13); ii. a V<sub>H </sub>CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15); iii. a V<sub>H </sub>CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or b. a variable light (V<sub>L</sub>) chain polypeptide comprising: i. a V<sub>L </sub>CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8); a V<sub>L </sub>CDR2 (CDRL2) of WASTRX<sub>1</sub>S (SEQ ID NO: 133); and a V<sub>L </sub>CDR3 (CDRL3) of X<sub>2</sub>QSYFRRT (SEQ ID NO: 134); wherein X<sub>1 </sub>and X<sub>2 </sub>are each independently any amino acid. In some embodiments, X<sub>1 </sub>is E or S. In some embodiments, X<sub>2 </sub>is K or V. In some embodiments, said antibody or antigen-binding antibody fragment comprises a CDRL2 of SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, said antibody or antigen-binding antibody fragment comprises a CDRL3 of SEQ ID NO: 5 or SEQ ID NO: 4.</p><p id="p-0080" num="0079">In some embodiments, said antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13), a V<sub>H </sub>chain CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15), and a V<sub>H </sub>chain CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or a V<sub>L </sub>chain CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8), a V<sub>L </sub>chain CDR2 (CDRL2) of WASTRES (SEQ ID NO: 10), and a V<sub>L </sub>chain CDR3 (CDRL3) of KQSYFRRT (SEQ ID NO: 5). In some embodiments, said antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13), a V<sub>H </sub>chain CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15), and a V<sub>H </sub>chain CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or a V<sub>L </sub>chain CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8), a V<sub>L </sub>chain CDR2 (CDRL2) of WASTRSS (SEQ ID NO: 11), and a V<sub>L </sub>chain CDR3 (CDRL3) of VQSYFRRT (SEQ ID NO: 4). In some embodiments, the anti-CD3 antibody may comprise any one or more CDRs of the antibody referred to as Ab1 and/or any one or more CDRs of the antibody referred to as Ab13. In some embodiments the anti-CD3 antibody may bind to the same or a substantially similar epitope or epitopes of CD3 as Ab1 and/or Ab13.</p><p id="p-0081" num="0080">In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17.</p><p id="p-0082" num="0081">In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18; and a Vii chain comprising the amino acid sequence of SEQ ID NO: 17. In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment comprises a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 34; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17.</p><p id="p-0083" num="0082">In some embodiments, said anti-CD3 antibody or antigen-binding antibody fragment binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 500 pM or less, about 470 pM or less, about 450 pM or less, about 400 pM or less, about 350 pM or less, about 300 pM or less, about 250 pM or less, about 200 pM or less, about 150 pM or less, or about 100 pM or less, optionally wherein said CD3 is human and/or cynomolgus, further optionally wherein said binding affinity is measured by surface plasmon resonance. In some embodiments, said K<sub>D </sub>is a monovalent K<sub>D </sub>and/or wherein said K<sub>D </sub>is measured using an scFv fragment of said anti-CD3 antibody or antibody fragment.</p><p id="p-0084" num="0083">Moreover, the present disclosure generally relates to an anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises one or more CDRs of any one or more of Ab1-Ab50 and/or binds to the same epitope(s) as any one or more of Ab1-Ab50. Furthermore, the present disclosure generally relates to an anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises one or more V<sub>H </sub>and/or V<sub>L </sub>chains comprising an amino acid sequence selected from those in Table 4.</p><heading id="h-0008" level="2">Production of the Anti-CD3 Antibodies and Antigen-Binding Fragments Thereof</heading><p id="p-0085" num="0084">Anti-CD3 antibodies and/or antigen-binding fragments thereof may be produced using recombinant methods. For example, isolated nucleic acids encoding an anti-CD3 antibody as described herein is provided. Such nucleic acids may encode an amino acid sequence comprising the VL, and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acids are provided. In a further embodiment, a host cell comprising such nucleic acids is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid sequence that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-CD3 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).</p><p id="p-0086" num="0085">The term &#x201c;host cell&#x201d; refers to cells into which an exogenous nucleic acid sequence has been introduced, including the progeny of such cells. Host cells include transformants and transformed cells, which include the primary transformed cell and progeny derived therefrom without regard to the number of passages.</p><p id="p-0087" num="0086">For recombinant production of an anti-CD3 antibody, nucleic acids encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acids may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).</p><p id="p-0088" num="0087">Suitable host cells for cloning and/or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in <i>E. coli</i>.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been &#x201c;humanized,&#x201d; resulting in the production of an antibody with a partially or fully human glycosylation pattern. See, e.g., Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006); WO 2009/036379; WO 2010/105256; and WO 2012/009568. Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES&#x2122; technology for producing antibodies in transgenic plants). Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).</p><p id="p-0089" num="0088">Anti-CD3 antibodies and/or antigen-binding fragments thereof may be identified, screened for, selected for or characterized for their physical/chemical properties and/or biological activities by various assays known in the art, e.g., ELISA, Western blot, etc. or competition assays may be used to identify an antibody that competes with an anti-CD3 antibody of the invention for binding to CD3. In an exemplary competition assay, immobilized CD3 is incubated in a solution comprising a first labeled antibody that binds to CD3 and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to CD3. The second antibody may be present in a hybridoma supernatant. As a control, immobilized CD3 is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to CD3, excess unbound antibody is removed, and the amount of label associated with immobilized CD3 is measured. If the amount of label associated with immobilized CD3 is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to CD3. See, e.g., Harlow and Lane (1988) Antibodies: A Laboratory Manual. Ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).</p><p id="p-0090" num="0089">Anti-CD3 antibodies and/or antigen-binding fragments thereof possessing biological activity may be identified using standard approaches. Biological activity may include, e.g., binding to CD3 on the surface of a T cell, either in vivo, in vitro, or ex vivo. In the case of a multispecific anti-CD3 antibody (such as a bispecific antibody with one arm that binds to CD3 and another arm that binds to a different target, e.g., a cell surface antigen, e.g., a tumor antigen), biological activity may also include effector cell activation (such as CD8+ and/or CD4+ T cell activation), effector cell population expansion (i.e., an increase in T cell count), target cell population reduction (i.e., a decrease in the population of cells expressing the second biological molecule on their cell surfaces), and/or target cell killing.</p><heading id="h-0009" level="2">Diagnostic and Therapeutic Uses for the Anti-CD3 Antibodies and Antigen-Binding Fragments Thereof</heading><p id="p-0091" num="0090">Anti-CD3 antibodies and/or antigen-binding fragments described herein may be used for diagnosis and/or detection. &#x201c;Detection&#x201d; as used herein encompasses quantitative or qualitative detection. In one embodiment, a method of detecting the presence of CD3 in a biological sample is provided. Such method comprises (i) contacting the biological sample with an anti-CD3 antibody as described herein under conditions permissive for binding of the anti-CD3 antibody to CD3, and (ii) detecting whether a complex is formed between the anti-CD3 antibody and CD3. Such method may be an in vitro or in vivo method. In certain embodiments, the biological sample comprises a cell or tissue(s).</p><p id="p-0092" num="0091">In certain embodiments, labeled anti-CD3 antibodies are provided. The anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein include a label or moiety that is detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels or indirectly (such as enzymes or ligands). Non-limiting exemplary labels include, radioisotopes such as 32P, 14C, 125I, 3H, and 131I; fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, &#x3b2;-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase; heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase; biotin/avidin; spin labels; bacteriophage labels; stable free radicals; and the like.</p><p id="p-0093" num="0092">CD3 antibodies and/or antigen-binding fragments thereof as described herein, as well as pharmaceutical compositions of such antibodies, may be used in therapeutic methods. In one embodiment, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein, or pharmaceutical compositions comprising such antibodies, may be used for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder.</p><p id="p-0094" num="0093">A &#x201c;disorder&#x201d; refers to any condition or disease that would benefit from treatment including, but not limited to, chronic and acute disorders or diseases including those pathological conditions which predispose a mammal to the disorder in question.</p><p id="p-0095" num="0094">The terms &#x201c;cell proliferative disorder&#x201d; and &#x201c;proliferative disorder&#x201d; refer to disorders that are associated with some degree of abnormal cell proliferation. Cell proliferative disorders include cancer, e.g., a tumor.</p><p id="p-0096" num="0095">&#x201c;Tumor&#x201d; as used herein refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.</p><p id="p-0097" num="0096">&#x201c;Cancer&#x201d; refers to a physiological condition in mammals characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies; with more particular examples including squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer and gastrointestinal stromal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, superficial spreading melanoma, lentigo maligna melanoma, acral lentiginous melanomas, nodular melanomas, multiple myeloma and B-cell lymphoma (including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia); chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), Meigs' syndrome, brain, as well as head and neck cancer, and associated metastases. In certain embodiments, cancers that are amenable to treatment by antibodies of the disclosure include breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, glioblastoma, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma, kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, ovarian cancer, mesothelioma, and multiple myeloma. In some embodiments, the cancer is selected from: small cell lung cancer, gliblastoma, neuroblastomas, melanoma, breast carcinoma, gastric cancer, colorectal cancer (CRC), and hepatocellular carcinoma. Yet, in some embodiments, the cancer is selected from: non-small cell lung cancer, colorectal cancer, glioblastoma and breast carcinoma, including metastatic forms of those cancers. In other embodiments, the cancer is selected from a class of mature B-Cell cancers excluding Hodgkin's Lymphoma but including germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenstrom macroglobulinemia, Heavy chain diseases, a Heavy chain disease, &#x3b3; Heavy chain disease, &#x3bc; Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.</p><p id="p-0098" num="0097">As used herein, &#x201c;treatment&#x201d; or &#x201c;treat&#x201d; or &#x201c;treating&#x201d; refer to clinical intervention in an attempt to alter the natural course of an individual being treated and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.</p><p id="p-0099" num="0098">As used herein, the terms &#x201c;prevent,&#x201d; &#x201c;preventing,&#x201d; and &#x201c;prevention&#x201d; refer to the prevention or inhibition of the development or onset of a disorder or disease.</p><p id="p-0100" num="0099">As used herein, the terms &#x201c;ameliorate&#x201d; and &#x201c;alleviate&#x201d; refer to a reduction or diminishment in the severity a condition or any symptoms thereof.</p><p id="p-0101" num="0100">In some embodiments, antibodies of the invention are used to delay development of a disorder or disease or to delay the progression of a disorder or disease. As used herein, &#x201c;delaying progression&#x201d; of a disorder or disease means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or disorder (e.g., a cell proliferative disorder, e.g., cancer). The delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated.</p><p id="p-0102" num="0101">An effective amount of such antibody or composition may be administered to an individual suffering from cancer or arthritis, rheumatoid arthritis, colitis, inflammatory bowel disease, autoimmune type I diabetes, etc. An &#x201c;effective amount&#x201d; of an anti-CD3 antibody disclosed herein or a composition (e.g., pharmaceutical composition) comprising such antibody, is at least the minimum amount required to achieve the desired therapeutic or prophylactic result, e.g., a measurable improvement or prevention of a particular disorder, e.g., a cell proliferative disorder, e.g., cancer, preferably with minimal or no toxic or detrimental effects. An effective amount may vary according to inter alia disease state, age, sex, and weight of the patient, and the ability of the antibody (or antigen-binding fragment thereof) to elicit a desired response in the individual and, in some instances, by co-administering one or more additional therapeutic agents.</p><p id="p-0103" num="0102">In some embodiments, anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein may be used to enhance immune function in an individual having a cell proliferative disorder or an autoimmune disorder. Following administration, such antibody or composition may enhance immune function in an individual having a cell proliferative disorder or an autoimmune disorder by activating effector cells (e.g., T cells, e.g., CD8+ and/or CD4+ T cells including Tregs), expanding (increasing) the effector cell population, reducing the population of target cells (e.g., a cell expressing a second biological molecule recognized by an anti-CD3 antibody of the invention, such as a bispecific antibody), and/or killing a target cell (e.g., target tumor cell).</p><p id="p-0104" num="0103">Anti-CD3 antibodies and/or antigen-binding fragments thereof as disclosed herein may be used to treat disorders including, but not limited to, a proliferative disorder, an oncological disorder, an immune-oncological disorder, a neurological disorder, a cognitive disorder, a neurodegenerative disorder, an autoimmune disorder. In one embodiment, an effective amount of such anti-CD3 antibody may be administered, alone or in combination with at least one additional agent, to an individual having such disorder. Such &#x201c;individual&#x201d; may be a mammal and, in particular, a human.</p><p id="p-0105" num="0104">Non-limiting exemplary additional therapeutic agents include a chemotherapy agent, an antibody-drug conjugate (ADC), and/or a biological modifier. Chemotherapy agents may be selected from cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). ADC may be selected from an anti-CD79b antibody drug conjugate (such as anti-CD79b-MC-vc-PAB-MMAE or the anti-CD79b antibody drug conjugate described in any one of U.S. Pat. No. 8,088,378 and/or US 2014/0030280, or polatuzumab vedotin), an anti-CD19 antibody drug conjugate, an anti-CD22 antibody drug conjugate, an anti-CD45 antibody drug conjugate, and an anti-CD32 drug conjugate. A biological modifier may be selected from a BCL-2 inhibitor (such as GDC-0199/ABT-199), lenalidomide (Revlimid&#xae;), a PI3K-delta inhibitor (such as idelalisib (Zydelig&#xae;)), a PD-1 axis binding antagonist, an agonist, e.g., agonist antibody, directed against an activating co-stimulatory molecule, e.g., CD40, CD226, CD28, OX40 (e.g., AgonOX), GITR, CD137 (also known as TNFRSF9, 4-1 BB, or ILA), CD27 (e.g., CDX-1127), HVEM, or CD127, an antagonist, e.g., antagonist antibody, directed against an inhibitory co-stimulatory molecule, e.g., CTLA-4 (also known as CD152), PD-1, TIM-3, BTLA, VISTA, LAG-3, B7-H3, B7-H4, IDO (e.g., 1-methyl-D-tryptophan (also known as 1-D-MT)), TIGIT, MICA/B, GITR (e.g., TRX518) or arginase, ipilimumab (also known as MDX-010, MDX-101, or Yervoy&#xae;), tremelimumab (also known as ticilimumab or CP-675,206, urelumab (also known as BMS-663513), MGA271, an antagonist directed against a TGF beta, e.g., metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), LY2157299k, and an adoptive transfer of a T cell (e.g., a cytotoxic T cell or CTL) expressing a chimeric antigen receptor (CAR), e.g., adoptive transfer of a T cell comprising a dominant-negative TGF beta receptor, e.g, a dominant-negative TGF beta type II receptor.</p><p id="p-0106" num="0105">Anti-CD3 antibodies and/or antigen-binding fragments thereof as disclosed herein may be used to enhancing immune function in an individual, e.g., a human, having a disorder in an individual having such disorder. In one embodiment, a method of enhancing immune function comprises administering to an individual an effective amount of an anti-CD3 antibody to activate effector cells (e.g., T cells, e.g., CD8+ and/or CD4+ T cells), expand (increase) an effector cell population, reduce a target cell population, and/or kill a target cell (e.g., target tumor cell).</p><p id="p-0107" num="0106">In a further aspect, pharmaceutical formulations comprising anti-CD3 antibodies and/or antigen-binding fragments as described herein are also provided, e.g., for use in any of the above therapeutic methods. A &#x201c;pharmaceutical formulation&#x201d; refers to a preparation in such form as to permit the biological activity of an active ingredient contained therein, such as the anti-CD3 antibodies described herein, to be effective, and which preferably contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.</p><p id="p-0108" num="0107">In one embodiment, a pharmaceutical formulation comprises any of the anti-CD3 antibodies disclosed herein and a pharmaceutically acceptable carrier. A &#x201c;pharmaceutically acceptable carrier&#x201d; refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. In another embodiment, a pharmaceutical formulation comprises any of the anti-CD3 antibodies provided herein and at least one additional therapeutic agent.</p><p id="p-0109" num="0108">Antibodies of the disclosure can be used either alone or in combination with other agents in a therapy, e.g., an anti-CD3 antibody and/or antigen-binding fragment thereof may be co-administered with at least one additional therapeutic agent. In certain embodiments, an additional therapeutic agent is a chemotherapeutic agent, growth inhibitory agent, cytotoxic agent, agent used in radiation therapy, anti-angiogenesis agent, apoptotic agent, anti-tubulin agent, or other agent, such as a epidermal growth factor receptor (EGFR) antagonist (e.g., a tyrosine kinase inhibitor), HER1/EGFR inhibitor (e.g., erlotinib (Tarceva&#x2122;)), platelet derived growth factor inhibitor (e.g., Gleevec&#x2122; (Imatinib Mesylate)), a COX-2 inhibitor (e.g., celecoxib), interferon, cytokine, antibody other than the anti-CD3 antibody of the invention, such as an antibody that bind to one or more of the following targets ErbB2, ErbB3, ErbB4, PDGFR-beta, BIyS, APRIL, BCMA VEGF, or VEGF receptor(s), TRAIL/Apo2, PD-1, PD-L1, PD-L2, or another bioactive or organic chemical agent.</p><p id="p-0110" num="0109">In some embodiments, the disclosure provides a method wherein the additional therapeutic agent is a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone.</p><p id="p-0111" num="0110">Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of an antibody of the disclosure can occur prior to, simultaneously, and/or following, administration of additional therapeutic agent or agents. In one embodiment, administration of an anti-CD3 antibody and administration of an additional therapeutic agent occur within about one month, or within about one, two or three weeks, or within about one, two, three, four, five, or six days, of each other. Anti-CD3 antibodies of the disclosure (e.g., bispecific anti-CD3 antibodies of the invention that bind to CD3 and a second biological molecule, e.g., a cell surface antigen, e.g., a tumor antigen, such as a TDB antibody of the invention or variant thereof) can also be used in combination with radiation therapy.</p><p id="p-0112" num="0111">An antibody of the disclosure (and/or any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, the antibody is administered by subcutaneous administration. In some embodiments, an anti-CD3 antibody administered by subcutaneous injection exhibits a less toxic response in a patient than the same anti-CD3 antibody administered by intravenous injection. Dosing can be by any suitable route, for example, by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.</p><p id="p-0113" num="0112">Antibodies of the disclosure would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need not, but may optionally be, formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.</p><p id="p-0114" num="0113">For the prevention or treatment of disease, the appropriate dosage of an antibody of the disclosure (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments.</p><p id="p-0115" num="0114">As a general proposition, a therapeutically effective amount of the anti-CD3 antibody administered to human will be in the range of about 0.01 to about 100 mg/kg of patient body weight whether by one or more administrations. In some embodiments, an antibody used is administered in about 0.01 to about 45 mg/kg, about 0.01 to about 40 mg/kg, about 0.01 to about 35 mg/kg, about 0.01 to about 30 mg/kg, about 0.01 to about 25 mg/kg, about 0.01 to about 20 mg/kg, about 0.01 to about 15 mg/kg, about 0.01 to about 10 mg/kg, about 0.01 to about 5 mg/kg, or about 0.01 to about 1 mg/kg daily, for example. In one embodiment, an anti-CD3 antibody described herein is administered to a human at a dose of about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg or about 1400 mg on day 1 of 21-day cycles. The dose may be administered as a single dose or as multiple doses (e.g., 2 or 3 doses), such as infusions. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg, or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, for example, every week or every three weeks (e.g., such that the patient receives from about two to about twenty, or, for example, about six doses of the anti-CD3 antibody). An initial higher loading dose, followed by one or more lower doses, may be administered. The progress of this therapy is easily monitored by conventional techniques and assays.</p><p id="p-0116" num="0115">In some embodiments, methods of the disclosure may further comprise an additional therapy. The additional therapy may be radiation therapy, surgery, chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow transplantation, nanotherapy, monoclonal antibody therapy, or a combination of the foregoing. The additional therapy may be in the form of adjuvant or neoadjuvant therapy. In some embodiments, the additional therapy is the administration of small molecule enzymatic inhibitor or anti-metastatic agent. In some embodiments, the additional therapy is the administration of side-effect limiting agents (e.g., agents intended to lessen the occurrence and/or severity of side effects of treatment, such as anti-nausea agents, etc.). In some embodiments, the additional therapy is radiation therapy. In some embodiments, the additional therapy is surgery. In some embodiments, the additional therapy is a combination of radiation therapy and surgery. In some embodiments, the additional therapy is gamma irradiation. In some embodiments, the additional therapy may be a separate administration of one or more of the therapeutic agents described above.</p><p id="p-0117" num="0116">In another aspect of the disclosure, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.</p><p id="p-0118" num="0117">Accordingly, manufacture and/or preparation of a pharmaceutical composition comprising anti-CD3 antibodies and/or antigen-binding fragments as disclosed herein is also contemplated. The composition may be used alone or in combination with other active agents to treat a cell proliferative disorder (e.g., cancer) or an autoimmune disorder (e.g., arthritis, rheumatoid arthritis, colitis, inflammatory bowel disease, autoimmune type I diabetes, etc.).</p><p id="p-0119" num="0118">In some embodiments, pharmaceutical compositions comprising anti-CD3 antibodies and/or antigen-binding fragments thereof as described herein are prepared, e.g., by mixing such an antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions, optionally prepared for modified (e.g., sustained) release. Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.</p><p id="p-0120" num="0119">Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX&#xae;, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968.</p><p id="p-0121" num="0120">Such formulations may contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other and present in amounts that are effective for the purpose intended. For example, it may be desirable to further provide an additional therapeutic agent (e.g., a chemotherapeutic agent, a cytotoxic agent, a growth inhibitory agent, and/or an anti-hormonal agent).</p><p id="p-0122" num="0121">Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).</p><heading id="h-0010" level="1">Examples</heading><p id="p-0123" num="0122"></p><p id="p-0124" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Binding data for exemplary high affinity anti-</entry></row><row><entry>CD3 antibodies in a bispecific format.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><tbody valign="top"><row><entry/><entry>Biacore K<sub>D</sub></entry><entry>Cell Binding</entry><entry>Cell Binding</entry></row><row><entry/><entry>Biotinylated</entry><entry>Human CD3+</entry><entry>Cyno CD3+</entry></row><row><entry/><entry>Human CD3 &#x3b5;&#x3b4;</entry><entry>Jurkat Fold Over</entry><entry>Jurkat Fold Over</entry></row><row><entry/><entry>Fc (M)</entry><entry>Background</entry><entry>Background</entry></row><row><entry>Antibody</entry><entry>Monovalent</entry><entry>(FOB)</entry><entry>(FOB)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="63pt" align="char" char="."/><colspec colname="4" colwidth="56pt" align="char" char="."/><tbody valign="top"><row><entry>ADI-42594</entry><entry>4.7E&#x2212;10</entry><entry>14</entry><entry>16</entry></row><row><entry>ADI-46357</entry><entry>2.5E&#x2212;10</entry><entry>13</entry><entry>20</entry></row><row><entry>ADI-46359</entry><entry>2.2E&#x2212;10</entry><entry>15</entry><entry>28</entry></row><row><entry>ADI-46366</entry><entry>2.3E&#x2212;10</entry><entry>16</entry><entry>32</entry></row><row><entry>ADI-46378</entry><entry>1.2E&#x2212;10</entry><entry>17</entry><entry>30</entry></row><row><entry>ADI-45959</entry><entry>1.2E&#x2212;10</entry><entry>18</entry><entry>30</entry></row><row><entry>ADI-45975</entry><entry>2.1E&#x2212;10</entry><entry>10</entry><entry>17</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0125" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="294pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Developability profile of anti-CD3 antibodies in a bispecific format.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="offset" colwidth="42pt" align="left"/><colspec colname="1" colwidth="49pt" align="center"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry>scFv-Fc or IgG</entry><entry>scFv-Fc or IgG</entry><entry>Cell</entry><entry>Cell</entry><entry/><entry>HIC</entry><entry>SEC-HPLC</entry></row><row><entry/><entry>K<sub>D </sub>Human</entry><entry>K<sub>D </sub>Cyno</entry><entry>Binding</entry><entry>Binding</entry><entry>PSR</entry><entry>Retention</entry><entry>%</entry></row><row><entry/><entry>CD3<sub>&#x3b5;</sub>&#x3b4;-Fc</entry><entry>CD3<sub>&#x3b5;</sub>&#x3b4;-Fc</entry><entry>hCD3</entry><entry>cCD3</entry><entry>Score</entry><entry>Time</entry><entry>monomer</entry></row><row><entry/><entry>(M)</entry><entry>(M)</entry><entry>(FOB)</entry><entry>(FOB)</entry><entry>(0-1)</entry><entry>(min)</entry><entry>ProA</entry></row><row><entry/><entry namest="offset" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="49pt" align="center"/><colspec colname="3" colwidth="49pt" align="center"/><colspec colname="4" colwidth="28pt" align="char" char="."/><colspec colname="5" colwidth="28pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="35pt" align="char" char="."/><colspec colname="8" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>ADI-42594</entry><entry>2.0E&#x2212;10</entry><entry>2.0E&#x2212;09</entry><entry>36</entry><entry>122</entry><entry>0.21</entry><entry>8.8</entry><entry>98.7</entry></row><row><entry>ADI-42596</entry><entry>1.6E&#x2212;10</entry><entry>2.4E&#x2212;09</entry><entry>29</entry><entry>46</entry><entry>0.40</entry><entry>8.8</entry><entry>99.8</entry></row><row><entry>ADI-45959</entry><entry>1.3E&#x2212;10</entry><entry>1.7E&#x2212;09</entry><entry>19</entry><entry>112</entry><entry>0.19</entry><entry>9.5</entry><entry>99.5</entry></row><row><entry>ADI-45960</entry><entry>1.4E&#x2212;10</entry><entry>1.8E&#x2212;09</entry><entry>63</entry><entry>58</entry><entry>0.20</entry><entry>8.9</entry><entry>93.9</entry></row><row><entry>ADI-45961</entry><entry>2.3E&#x2212;10</entry><entry>3.0E&#x2212;09</entry><entry>18</entry><entry>30</entry><entry>0.16</entry><entry>8.8</entry><entry>98.7</entry></row><row><entry>ADI-45962</entry><entry>1.4E&#x2212;10</entry><entry>1.4E&#x2212;09</entry><entry>18</entry><entry>46</entry><entry>0.15</entry><entry>8.9</entry><entry>99.2</entry></row><row><entry>ADI-45963</entry><entry>6.9E&#x2212;11</entry><entry>2.1E&#x2212;09</entry><entry>14</entry><entry>69</entry><entry>0.26</entry><entry>8.9</entry><entry>93.8</entry></row><row><entry>ADI-45964</entry><entry>9.7E&#x2212;11</entry><entry>2.0E&#x2212;09</entry><entry>56</entry><entry>63</entry><entry>0.28</entry><entry>8.8</entry><entry>93.6</entry></row><row><entry>ADI-45965</entry><entry>6.5E&#x2212;11</entry><entry>1.4E&#x2212;09</entry><entry>33</entry><entry>124</entry><entry>0.24</entry><entry>9.6</entry><entry>99.4</entry></row><row><entry>ADI-45966</entry><entry>6.1E&#x2212;11</entry><entry>1.2E&#x2212;09</entry><entry>14</entry><entry>27</entry><entry>0.26</entry><entry>9.5</entry><entry>99.3</entry></row><row><entry>ADI-45967</entry><entry>7.6E&#x2212;11</entry><entry>1.4E&#x2212;09</entry><entry>40</entry><entry>59</entry><entry>0.18</entry><entry>9.5</entry><entry>99.4</entry></row><row><entry>ADI-45968</entry><entry>6.8E&#x2212;11</entry><entry>1.4E&#x2212;09</entry><entry>16</entry><entry>18</entry><entry>0.24</entry><entry>9.5</entry><entry>99.3</entry></row><row><entry>ADI-45969</entry><entry>6.0E&#x2212;11</entry><entry>1.5E&#x2212;09</entry><entry>28</entry><entry>63</entry><entry>0.24</entry><entry>8.9</entry><entry>96.5</entry></row><row><entry>ADI-45970</entry><entry>1.5E&#x2212;10</entry><entry>1.6E&#x2212;09</entry><entry>53</entry><entry>68</entry><entry>0.20</entry><entry>8.9</entry><entry>99.2</entry></row><row><entry>ADI-45971</entry><entry>1.1E&#x2212;10</entry><entry>1.9E&#x2212;09</entry><entry>21</entry><entry>20</entry><entry>0.30</entry><entry>8.8</entry><entry>99.4</entry></row><row><entry>ADI-45972</entry><entry>8.1E&#x2212;11</entry><entry>1.4E&#x2212;09</entry><entry>32</entry><entry>45</entry><entry>0.17</entry><entry>9.5</entry><entry>99.2</entry></row><row><entry>ADI-45973</entry><entry>1.6E&#x2212;10</entry><entry>1.8E&#x2212;09</entry><entry>55</entry><entry>91</entry><entry>0.15</entry><entry>8.9</entry><entry>97.7</entry></row><row><entry>ADI-45974</entry><entry>1.9E&#x2212;10</entry><entry>2.1E&#x2212;09</entry><entry>47</entry><entry>67</entry><entry>0.28</entry><entry>8.9</entry><entry>99.4</entry></row><row><entry>ADI-45975</entry><entry>6.7E&#x2212;11</entry><entry>1.4E&#x2212;09</entry><entry>86</entry><entry>142</entry><entry>0.32</entry><entry>8.8</entry><entry>99.6</entry></row><row><entry>ADI-45976</entry><entry>1.2E&#x2212;10</entry><entry>1.8E&#x2212;09</entry><entry>45</entry><entry>109</entry><entry>0.19</entry><entry>11.4</entry><entry>99.4</entry></row><row><entry>ADI-45977</entry><entry>9.1E&#x2212;11</entry><entry>1.1E&#x2212;09</entry><entry>59</entry><entry>159</entry><entry>0.23</entry><entry>8.9</entry><entry>99.5</entry></row><row><entry>ADI-45978</entry><entry>7.4E&#x2212;11</entry><entry>1.2E&#x2212;09</entry><entry>25</entry><entry>37</entry><entry>0.26</entry><entry>9.5</entry><entry>99.7</entry></row><row><entry>ADI-45979</entry><entry>1.9E&#x2212;10</entry><entry>1.7E&#x2212;09</entry><entry>54</entry><entry>72</entry><entry>0.17</entry><entry>8.9</entry><entry>99.6</entry></row><row><entry>ADI-45980</entry><entry>8.0E&#x2212;11</entry><entry>1.2E&#x2212;09</entry><entry>8</entry><entry>85</entry><entry>0.22</entry><entry>9.5</entry><entry>99.7</entry></row><row><entry>ADI-45981</entry><entry>8.9E&#x2212;11</entry><entry>1.6E&#x2212;09</entry><entry>33</entry><entry>78</entry><entry>0.25</entry><entry>8.9</entry><entry>99.7</entry></row><row><entry>ADI-45982</entry><entry>1.2E&#x2212;10</entry><entry>1.4E&#x2212;09</entry><entry>24</entry><entry>31</entry><entry>0.21</entry><entry>9.0</entry><entry>99.2</entry></row><row><entry>ADI-45983</entry><entry>2.3E&#x2212;10</entry><entry>2.0E&#x2212;09</entry><entry>24</entry><entry>101</entry><entry>0.16</entry><entry>10.9</entry><entry>99.2</entry></row><row><entry>ADI-45984</entry><entry>9.5E&#x2212;11</entry><entry>1.3E&#x2212;09</entry><entry>88</entry><entry>92</entry><entry>0.29</entry><entry>9.5</entry><entry>100.0</entry></row><row><entry>ADI-45985</entry><entry>8.0E&#x2212;11</entry><entry>1.2E&#x2212;09</entry><entry>21</entry><entry>23</entry><entry>0.21</entry><entry>10.5</entry><entry>99.5</entry></row><row><entry>ADI-42596</entry><entry>1.1E&#x2212;09</entry><entry>N.A.</entry><entry>11</entry><entry>81</entry><entry>0.36</entry><entry>8.9</entry><entry>99.7</entry></row><row><entry>ADI-46356</entry><entry>9.8E&#x2212;10</entry><entry>N.A.</entry><entry>39</entry><entry>59</entry><entry>0.20</entry><entry>10.9</entry><entry>98.5</entry></row><row><entry>ADI-46357</entry><entry>9.7E&#x2212;10</entry><entry>N.A.</entry><entry>24</entry><entry>80</entry><entry>0.21</entry><entry>8.9</entry><entry>94.4</entry></row><row><entry>ADI-46358</entry><entry>9.9E&#x2212;10</entry><entry>N.A.</entry><entry>35</entry><entry>82</entry><entry>0.21</entry><entry>9.5</entry><entry>98.8</entry></row><row><entry>ADI-46359</entry><entry>8.9E&#x2212;10</entry><entry>N.A.</entry><entry>43</entry><entry>102</entry><entry>0.26</entry><entry>9.0</entry><entry>98.4</entry></row><row><entry>ADI-46360</entry><entry>9.7E&#x2212;10</entry><entry>N.A.</entry><entry>40</entry><entry>106</entry><entry>0.20</entry><entry>9.0</entry><entry>99.5</entry></row><row><entry>ADI-46361</entry><entry>9.3E&#x2212;10</entry><entry>N.A.</entry><entry>23</entry><entry>84</entry><entry>0.21</entry><entry>9.5</entry><entry>98.9</entry></row><row><entry>ADI-46362</entry><entry>8.0E&#x2212;10</entry><entry>N.A.</entry><entry>7</entry><entry>95</entry><entry>0.21</entry><entry>8.9</entry><entry>99.1</entry></row><row><entry>ADI-46363</entry><entry>9.3E&#x2212;10</entry><entry>N.A.</entry><entry>49</entry><entry>129</entry><entry>0.20</entry><entry>9.5</entry><entry>98.6</entry></row><row><entry>ADI-46364</entry><entry>9.7E&#x2212;10</entry><entry>N.A.</entry><entry>33</entry><entry>63</entry><entry>0.18</entry><entry>9.5</entry><entry>99.4</entry></row><row><entry>ADI-46365</entry><entry>1.0E&#x2212;09</entry><entry>N.A.</entry><entry>36</entry><entry>84</entry><entry>0.16</entry><entry>10.1</entry><entry>99.4</entry></row><row><entry>ADI-46366</entry><entry>9.3E&#x2212;10</entry><entry>N.A.</entry><entry>43</entry><entry>108</entry><entry>0.20</entry><entry>9.0</entry><entry>98.5</entry></row><row><entry>ADI-46367</entry><entry>9.5E&#x2212;10</entry><entry>N.A.</entry><entry>8</entry><entry>62</entry><entry>0.21</entry><entry>8.9</entry><entry>94.8</entry></row><row><entry>ADI-46369</entry><entry>9.2E&#x2212;10</entry><entry>N.A.</entry><entry>33</entry><entry>71</entry><entry>0.17</entry><entry>9.5</entry><entry>98.6</entry></row><row><entry>ADI-46370</entry><entry>1.0E&#x2212;09</entry><entry>N.A.</entry><entry>40</entry><entry>46</entry><entry>0.20</entry><entry>8.9</entry><entry>98.8</entry></row><row><entry>ADI-46371</entry><entry>8.6E&#x2212;10</entry><entry>N.A.</entry><entry>47</entry><entry>121</entry><entry>0.22</entry><entry>8.9</entry><entry>98.9</entry></row><row><entry>ADI-46372</entry><entry>1.1E&#x2212;09</entry><entry>N.A.</entry><entry>14</entry><entry>80</entry><entry>0.16</entry><entry>10.3</entry><entry>99.2</entry></row><row><entry>ADI-46374</entry><entry>8.4E&#x2212;10</entry><entry>N.A.</entry><entry>37</entry><entry>29</entry><entry>0.22</entry><entry>9.5</entry><entry>94.4</entry></row><row><entry>ADI-46375</entry><entry>8.6E&#x2212;10</entry><entry>N.A.</entry><entry>48</entry><entry>40</entry><entry>0.25</entry><entry>9.5</entry><entry>99.7</entry></row><row><entry>ADI-46376</entry><entry>1.0E&#x2212;09</entry><entry>N.A.</entry><entry>4</entry><entry>96</entry><entry>0.20</entry><entry>9.5</entry><entry>99.1</entry></row><row><entry>ADI-46378</entry><entry>9.2E&#x2212;10</entry><entry>N.A.</entry><entry>22</entry><entry>91</entry><entry>0.31</entry><entry>9.5</entry><entry>98.8</entry></row><row><entry>ADI-46379</entry><entry>1.0E&#x2212;09</entry><entry>N.A.</entry><entry>43</entry><entry>105</entry><entry>0.21</entry><entry>9.5</entry><entry>99.5</entry></row><row><entry>ADI-46381</entry><entry>7.2E&#x2212;10</entry><entry>N.A.</entry><entry>71</entry><entry>174</entry><entry>0.18</entry><entry>0.0</entry><entry>99.6</entry></row><row><entry>ADI-26140</entry><entry>N.B.</entry><entry>N.B.</entry><entry>5</entry><entry>6</entry><entry>N.A.</entry><entry/><entry>N.A.</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0126" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Thermostability measurements for exemplary anti-CD3 antibodies.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="133pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>scFv-Fc Tm DSF</entry></row><row><entry/><entry>ADI Name</entry><entry>(&#xb0; C.)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>ADI-42594</entry><entry>66.0</entry></row><row><entry/><entry>ADI-42596</entry><entry>66.0</entry></row><row><entry/><entry>ADI-46356</entry><entry>62.0</entry></row><row><entry/><entry>ADI-46357</entry><entry>66.5</entry></row><row><entry/><entry>ADI-46358</entry><entry>62.0</entry></row><row><entry/><entry>ADI-46359</entry><entry>62.5</entry></row><row><entry/><entry>ADI-46360</entry><entry>52.5</entry></row><row><entry/><entry>ADI-46361</entry><entry>58.5</entry></row><row><entry/><entry>ADI-46362</entry><entry>59.0</entry></row><row><entry/><entry>ADI-46363</entry><entry>58.5</entry></row><row><entry/><entry>ADI-46364</entry><entry>58.0</entry></row><row><entry/><entry>ADI-46365</entry><entry>58.5</entry></row><row><entry/><entry>ADI-46366</entry><entry>63.5</entry></row><row><entry/><entry>ADI-46367</entry><entry>66.5</entry></row><row><entry/><entry>ADI-46369</entry><entry>62.5</entry></row><row><entry/><entry>ADI-46370</entry><entry>62.0</entry></row><row><entry/><entry>ADI-46371</entry><entry>59.0</entry></row><row><entry/><entry>ADI-46372</entry><entry>59.0</entry></row><row><entry/><entry>ADI-46374</entry><entry>64.0</entry></row><row><entry/><entry>ADI-46375</entry><entry>58.5</entry></row><row><entry/><entry>ADI-46376</entry><entry>57.0</entry></row><row><entry/><entry>ADI-46378</entry><entry>58.5</entry></row><row><entry/><entry>ADI-46379</entry><entry>58.5</entry></row><row><entry/><entry>ADI-46381</entry><entry>56.5</entry></row><row><entry/><entry>ADI-26140</entry><entry>N.A.</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0011" level="2">Materials and Methods</heading><p id="p-0127" num="0123">In addition to the description provided above, the following Materials and Methods were employed in the Examples.</p><p id="p-0128" num="0124">FACS affinity pressured selection methods. Briefly, yeast cells (at least &#x2dc;2&#xd7;10<sup>7 </sup>cells/labeling condition) were incubated with a volume of biotinylated antigen sufficient to represent a stoichiometric excess with respect to the average IgG presentation number. Antigen labeling conditions are 100 to 1 nM under equilibrium conditions, typically carried out for 20 min to several hours at room temperature in FACS wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing three times with wash buffer, yeast were then stained with secondary reagents anti-human light chain FITC conjugate (LC-FITC) diluted 1:100 and either streptavidin-633 (SA-633) diluted 1:500 or extravidin-phycoerythrin (EA-PE) diluted 1:50 for 15 min at 4&#xb0; C. After washing twice with ice-cold wash buffer, the cell pellets were resuspended in wash buffer in a typical volume of at least 1 mL per 1&#xd7;10<sup>7 </sup>yeast and transferred to strainer-capped sort tubes. Sorting is performed using a FACS ARIA sorter (BD Biosciences) and sort gates were determined to select for binders. After the final round of sorting, yeast were plated and individual colonies picked for characterization.</p><p id="p-0129" num="0125">FACS thermal pressured selection methods. The parent antibody was diversified by error-prone PCR to derive an optimization library in yeast. This yeast library first proceeds through a positive antigen selection round to select for expressing binders, using CD38N27. This enriched population then proceeded through a series of thermally pressured conditions ranging from &#x2212;50&#xb0; C. up to 65&#xb0; C. for 10 min with room temperature as a control. Optimally pressured conditions were gated on LC presentation (anti-human lambda PE) and antigen binding (SA-APC), reflecting the residual folded IgG competent to bind the selection reagents. Sorted cells are pelleted and the plasmids extracted using a commercial yeast plasmid purification kit (Zymo Research) in which the yeast cell walls are disrupted with Zymolase and the DNA is subsequently purified by a DNA mini-column. Plasmid DNA is then transformed into <i>E. coli </i>for amplification, followed by mini-prep isolation of the plasmid DNA with an <i>E. coli </i>plasmid purification kit (Qiagen). Plasmid DNA is then prepared for transformation into the appropriate yeast strain for subsequent cycles selection or sequencing and IgG production.</p><p id="p-0130" num="0126">Error-prone PCR optimization. Error-prone PCR-based mutagenesis of the heavy chain (VH) and/or light chain (VL) using standard molecular biology techniques introduced stochastic diversity. Briefly, mutagenic nucleotide analogues dPTP and 8-oxo-dGTP were incorporated into the VH and VL amplification process at 1 uM concentration to increase the base mis-incorporation frequency up to approx. 0.01 bp. The mutated PCR product was recombined in situ by homologous recombination with a linearized vector containing the HC or LC constant region sequences. This typically results in a library of 1&#xd7;10<sup>7-8 </sup>diversity. Affinity and expression co-pressures were applied by incubating the antigen antibody yeast complex at decreasing concentrations of antigen (equilibrium pressure) or with parental Fab competition (equilibrium and kinetic pressures) for varying amounts of time to select for the highest affinity antibodies on FACS over successive rounds of selection.</p><p id="p-0131" num="0127">Oligonucleotide-based CDR H3 mutagenesis. Discovered or previously optimized antibodies can progress through additional optimization by diversification of the CDR H3 sequence. To do so, the light chain variable region of the starting antibody is PCR amplified, and then, using yeast homologous recombination, is inserted into a yeast strain containing the light chain empty vector. This constitutes the parental light chain yeast strain. The heavy chain of the starting antibody is used as PCR input in combination with germline specific primers that generate a PCR product that contains from framework 1 through framework three of the heavy chain. This amplification is perform using the mutagenic nucleotide 8-oxo-dGTP to provide additional low levels of mutagenesis in the amplified heavy chain region. In order to create designed diversity in the CDR H3 region of the starting antibody, a library of CDR H3 oligos is generated/ordered (i.e. from IDT). The oligo pool is amplified with primers containing 5&#x2032; tails that allow for germline specific recombination with the amplified FW1-FW3 region and the empty. A universal 3&#x2032; primer is used for FW4. Alternatively, mutagenic PCR can be performed that incorporates 8-oxo-dGTP into a PCR reaction using germline specific 5&#x2032; primers, the universal 3&#x2032; primer and VH DNA. Once the LC strain, HC FW1-FW3 and diversified CDR H3-FW4 inputs have been generated, a three piece transformation is performed by introducing the two HC components along with a HC empty vector into the LC strain. Subsequently, the cells are grown out under selective pressure to ensure HC and LC components are present.</p><p id="p-0132" num="0128">Antibody yeast production and purification. Yeast clones were grown to saturation and then induced for 48 h at 30&#xb0; C. with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. IgGs were purified using a Protein A column and eluted with acetic acid, pH 2.0. Fab fragments were generated by papain digestion and purified over KappaSelect or CaptureSelect IgG-CH1 (GE Healthcare LifeSciences).</p><p id="p-0133" num="0129">Antibody HEK production and purification. Mammalian expression of IgG was done by sub-cloning antibodies into a new expression vector followed by transient transfection and expression in HEK293ADI1, a monoclonal cell line derived from HEK293 (DSMZ) selected for clump-free growth, growth rate, and transfectability. Briefly, expression vectors containing the antibody of interest were transfected by complexing with a transfection reagent followed by exposure to HEK cells for one hour followed by dilution of culture media to a final density of 4 million cells per mL. The cells were then cultured for 7 days with fresh feed media every 48 hours. After 7 days, the supernatant was collected following centrifugation and purification was performed using protein A. If necessary, a CHT column purification was added to reach &#x3e;95% monomer.</p><p id="p-0134" num="0130">ForteBio KD measurements (Biolayer interferometry; BLI). ForteBio affinity measurements were performed generally as previously described (Estep, P., et al., High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs, 2013. 5(2): p. 270-8.). Briefly, ForteBio affinity measurements were performed by loading IgGs online onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 5 min, afterwards they were transferred to assay buffer for 5 min for off-rate measurement. Kinetics was analyzed using the 1:1 binding model.</p><p id="p-0135" num="0131">BiaCore KD measurements (Surface plasmon resonance; SPR). Biosensor analysis was conducted at 25&#xb0; C. in HBS-EP buffer system (10 mM HEPES pH 7.3, 150 mM NaCl, 3 mM EDTA, 0.05% Surfactant P20) using a Biacore 8K optical biosensor docked with a CM5 sensor chip (GE Healthcare, Marlboro, Mass.). The sample hotel was maintained at 10&#xb0; C. Goat anti-human IgG capture antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.; 109-005-098) was immobilized (11700+/&#x2212;400 RU) to both flow cells of the sensor chip using standard amine coupling chemistry. This surface type provided a format for reproducibly capturing fresh analysis antigen after each regeneration step. Flow cell 2 was used to analyze captured antigen (35.7+/&#x2212;0.8 RU) while flow cell 1 was used as a reference flow cell. Fab concentrations ranging from 100 to 0.412 nM (3-fold dilutions) were prepared in running buffer. Each of the Fab sample concentrations were run as a single replicate. Two blank (buffer) injections also were run and used to assess and subtract system artifacts. The association and dissociation phases for all Fab concentrations were monitored for 180 s each, at a flow rate of 30 &#x3bc;L/min. The surface was regenerated with 10 mM glycine, pH 1.5 for 30 s, at a flow rate of 30 &#x3bc;L/min. The data was aligned, double referenced, and fit using Biacore 8K Evaluation Software, version 1.0.</p><p id="p-0136" num="0132">Octet Red384 Epitope Binning ligand blocking. Epitope binning/ligand blocking was performed using a standard sandwich format cross-blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc-binding sites on the sensor were blocked with an irrelevant human IgG1 antibody. The sensors were then exposed to 100 nM target antigen followed by a second anti-target antibody or ligand. Data was processed using ForteBio's Data Analysis Software 7.0. Additional binding by the second antibody or ligand after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking).</p><p id="p-0137" num="0133">Size Exclusion Chromatography. A TSKgel SuperSW mAb HTP column (22855) was used for fast SEC analysis of yeast and mammalian produced mAbs at 0.4 m/min with a cycle time of 6 min/run. 200 mM Sodium Phosphate and 250 mM Sodium Chloride was used as the mobile phase.</p><p id="p-0138" num="0134">Dynamic Scanning Fluorimetry (DSF). 10 &#x3bc;L of 20&#xd7; Sypro Orange is added to 20 &#x3bc;L of 0.2-1 mg/mL mAb or Fab solution. A RT-PCR instrument (BioRad CFX96 RT PCR) is used to ramp the sample plate temperature from 40 to 95&#xb0; C. at 0.5&#xb0; C. increments, with 2 min equilibrate at each temperature. The negative of first derivative for the raw data is used to extract Tm.</p><p id="p-0139" num="0135">PSR Preparation. Polyspecific reactivity reagent (PSR) was prepared as described in, e.g., WO 2014/179363 and Xu et al., <i>mAbs, </i>2013. In brief, 2.5 liters CHO-S cells were used as starting material. The cells were pelleted at 2,400&#xd7;g for 5 min in 500 mL centrifuge bottles filled to 400 mL. Cell pellets were combined and then resuspended in 25 ml Buffer B and pelleted at 2,400&#xd7;g for 3 min. The buffer was decanted and the wash repeated one time. Cell pellets were resuspend in 3&#xd7; the pellet volume of Buffer B containing 1&#xd7; protease inhibitors (Roche, Complete, EDTA-free) using a polytron homogenizer with the cells maintained on ice. The homogenate was then centrifuged at 2,400&#xd7;g for 5 min and the supernatant retained and pelleted one additional time (2,400&#xd7;g/5 min) to ensure the removal of unbroken cells, cell debris and nuclei; the resultant supernatant is the total protein preparation. The supernatant was then transferred into two Nalgene Oak Ridge 45 mL centrifuge tubes and pelleted at 40,000&#xd7;g for 40 min at 4&#xb0; C. The supernatants containing the Separated Cytosolic Proteins (SCPs) were then transferred into clean Oak Ridge tubes, and centrifuged at 40,000&#xd7;g one more time. In parallel, the pellets containing the membrane fraction (EMF) were retained and centrifuged at 40,000 for 20 min to remove residual supernatant. The EMF pellets were then rinsed with Buffer B. 8 mL Buffer B was then added to the membrane pellets to dislodge the pellets and transfer into a Dounce Homogenizer. After the pellets were homogenized, they were transferred to a 50 mL conical tube and represented the final EMF preparation.</p><p id="p-0140" num="0136">One billion mammalian cells (e.g. CHO, HEK293, Sf9) at &#x2dc;10<sup>6</sup>-10<sup>7 </sup>cells/mL were transferred from tissue culture environment into 4&#xd7;250 mL conical tubes and pelleted at 550&#xd7;g for 3 min. All subsequent steps were performed at 4&#xb0; C. or on ice with ice-cold buffers. Cells were washed with 100 mL of PBSF (1&#xd7;PBS+1 mg/mL BSA) and combined into one conical tube. After removing the supernatant, the cell pellet was then re-suspended in 30 mL Buffer B (50 mM HEPES, 0.15 M NaCl, 2 mM CaCl<sub>2</sub>), 5 mM KCl, 5 mM MgCl<sub>2</sub>, 10% Glycerol, pH 7.2) and pelleted at 550&#xd7;g for 3 min. Buffer B supernatant was decanted and cells re-suspended in 3&#xd7; pellet volume of Buffer B plus 2.5&#xd7; protease inhibitor (Roche, cOmplete, EDTA-free). Protease inhibitors in Buffer B were included from here on forward. Cells were homogenized four times for 30 sec pulses (Polyton homogenizer, PT1200E) and the membrane fraction was pelleted at 40,000&#xd7;g for 1 hour at 4&#xb0; C. The pellet is rinsed with 1 mL Buffer B; the supernatant is retained and represents the s. The pellet is transferred into a Dounce homogenizer with 3 mL of Buffer B and re-suspended by moving the pestle slowly up and down for 30-35 strokes. The enriched membrane fraction (EMF) is moved into a new collection tube, rinsing the pestle to collect all potential protein. Determine the protein concentration of the purified EMF using the Dc-protein assay kit (BioRad). To solubilize the EMF, transfer into Solubilization Buffer (50 mM HEPES, 0.15 M NaCl, 2 mM CaCl<sub>2</sub>), 5 mM KCl, 5 mM MgCl<sub>2</sub>, 1% n-Dodecyl-b-D-Maltopyranoside (DDM), 1&#xd7; protease inhibitor, pH 7.2) to a final concentration of 1 mg/mL. Rotate the mixture overnight at 4&#xb0; C. rotating followed by centrifugation in a 50 mL Oak Ridge tube (Fisher Scientific, 050529-ID) at 40,000&#xd7;g for 1 hour. Collect the supernatant which represents the soluble membrane proteins (SMPs) and quantify the protein yield as described above.</p><p id="p-0141" num="0137">For biotinylation, prepare the NHS-LC-Biotin stock solution according to manufacturer's protocol (Pierce, Thermo Fisher). In brief, 20 &#x3bc;l of biotin reagent is added for every 1 mg of EMF sample and incubated at 4&#xb0; C. for 3 hours with gentle agitation. Adjust the volume to 25 mL with Buffer B and transfer to an Oak Ridge centrifuge tube. Pellet the biotinylated EMF (b-EMF) at 40,000&#xd7;g for 1 hour, and rinse two times with 3 mL of Buffer C (Buffer B minus the glycerol) without disturbing the pellet. Remove the residual solution. Re-suspended the pellet with a Dounce homogenizer in 3 mL of Buffer C as described previously. The re-suspended pellet now represents biotinylated EMF (b-EMF). Solubilized as described above to prepare b-SMPs.</p><p id="p-0142" num="0138">PSR Binding Analyses. Assays were performed generally as described in, e.g., Xu et al. To characterize the PSR profile of monoclonal antibodies presented on yeast, two million IgG-presenting yeast were transferred into a 96-well assay plate and pellet at 3000&#xd7;g for 3 min to remove supernatant. Re-suspend the pellet in 50 &#x3bc;l of freshly prepared 1:10 dilution of stock b-PSRs and incubate on ice for 20 minutes. Wash the cells twice with 200 &#x3bc;l of cold PBSF and pellet re-suspended in 50 &#x3bc;l of secondary labeling mix (Extravidin-R-PE, anti-human LC-FITC, and propidium iodide). Incubate the mix on ice for 20 minutes followed by two washes with 200 &#x3bc;l ice-cold PBSF. Re-suspend the cells in 100 &#x3bc;l of ice-cold PBSF and run the plate on a FACSCanto (BD Biosciences) using HTS sample injector. Flow cytometry data was analyzed for mean fluorescence intensity in the R-PE channel and normalized to proper controls in order to assess non-specific binding. Numerous methods for presentation or display of antibodies or antibody fragments on the surface of yeast have been described previously, all of which are consistent with this protocol (Blaise et al., 2004, Boder and Wittrup, 1997, Kuroda and Ueda, 2011, Orcutt and Wittrup, 2010, Rakestraw et al., 2011, Sazinsky et al., 2008, Tasumi et al., 2009, Vasquez et al., 2009).</p><p id="p-0143" num="0139">ForteBio Kinetics. FortBio Octet HTX instruments were used in 12 channel mode (8 sensors per channel, 96 sensors per experiment) with either AHC, SA, or AHQ sensors. Instrumentation was driven by manufacturer supplied software (versions 8.2 and 9.0). Sample names and concentrations were input into the plate data page, and sensor associated proteins were identified in the &#x201c;information&#x201d; column on the sensor data page. Kinetic experiments are collected with either a 90 or 180 s baseline, 180 s association phase, and 180 s dissociation phase. Binning experiments were collected in 5 steps: 90 s of baseline1, 90 s of a sensor binding check with the secondary binder, 90 s of baseline2, 180 s of association, and 180 s of dissociation in the well containing the secondary mAb. All files were saved into a shared network drive with a naming convention that identifies the format of the experiment.</p><p id="p-0144" num="0140">HIC. IgG1 samples were buffer exchanged into 1 M ammonium sulfate and 0.1 M sodium phosphate at pH 6.5 using a Zeba 40 kDa 0.5 mL spin column (Thermo Pierce, cat #87766). A salt gradient was established on a Dionex ProPac HIC-10 column from 1.8 M ammonium sulfate, 0.1 M sodium phosphate at pH 6.5 to the same condition without ammonium sulfate. The gradient ran for 17 min at a flow rate of 0.75 ml/min. An acetonitrile wash step was added at the end of the run to remove any remaining protein and the column was re-equilibrated over 7 column volumes before the next injection cycle. Peak retention times were monitored at A280 absorbance and concentrations of ammonium sulfate at elution were calculated based on gradient and flow rate.</p><p id="p-0145" num="0141">LCMS. mAb samples were reduced by DTT, followed by middle down LCMS analysis on a Bruker maXis4G mass spectrometer coupled with an Agilent 1100 HPLC (Agilent). A POROS R2 10 &#x3bc;m (2.1&#xd7;30 mm) reversed phase column was used to remove salt in the samples. A fast LC flow at 2 mL/min allows the separation between sample and salt and elution of samples and regeneration of column to finish within a 2.1 min cycle. A T-junction is used to deliver only 0.15 mL/min sample flow into the mass spectrometer for sample analysis. The Bruker maXis 4G mass spectrometer was run in positive ion mode with detection in the range of 750 to 2500 m/z. The remaining source parameters were set as follows; the capillary was set at 5500V, the Nebulizer at 4.0 Bar, dry gas at 4.0 l/min, and dry temp set at 200&#xb0; C.</p><p id="p-0146" num="0142">MS spectra were analyzed using Bruker Data Analysis version 4.1 and the deconvolution was accomplished using maximum entropy deconvolution with a mass range of 20 to 30 kDa.</p><p id="p-0147" num="0143">An informal sequence listing is provided in Table 4. The informal sequence listing provides the heavy chain variable region (&#x201c;HC&#x201d;) amino acid sequence, with each of the heavy chain variable region CDRs underlined, and the light chain variable region (&#x201c;LC&#x201d;), with each of the light chain variable region CDRs underlined.</p><p id="p-0148" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="378pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Informal&#x2003;sequence&#x2003;listing.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="161pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="98pt" align="left"/><tbody valign="top"><row><entry>Antibody</entry><entry>SEQ&#x2003;ID</entry><entry/><entry>Clone&#x2003;#</entry><entry/></row><row><entry>No.</entry><entry>NO:</entry><entry>Sequence</entry><entry>(ADI)</entry><entry>Descriptors</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>Ab1</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-42594</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab1</entry><entry>18</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-42594</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab2</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-42596</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab2</entry><entry>19</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRKN</u></entry><entry>ADI-42596</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab3</entry><entry>20</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45967</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>ARDTSASTVYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab3</entry><entry>21</entry><entry>DIVMTQSPDSLAVSLGERAIINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45967</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab4</entry><entry>22</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45968</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDASASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab4</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45968</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab5</entry><entry>24</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45969</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELGSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab5</entry><entry>25</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45969</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">AQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab6</entry><entry>26</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNVKDYYMH</u></entry><entry>ADI-45970</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab6</entry><entry>18</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45970</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab7</entry><entry>27</entry><entry>QVQLVQSGAEVKKPGATVKVSCKASG<u style="single">FNIKDYYIH</u>W</entry><entry>ADI-45971</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>VRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTITR</entry><entry/><entry/></row><row><entry/><entry/><entry>DTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYDV</u></entry><entry/><entry/></row><row><entry/><entry/><entry>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab7</entry><entry>28</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRKN</u></entry><entry>ADI-45971</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab8</entry><entry>29</entry><entry>QVQLVQSGAEVKRPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45972</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab8</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45972</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab9</entry><entry>30</entry><entry>QVQLVQSEAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45973</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab9</entry><entry>18</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45973</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab10</entry><entry>31</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45974</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSNLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab10</entry><entry>18</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45974</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab11</entry><entry>32</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45975</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGQYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab11</entry><entry>19</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRKN</u></entry><entry>ADI-45975</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab12</entry><entry>33</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45976</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">VRDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab12</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45976</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab13</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45959</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab13</entry><entry>34</entry><entry>DIVMSQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45959</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRSS</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab14</entry><entry>35</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45977</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKLQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLGSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab14</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45977</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab15</entry><entry>37</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45978</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWLG<u style="single">WIDLENANTVYDAKFQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab15</entry><entry>38</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45978</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASARES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab16</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45979</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab16</entry><entry>39</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQELLNARTGKN</u></entry><entry>ADI-45979</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab17</entry><entry>40</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45980</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELNSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab17</entry><entry>41</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45980</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WAFTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab18</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45981</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab18</entry><entry>42</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45981</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASMRES</u>GVPDRFSGSRS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">SQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab19</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45982</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab19</entry><entry>43</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45982</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTREN</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab20</entry><entry>44</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45983</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSAGTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab20</entry><entry>45</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTMKN</u></entry><entry>ADI-45983</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">AASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">AQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab21</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45984</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab21</entry><entry>28</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRKN</u></entry><entry>ADI-45984</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab22</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45985</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab22</entry><entry>46</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KTSQSLLNARTNKN</u></entry><entry>ADI-45985</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab23</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45960</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab23</entry><entry>47</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45960</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDAAVYYC<u style="single">AQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab24</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45961</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab24</entry><entry>48</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRRN</u></entry><entry>ADI-45961</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WGSTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab25</entry><entry>49</entry><entry>QVQLVQSGAEVEEPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45962</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab25</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45962</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab26</entry><entry>50</entry><entry>QVQLVQSGAEVKKPGAPVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45963</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab26</entry><entry>18</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45963</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">KQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab27</entry><entry>51</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYIH</u>W</entry><entry>ADI-45964</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>VRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTITR</entry><entry/><entry/></row><row><entry/><entry/><entry>DTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYDV</u></entry><entry/><entry/></row><row><entry/><entry/><entry>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab27</entry><entry>25</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45964</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">AQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab28</entry><entry>52</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45965</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANAVYDAKFQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab28</entry><entry>53</entry><entry>DIVMTQSPDSLAVSLGGRATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45965</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab29</entry><entry>54</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-45966</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVAI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab29</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-45966</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab30</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46357</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab30</entry><entry>25</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46357</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">AQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab31</entry><entry>31</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46358</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSNLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab31</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46358</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab32</entry><entry>55</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46367</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASIAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab32</entry><entry>25</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46367</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">AQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab33</entry><entry>56</entry><entry>QAQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46369</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDTKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab33</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46369</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab34</entry><entry>57</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46370</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDHKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab34</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46370</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab35</entry><entry>58</entry><entry>QAQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46371</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRPEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAAYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab35</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46371</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab36</entry><entry>59</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46372</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSAGTAHMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTPVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab36</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46372</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab37</entry><entry>60</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46374</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLNNANTVYDAKFQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab37</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46374</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">VQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab38</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46375</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab38</entry><entry>61</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRKN</u></entry><entry>ADI-46375</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab39</entry><entry>62</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46376</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKLQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLGSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTPVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab39</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46376</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYC<u style="single">TQSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab40</entry><entry>63</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46378</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASAAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab40</entry><entry>64</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTRKN</u></entry><entry>ADI-46378</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGRPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCV<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab41</entry><entry>63</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46379</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASAAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab41</entry><entry>38</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46379</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASARES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCT<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab42</entry><entry>32</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46359</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGQYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab42</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46359</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCT<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab43</entry><entry>65</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46381</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDTKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab43</entry><entry>66</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KTSQGLLNARTNKN</u></entry><entry>ADI-46381</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCV<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab44</entry><entry>67</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46360</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRPEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDAAAYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab44</entry><entry>68</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46360</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPELLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCT<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab45</entry><entry>69</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNNKDYYMH</u></entry><entry>ADI-46361</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab45</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46361</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCT<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab46</entry><entry>70</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46362</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRPEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAAYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab46</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46362</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCV<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab47</entry><entry>17</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46363</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab47</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46363</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCT<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab48</entry><entry>35</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46364</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKLQG</u>RVTI</entry><entry/><entry/></row><row><entry/><entry/><entry>TRDTSASTAYMELSSLGSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab48</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46364</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCV<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab49</entry><entry>59</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46365</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSAGTAHMELSSLRSEDTAVYYC<u style="single">ARDAYGRYFY</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">DV</u>WGQGTPVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab49</entry><entry>36</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46365</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCT<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab50</entry><entry>32</entry><entry>QVQLVQSGAEVKKPGASVKVSCKASG<u style="single">FNIKDYYMH</u></entry><entry>ADI-46366</entry><entry>HC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry>WVRQAPGQRLEWIG<u style="single">WIDLENANTVYDAKFQG</u>RVTIT</entry><entry/><entry/></row><row><entry/><entry/><entry>RDTSASTAYMELSSLRSEDTAVYYC<u style="single">ARDAYGQYFYD</u></entry><entry/><entry/></row><row><entry/><entry/><entry><u style="single">V</u>WGQGTLVTVSS</entry><entry/><entry/></row><row><entry> </entry></row><row><entry>Ab50</entry><entry>23</entry><entry>DIVMTQSPDSLAVSLGERATINC<u style="single">KSSQSLLNARTGKN</u></entry><entry>ADI-46366</entry><entry>LC&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry/><entry/><entry><u style="single">YLA</u>WYQQKPGQPPKLLIY<u style="single">WASTRES</u>GVPDRFSGSGS</entry><entry/><entry/></row><row><entry/><entry/><entry>GTDFTLTISSLQAEDVAVYYCV<u style="single">QSYFRRT</u>FGGGTKVE</entry><entry/><entry/></row><row><entry/><entry/><entry>IK</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0149" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="392pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Antibody&#x2003;VH&#x2003;sequence&#x2003;information.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="15"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="28pt" align="left"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="28pt" align="left"/><colspec colname="7" colwidth="14pt" align="center"/><colspec colname="8" colwidth="35pt" align="left"/><colspec colname="9" colwidth="21pt" align="center"/><colspec colname="10" colwidth="35pt" align="left"/><colspec colname="11" colwidth="21pt" align="center"/><colspec colname="12" colwidth="35pt" align="left"/><colspec colname="13" colwidth="21pt" align="center"/><colspec colname="14" colwidth="28pt" align="left"/><colspec colname="15" colwidth="21pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry></row><row><entry/><entry/><entry>ID</entry><entry>VH</entry><entry>ID</entry><entry/><entry>ID</entry><entry>VH</entry><entry>ID</entry><entry/><entry>ID</entry><entry>VH</entry><entry>ID</entry><entry/><entry>ID</entry></row><row><entry/><entry>VH&#x2003;FR1</entry><entry>NO:</entry><entry>CDR1</entry><entry>NO:</entry><entry>VH&#x2003;FR2</entry><entry>NO:</entry><entry>CDR2</entry><entry>NO:</entry><entry>VH&#x2003;FR3</entry><entry>NO:</entry><entry>CDR3</entry><entry>NO:</entry><entry>VH&#x2003;FR4</entry><entry>NO:</entry></row><row><entry namest="1" nameend="15" align="center" rowsep="1"/></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>42594</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>42596</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46356</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46357</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;90</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46358</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>NLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>104</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46359</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>QYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>82</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;91</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46360</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRPEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>AAAYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNNKDY</entry><entry>78</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46361</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>82</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;92</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46362</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRPEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAAYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46363</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>84</entry><entry>RVTITR</entry><entry>&#x2003;93</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46364</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLGSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;94</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>107</entry></row><row><entry>46365</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAGT</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AHMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>104</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46366</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>QYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;95</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46367</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSASI</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QAQLVQS</entry><entry>72</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>85</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46369</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>TKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>86</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46370</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>HKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QAQLVQS</entry><entry>72</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>82</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;92</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46371</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRPEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAAYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;94</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTP</entry><entry>107</entry></row><row><entry>46372</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAGT</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AHMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>87</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46374</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46375</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>84</entry><entry>RVTIIR</entry><entry>&#x2003;93</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTP</entry><entry>107</entry></row><row><entry>46376</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLGSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;96</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46378</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSASA</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;96</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46379</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSASA</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>85</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>46381</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>42596</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45959</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45960</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45961</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>73</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45962</entry><entry>GAEVEEP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>74</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45963</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GAPVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>79</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45964</entry><entry>GAEVKKP</entry><entry/><entry>YIH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>88</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45965</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANAVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVAITR</entry><entry>&#x2003;97</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45966</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIAR</entry><entry>&#x2003;98</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45967</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>VYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;99</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45968</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DASAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>100</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45969</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELG</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNVKDY</entry><entry>80</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45970</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>75</entry><entry>FNIKDY</entry><entry>79</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45971</entry><entry>GAEVKKP</entry><entry/><entry>YIH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GATVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>76</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45972</entry><entry>GAEVKRP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>77</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45973</entry><entry>EAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;90</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45974</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>NLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>104</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45975</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>QYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>VRDAYG</entry><entry>105</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45976</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>84</entry><entry>RVTITR</entry><entry>&#x2003;93</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45977</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLGSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>83</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45978</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>LG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45979</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTIIR</entry><entry>101</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45980</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELN</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45981</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45982</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>102</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45983</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAGT</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45984</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>QVQLVQS</entry><entry>71</entry><entry>FNIKDY</entry><entry>13</entry><entry>WVRQAP</entry><entry>81</entry><entry>WIDLEN</entry><entry>15</entry><entry>RVTITR</entry><entry>&#x2003;89</entry><entry>ARDAYG</entry><entry>103</entry><entry>WGQGTL</entry><entry>106</entry></row><row><entry>45985</entry><entry>GAEVKKP</entry><entry/><entry>YMH</entry><entry/><entry>GQRLEW</entry><entry/><entry>ANTVYD</entry><entry/><entry>DTSAST</entry><entry/><entry>RYFYDV</entry><entry/><entry>VTVSS</entry><entry/></row><row><entry/><entry>GASVKVS</entry><entry/><entry/><entry/><entry>IG</entry><entry/><entry>AKFQG</entry><entry/><entry>AYMELS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>CKASG</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>SLRSED</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>TAVYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="15" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0150" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="392pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Antibody&#x2003;VL&#x2003;sequence&#x2003;information.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="15"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="35pt" align="left"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="35pt" align="left"/><colspec colname="7" colwidth="21pt" align="center"/><colspec colname="8" colwidth="28pt" align="left"/><colspec colname="9" colwidth="21pt" align="center"/><colspec colname="10" colwidth="35pt" align="left"/><colspec colname="11" colwidth="21pt" align="center"/><colspec colname="12" colwidth="28pt" align="left"/><colspec colname="13" colwidth="21pt" align="center"/><colspec colname="14" colwidth="28pt" align="left"/><colspec colname="15" colwidth="21pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry><entry/><entry>SEQ</entry></row><row><entry/><entry/><entry>ID</entry><entry/><entry>ID</entry><entry>VL</entry><entry>ID</entry><entry>VL</entry><entry>ID</entry><entry/><entry>ID</entry><entry>VL</entry><entry>ID</entry><entry>VL</entry><entry>ID</entry></row><row><entry/><entry>VL&#x2003;FR1</entry><entry>NO:</entry><entry>VL&#x2003;CDR1</entry><entry>NO:</entry><entry>FR2</entry><entry>NO:</entry><entry>CDR2</entry><entry>NO:</entry><entry>VL&#x2003;FR3</entry><entry>NO:</entry><entry>CDR3</entry><entry>NO:</entry><entry>CDR4</entry><entry>NO:</entry></row><row><entry namest="1" nameend="15" align="center" rowsep="1"/></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>42594</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>42596</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46356</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>AQSYFR</entry><entry>&#x2003;&#x2003;2</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46357</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46358</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46359</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>118</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46360</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPEL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46361</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46362</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46363</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46364</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46365</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46366</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>AQSYFR</entry><entry>&#x2003;&#x2003;2</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46367</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46369</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46370</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46371</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46372</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46374</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46375</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46376</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>119</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46378</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GRPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASARE</entry><entry>120</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46379</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KTSQGL</entry><entry>112</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>46381</entry><entry>SPDSLA</entry><entry/><entry>LNARTN</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>KNYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>42596</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMSQ</entry><entry>109</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRS</entry><entry>&#x2003;11</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45959</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>127</entry><entry>AQSYFR</entry><entry>&#x2003;&#x2003;2</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45960</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>113</entry><entry>WYQQKP</entry><entry>117</entry><entry>WGSTRE</entry><entry>121</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45961</entry><entry>SPDSLA</entry><entry/><entry>NARTRR</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45962</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45963</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>AQSYFR</entry><entry>&#x2003;&#x2003;2</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45964</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>110</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45965</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGGR</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45966</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>ill</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45967</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>AUNC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45968</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>AQSYFR</entry><entry>&#x2003;&#x2003;2</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45969</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45970</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45971</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45972</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45973</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45974</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45975</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45976</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45977</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASARE</entry><entry>120</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45978</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQELL</entry><entry>114</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>KQSYFR</entry><entry>&#x2003;&#x2003;5</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45979</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WAFTRE</entry><entry>122</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45980</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASMRE</entry><entry>123</entry><entry>GVPDRFS</entry><entry>128</entry><entry>SQSYFR</entry><entry>129</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45981</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;8</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>124</entry><entry>GVPDRFS</entry><entry>126</entry><entry>TQSYFR</entry><entry>&#x2003;&#x2003;3</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45982</entry><entry>SPDSLA</entry><entry/><entry>NARTGK</entry><entry/><entry>GQPPKL</entry><entry/><entry>N</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>115</entry><entry>WYQQKP</entry><entry>117</entry><entry>AASTRE</entry><entry>125</entry><entry>GVPDRFS</entry><entry>126</entry><entry>AQSYFR</entry><entry>&#x2003;&#x2003;2</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45983</entry><entry>SPDSLA</entry><entry/><entry>NARTMK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KSSQSLL</entry><entry>&#x2003;&#x2003;9</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45984</entry><entry>SPDSLA</entry><entry/><entry>NARTRK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry>ADI-</entry><entry>DIVMTQ</entry><entry>108</entry><entry>KTSQSLL</entry><entry>116</entry><entry>WYQQKP</entry><entry>117</entry><entry>WASTRE</entry><entry>&#x2003;10</entry><entry>GVPDRFS</entry><entry>126</entry><entry>VQSYFR</entry><entry>&#x2003;&#x2003;4</entry><entry>FGGGT</entry><entry>130</entry></row><row><entry>45985</entry><entry>SPDSLA</entry><entry/><entry>NARTNK</entry><entry/><entry>GQPPKL</entry><entry/><entry>S</entry><entry/><entry>GSGSGTD</entry><entry/><entry>RT</entry><entry/><entry>KVEIK</entry><entry/></row><row><entry/><entry>VSLGER</entry><entry/><entry>NYLA</entry><entry/><entry>LIY</entry><entry/><entry/><entry/><entry>FTLTISS</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>ATINC</entry><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>LQAEDVA</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry/><entry>VYYC</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="15" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0151" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE&#x2003;7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Human&#x2003;and&#x2003;Cynomolgus&#x2003;CD3:&#x2003;Sequences</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="147pt" align="left"/><colspec colname="3" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>SEQ</entry></row><row><entry>Name</entry><entry>Sequence:</entry><entry>ID&#x2003;NO:</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>Hu&#x2003;CD3&#x3f5;</entry><entry>QDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSE</entry><entry>131</entry></row><row><entry>Fc</entry><entry>ILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELE</entry><entry/></row><row><entry/><entry>QSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMD</entry><entry/></row><row><entry/><entry>GGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM</entry><entry/></row><row><entry/><entry>ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA</entry><entry/></row><row><entry/><entry>KTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK</entry><entry/></row><row><entry/><entry>VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE</entry><entry/></row><row><entry/><entry>LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK</entry><entry/></row><row><entry/><entry>TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV</entry><entry/></row><row><entry/><entry>MHEALHNHYTQKSLSLSPGK</entry><entry/></row><row><entry> </entry></row><row><entry>Cy&#x2003;CD3&#x3f5;</entry><entry>QDGNEEMGSITQTPYQVSISGTTVILTCSQHLGSE</entry><entry>132</entry></row><row><entry>Fc</entry><entry>AQWQHNGKNKEDSGDRLFLPEFSEMEQSGYYVCYP</entry><entry/></row><row><entry/><entry>RGSNPEDASHHLYLKARVCENCMEMDGGSDKTHTC</entry><entry/></row><row><entry/><entry>PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC</entry><entry/></row><row><entry/><entry>VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY</entry><entry/></row><row><entry/><entry>ASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP</entry><entry/></row><row><entry/><entry>IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT</entry><entry/></row><row><entry/><entry>CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD</entry><entry/></row><row><entry/><entry>GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY</entry><entry/></row><row><entry/><entry>TQKSLSLSPGK</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002487A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antigen-binding antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises:<claim-text>a. a variable heavy (V<sub>H</sub>) chain polypeptide comprising:<claim-text>i. a V<sub>H </sub>CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13);</claim-text><claim-text>ii. a V<sub>H </sub>CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15);</claim-text><claim-text>iii. a V<sub>H </sub>CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or</claim-text></claim-text><claim-text>b. a variable light (V<sub>L</sub>) chain polypeptide comprising:<claim-text>i. a V<sub>L </sub>CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8);</claim-text><claim-text>ii. a V<sub>L </sub>CDR2 (CDRL2) of WASTRX<sub>1</sub>S (SEQ ID NO: 133); and</claim-text><claim-text>iii. a V<sub>L </sub>CDR3 (CDRL3) of X<sub>2</sub>QSYFRRT (SEQ ID NO: 134);</claim-text><claim-text>wherein X<sub>1 </sub>and X<sub>2 </sub>are each independently any amino acid.</claim-text></claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein:<claim-text>a. X<sub>1 </sub>is E or S; and/or</claim-text><claim-text>b. X<sub>2 </sub>is K or V.</claim-text></claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said antibody or antigen-binding antibody fragment comprises:<claim-text>a. a CDRL2 of SEQ ID NO: 10 or SEQ ID NO: 11; and/or</claim-text><claim-text>b. a CDRL3 of SEQ ID NO: 5 or SEQ ID NO: 4.</claim-text></claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said anti-CD3 antibody or antigen-binding antibody fragment is selected from the group consisting of:<claim-text>a. one which comprises a V<sub>H </sub>chain CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13), a V<sub>H </sub>chain CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15), and a V<sub>H </sub>chain CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or a V<sub>L </sub>chain CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8), a V<sub>L </sub>chain CDR2 (CDRL2) of WASTRES (SEQ ID NO: 10), and a V<sub>L </sub>chain CDR3 (CDRL3) of KQSYFRRT (SEQ ID NO: 5); and</claim-text><claim-text>b. one which comprises a V<sub>H </sub>chain CDR1 (CDRH1) of FNIKDYYMH (SEQ ID NO: 13), a V<sub>H </sub>chain CDR2 (CDRH2) of WIDLENANTVYDAKFQG (SEQ ID NO: 15), and a V<sub>H </sub>chain CDR3 (CDRH3) of ARDAYGRYFYDV (SEQ ID NO: 103); and/or a V<sub>L </sub>chain CDR1 (CDRL1) of KSSQSLLNARTGKNYLA (SEQ ID NO: 8), a V<sub>L </sub>chain CDR2 (CDRL2) of WASTRSS (SEQ ID NO: 11), and a V<sub>L </sub>chain CDR3 (CDRL3) of VQSYFRRT (SEQ ID NO: 4).</claim-text></claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises:<claim-text>a. a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34;</claim-text><claim-text>b. a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34;</claim-text><claim-text>c. a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34;</claim-text><claim-text>d. a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 17;</claim-text><claim-text>e. a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 17; and/or</claim-text><claim-text>f. a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17.</claim-text></claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises:<claim-text>a. a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 90% sequence identity to SEQ ID NO: 17;</claim-text><claim-text>b. a V<sub>L </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain polypeptide comprising an amino acid sequence that possesses at least 95% sequence identity to SEQ ID NO: 17;</claim-text><claim-text>c. a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17;</claim-text><claim-text>d. a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 18; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17; and/or</claim-text><claim-text>e. a V<sub>L </sub>chain polypeptide comprising the amino acid sequence of SEQ ID NO: 34; and a V<sub>H </sub>chain comprising the amino acid sequence of SEQ ID NO: 17.</claim-text></claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said anti-CD3 antibody or antigen-binding antibody fragment binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 500 pM or less, about 450 pM or less, about 400 pM or less, about 350 pM or less, about 300 pM or less, about 250 pM or less, about 200 pM or less, about 150 pM or less, or about 100 pM or less, optionally wherein said CD3 is human and/or cynomolgus, further optionally wherein said binding affinity is measured by surface plasmon resonance; or said K<sub>D </sub>is a monovalent K<sub>D </sub>and/or wherein said K<sub>D </sub>is measured using an scFv fragment of said anti-CD3 antibody or antibody fragment.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. (canceled)</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The anti-CD3 antibody or antigen-binding antibody fragment according <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein:<claim-text>a. said antibody or antigen-binding antibody fragment elicits T cell activation or T cell killing while displaying a decreased propensity to elicit cytokine production to levels capable of inducing cytokine release syndrome;</claim-text><claim-text>b. the antibody or antigen-binding antibody fragment comprises a multispecific antibody;</claim-text><claim-text>c. the antibody or antigen-binding antibody fragment comprises a bispecific antibody;</claim-text><claim-text>d. the antibody or antigen-binding antibody fragment comprises an scFv;</claim-text><claim-text>e. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an oncology target; an immune-oncology target; a neurodegenerative disease targets; an autoimmune disorder target; an infectious disease target; a metabolic disease target; a cognitive disorder target; a blood-brain barrier target; or a blood disease target;</claim-text><claim-text>f. the antibody or antigen-biding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen selected from the group consisting of: 17-IA, 4-1BB, 4Dc, 6- keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, A1 Adenosine Receptor, A33, ACE, ACE-2, Activin, Activin A, Activin AB, Activin B, Activin C, Activin RIA, Activin RIA ALK-2, Activin RIB ALK-4, Activin RIIA, Activin RUB, ADAM, ADAM10, ADAM12, ADAM 15, ADAM 17/T ACE, ADAM8, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, Addressins, aFGF, ALCAM, ALK, ALK-1, ALK-7, alpha-l-antitrypsin, alpha-V/beta-1 antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, ARC, ART, Artemin, anti-Id, ASPARTIC, Atrial natriuretic factor, av/b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B-lymphocyte Stimulator (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bel, BCMA, BDNF, b-ECGF, bFGF, BID, Bik, BFM, BLC, BL-CAM, BLK, BMP, BMP-2 BMP-2a, BMP-3 Osteogenin, BMP-4 BMP-2b, BMP-5, BMP-6 Vgr-1, BMP-7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1, BMPR-II (BRK-3), BMPs, b-NGF, BOK, Bombesin, Bone-derived neurotrophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, CIO, CA125, CAD-8, Calcitonin, cAMP, carcinoembryonic antigen (CEA), carcinoma-associated antigen, Cathepsin A, Cathepsin B, Cathepsin C/DPPI, Cathepsin D, Cathepsin E, Cathepsin H, Cathepsin L, Cathepsin O, Cathepsin S, Cathepsin V, Cathepsin X/Z/P, CBL, CCI, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL 14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/10, CCR, CCR1, CCR10, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD4, CD5, CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, CD32, CD33 (p67 proteins), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80 (B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, <i>Clostridium botulinum </i>toxin, <i>Clostridium perfringens </i>toxin, CKb8-1, CLC, CMV, CMV UL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-associated antigen, DAN, DCC, DcR3, DC-SIGN, Decay accelerating factor, des(1-3)-IGF-I (brain IGF-1), Dhh, digoxin, DNAM-1, Dnase, Dpp, DPPIV/CD26, Dtk, ECAD, EDA, EDA-A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, EN A, endothelin receptor, Enkephalinase, eNOS, Eot, eotaxinl, EpCAM, Ephrin B2/EphB4, EPO, ERCC, E-selectin, ET-1, Factor IIa, Factor VII, Factor VIIIc, Factor IX, fibroblast activation protein (FAP), Fas, FcR1, FEN-1, Ferritin, FGF, FGF-19, FGF-2, FGF3, FGF-8, FGFR, FGFR-3, Fibrin, FL, FLIP, Flt-3, Flt-4, Follicle stimulating hormone, Fractalkine, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas 6, GCP-2, GCSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr-2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-2), GDF-7 (BMP-12, CDMP-3), GDF-8 (Myostatin), GDF-9, GDF-15 (MIC-1), GDNF, GFAP, GFRa-1, GFR-alpha1, GFR-alpha2, GFR-alpha3, GITR, Glucagon, Glut 4, glycoprotein IIb/IIIa (GP IIb/IIIa), GM-CSF, gp130, gp72, GRO, Growth hormone releasing factor, Hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMV gB envelope glycoprotein, HCMV) gH envelope glycoprotein, HCMV UL, Hemopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2/neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV) gB glycoprotein, HSV gD glycoprotein, HGFA, High molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp 120 V3 loop, HLA, HLA-DR, HM1.24, HMFG PEM, HRG, Hrk, human cardiac myosin, human cytomegalovirus (HCMV), human growth hormone (HGH), HVEM, 1-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF binding proteins, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-18R, IL-23, interferon (INF)-alpha, INF-beta, INF-gamma, Inhibin, iNOS, Insulin A-chain, Insulin B-chain, Insulin-like growth factor 1, integrin alpha2, integrin alpha3, integrin alpha4, integrin alpha4/beta1, integrin, alpha4/beta7, integrin alpha5 (alphaV), integrin alpha5/beta1, integrin alpha5/beta3, integrin alpha6, integrin beta1, integrin beta2, interferon gamma, IP-10, 1-TAC, JE, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 15, Kallikrein LI, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), laminin 5, LAMP, LAP, LAP (TGF-1), Latent TGF-1, Latent TGF-1 bpl, LBP, LDGF, LECT2, Lefty, Lewis-Y antigen, Lewis-Y related antigen, LFA-1, LFA-3, Lfo, LIF, LIGHT, lipoproteins, LIX, LKN, Lptn, L-Selectin, LT-a, LT-b, LTB4, LTBP-1, Lung surfactant, Luteinizing hormone, Lymphotoxin Beta Receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCAM, MCK-2, MCP, M-CSF, MDC, Mer, a metalloprotease, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP-1-alpha, MK, MMAC1, MMP, MMP-1, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3, MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Mucl), MUC18, Muellerian-inhibiting substance, Mug, MuSK, NAIP, NAP, NCAD, N-Cadherin, NCA 90, NCAM, NCAM, Neprilysin, Neurotrophin-3, -4, or -6, Neurturin, Neuronal growth factor (NGF), NGFR, NGF-beta, nNOS, NO, NOS, Npn, NRG-3, NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, Parathyroid hormone, PARC, PARP, PBR, PBSF, PCAD, P-Cadherin, PCNA, PDGF, PDGF, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), PIGF, PLP, PP14, Proinsulin, Prorelaxin, Protein C, PS, PSA, PSCA, prostate specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK, RANKL, RANTES, Relaxin A-chain, Relaxin B-chain, renin, respiratory syncytial virus (RSV) F, RSV Fgp, Ret, Rheumatoid factors, RLIP76, RPA2, RSK, S100, SCF/KL, SDF-1, SERINE, Serum albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (tumor-associated glycoprotein-72), TARC, TCA-3, T-cell receptors (e.g., T-cell receptor alpha/beta), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, testicular PLAP-like alkaline phosphatase, TfR, TGF, TGF-alpha, TGF-beta, TGF-beta Pan Specific, TGF-beta RI (ALK-5), TGF-beta RII, TGF-beta RIIb, TGF-beta RIII, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta4, TGF-beta5, Thrombin, Thymus Ck-1, Thyroid stimulating hormone, Tie, TIMP, TIQ, Tissue Factor, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-alpha, TNF-alpha beta, TNF-beta2, TNFc, TNF-RI, TNF-RII, TNFRSF10A (TRAIL R Apo-2, DR4), TNFRSFIOB (TRAIL R2 DR5, KILLER, TRICK-2A, TRICK-B), TNFRSF10C (TRAIL R3 DcR1, LIT, TRID), TNFRSF10D (TRAIL R4 DcR2, TRUNDD), TNFRSF11A (RANK ODF R, TRANCE R), TNFRSF11B (OPG OCIF, TR1), TNFRSF12 (TWEAK R FN14), TNFRSF13B (TACI), TNFRSF13C (BAFF R), TNFRSF14 (HVEM ATAR, HveA, LIGHT R, TR2), TNFRSF16 (NGFR p75NTR), TNFRSF17 (BCMA), TNFRSF 18 (GITR AITR), TNFRSF19 (TROY TAJ, TRADE), TNFRSF19L (RELT), TNFRSFIA (TNF RI CD120a, p55-60), TNFRSFIB (TNF RII CD120b, p75-80), TNFRSF26 (TNFRH3), TNFRSF3 (LTbR TNF RIII, TNFC R), TNFRSF4 (OX40 ACT35, TXGP1 R), TNFRSF 5 (CD40 p50), TNFRSF6 (Fas Apo-1, APT1, CD95), TNFRSF6B (DcR3 M68, TR6), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB CD137, ILA), TNFRSF21 (DR6), TNFRSF22 (DcTRAIL R2 TNFRH2), TNFRST23 (DcTRAIL RI TNFRH1), TNFRSF25 (DR3 Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10 (TRAIL Apo-2 Ligand, TL2), TNFSF 11 (TRANCE/RANK Ligand ODF, OPG Ligand), TNFSF12 (TWEAK Apo-3 Ligand, DR3 Ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM Ligand, LTg), TNFSF15 (TLIA/VEGI), TNFSF18 (GITR Ligand AITR Ligand, TL6), TNFSFIA (TNF-&#x3b1; Conectin, DIF, TNFSF2), TNFSF1B (TNF-b LTa, TNFSF1), TNFSF3 (LTb TNFC, p33), TNFSF4 (OX40 Ligand gp34, TXGP1), TNFSF5 (CD40 Ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas Ligand Apo-1 Ligand, APT1 Ligand), TNFSF7 (CD27 Ligand CD70), TNFSF8 (CD30 Ligand CD153), TNFSF9 (4-1BB Ligand CD137 Ligand), TP-1, t-PA, Tpo, TRAIL, TRAIL R, TRAIL-R1, TRAIL-R2, TRANCE, transferring receptor, TRF, Trk, TROP-2, TSG, TSLP, tumor-associated antigen CA 125, tumor-associated antigen expressing Lewis Y related carbohydrate, TWEAK, TXB2, Ung, uPAR, uPAR-1, Urokinase, VCAM, VCAM-1, VECAD, VE-Cadherin, VE-cadherin-2, VEFGR-1 (fit-1), VEGF, VEGFR, VEGFR-3 (fit-4), VEGI, VFM, Viral antigens, VLA, VLA-1, VLA-4, VNR integrin, von Willebrands factor, WIF-1, WNT1, WNT2, WNT2B/13, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, XCL1, XCL2, XCR1, XCR1, XEDAR, XIAP, XPD, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3 (T cell immunoglobulin and mucin protein-3), hormone receptors and growth factors;</claim-text><claim-text>g. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen selected from the group consisting of: BCMA, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3, CD20, CD2, CD19, Her2, EGFR, EpCAM, Fc&#x3b3;RIIIa (CD16), Fc&#x3b3;RIIa (CD32a), Fc&#x3b3;RIIb (CD32b), Fc&#x3b3;RI (CD64), Toll-like receptors (TLRs), TLR4, TLR9, cytokines, IL-2, IL-5, IL-13, IL-6, IL-17, IL-12, IL-23, TNF&#x3b1;, TGFb, cytokine receptors, IL-2R, chemokines, chemokine receptors, growth factors, VEGF, and HGF;</claim-text><claim-text>h. the antibody or antigen-binding antibody fragment is comprised in a chimeric antigen receptor (CAR), which optionally comprises at least one transmembrane domain, and at least one intracellular domain from a T-cell receptor, optionally a CD3&#x3b6; subunit, and at least one co-stimulatory domain;</claim-text><claim-text>i. the antibody or antigen-binding antibody fragment comprises an scFv2-Fc2 and/or scFv-IgG;</claim-text><claim-text>j. the antibody or antigen-binding antibody fragment comprises an IgG constant domain; and/or</claim-text><claim-text>k. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen, wherein said antibody or antigen-binding antibody fragment comprises a multispecific format selected from the group consisting of: Fab-Fc-scFv, &#x201c;bottle-opener, Mab-scFv, Mab-Fv, Dual scFv, central Fv, central scFv, one-arm central scFv, Fab-Fab, Fab-Fv, mAb-Fv, mAb-Fab, DART, BiTE, common light chain-IgG, TandAb, Cross-Mab, SEED, BEAT, TrioMab, and DuetMab.</claim-text></claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. An isolated or recombinant nucleic acid encoding an antibody or antigen-binding antibody fragment according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, or an expression vector containing said nucleic acid.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. (canceled)</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. A host cell transfected, transformed, or transduced with a nucleic acid according to <claim-ref idref="CLM-00010">claim 10</claim-ref>, optionally a mammalian or yeast cell, or a vector containing said nucleic acid sequence.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. A pharmaceutical composition comprising an antibody or antigen-binding antibody fragment according to <claim-ref idref="CLM-00001">claim 1</claim-ref>; and a pharmaceutically acceptable carrier and/or excipient.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A method of treating a disorder in a mammal in need of such treatment, wherein the disorder comprises a proliferative disorder, an oncological disorder, an immuno-oncological disorder, a neurological disorder, a neurodegenerative disorder, or an autoimmune disorder, comprising administering an effective amount of one or more antibodies or antibody fragments according <claim-ref idref="CLM-00001">claim 1</claim-ref> or a host cell which expresses one of said antibodies or antibody fragments according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, optionally an immune cell, further optionally a T or NK cell, wherein the method optionally further comprises administering to the mammal an additional therapeutic agent, optionally wherein the mammal is a human.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. (canceled)</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. An anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antibody fragment, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises:<claim-text>a. a variable light (V<sub>L</sub>) chain polypeptide comprising a V<sub>L </sub>CDR3 (CDRL3) of X<sub>1</sub>QSYFRRT (SEQ ID NO: 1), optionally wherein X<sub>1 </sub>is K, A, T, or V;</claim-text><claim-text>b. a variable heavy (V<sub>H</sub>) chain polypeptide comprising a V<sub>H </sub>CDR3 (CDRH3) of X<sub>3</sub>RDAYGX<sub>4</sub>YFYDV (SEQ ID NO: 6), optionally wherein X<sub>3 </sub>is A or V and X<sub>4 </sub>is R or Q;</claim-text><claim-text>c. a variable light (V<sub>L</sub>) chain polypeptide comprising a V<sub>L </sub>CDR1 (CDRL1) of KSSQSLLNARTX<sub>5</sub>KNYLA (SEQ ID NO: 7), optionally wherein X<sub>5 </sub>is G, M, N, or R;</claim-text><claim-text>d. a variable light (V<sub>L</sub>) chain polypeptide comprising a V<sub>L </sub>CDR2 (CDRL2) of WASTRES (SEQ ID NO: 10) or WASTRSS (SEQ ID NO: 11);</claim-text><claim-text>e. a variable heavy (V<sub>H</sub>) chain polypeptide comprising a V<sub>H </sub>CDR1 (CDRH1) of FNX<sub>6</sub>KDYYX<sub>7</sub>H (SEQ ID NO: 12), wherein X<sub>6 </sub>is I, N or V and X<sub>7 </sub>is M or I; and/or</claim-text><claim-text>f. a variable heavy (V<sub>H</sub>) chain polypeptide comprising a V<sub>H </sub>CDR2 (CDRH2) of WIDLX<sub>5</sub>NANTVYDX<sub>9</sub>KX<sub>10</sub>QG (SEQ ID NO: 14), wherein X<sub>5 </sub>is E or N, X<sub>9 </sub>is A, H, or T, and X<sub>10 </sub>is F or L.</claim-text></claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein:<claim-text>a. X<sub>1 </sub>is A, T or V;</claim-text><claim-text>b. the CDRL3 comprises an amino acid sequence of AQSYFRRT (SEQ ID NO: 2); TQSYFRRT (SEQ ID NO: 3); VQSYFRRT (SEQ ID NO: 4); or KQSYFRRT (SEQ ID NO: 5);</claim-text><claim-text>c. X<sub>3 </sub>is A;</claim-text><claim-text>d. X<sub>5 </sub>is G or R;</claim-text><claim-text>e. the CDRL1 comprises an amino acid sequence of KSSQSLLNARTGKNYLA (SEQ ID NO: 8) or KSSQSLLNARTRKNYLA (SEQ ID NO: 9);</claim-text><claim-text>f. the CDRL2 comprises an amino acid sequence of WASTRES (SEQ ID NO: 10);</claim-text><claim-text>g. the CDRL2 comprises an amino acid sequence of WASTRSS (SEQ ID NO: 11);</claim-text><claim-text>h. X<sub>6 </sub>is I;</claim-text><claim-text>i. X<sub>7 </sub>is M;</claim-text><claim-text>j. the CDRH1 comprises an amino acid sequence of FNIKDYYMH (SEQ ID NO: 13);</claim-text><claim-text>k. X<sub>8 </sub>is E;</claim-text><claim-text>l. X<sub>9 </sub>is A;</claim-text><claim-text>m. X<sub>10 </sub>is F;</claim-text><claim-text>n. the CDRH2 comprises an amino acid sequence of WIDLENANTVYDAKFQG (SEQ ID NO: 15); and/or</claim-text><claim-text>o. the CDRH2 comprises an amino acid sequence of WIDLENANTIYDAKFQG (SEQ ID NO: 16).</claim-text></claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The anti-CD3 antibody or antigen-binding antibody fragment of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein:<claim-text>a. said anti-CD3 antibody or antigen-binding antibody fragment binds to CD3 with a dissociation constant (K<sub>D</sub>) of about 500 pM or more, about 500 pM or less, about 450 pM or less, about 400 pM or less, about 350 pM or less, about 300 pM or less, about 250 pM or less, about 200 pM or less, about 150 pM or less, or about 100 pM or less, optionally wherein said CD3 is human and/or cynomolgus, further optionally wherein said binding affinity is measured by surface plasmon resonance;</claim-text><claim-text>b. said antibody or antigen-binding antibody fragment elicits T cell activation or T cell killing while displaying a decreased propensity to elicit cytokine production to levels capable of inducing cytokine release syndrome;</claim-text><claim-text>c. the antibody or antigen-binding antibody fragment comprises a multispecific antibody;</claim-text><claim-text>d. the antibody or antigen-binding antibody fragment comprises a bispecific antibody;</claim-text><claim-text>e. the antibody or antigen-binding antibody fragment comprises an scFv;</claim-text><claim-text>f. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an oncology target; an immune-oncology target; a neurodegenerative disease targets; an autoimmune disorder target; an infectious disease target; a metabolic disease target; a cognitive disorder target; a blood-brain barrier target; or a blood disease target;</claim-text><claim-text>g. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen selected from the group consisting of: 17-IA, 4-1BB, 4Dc, 6- keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, Al Adenosine Receptor, A33, ACE, ACE-2, Activin, Activin A, Activin AB, Activin B, Activin C, Activin RIA, Activin RIA ALK-2, Activin RIB ALK-4, Activin RIIA, Activin RUB, ADAM, ADAM10, ADAM12, ADAM 15, ADAM 17/T ACE, ADAM8, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, Addressins, aFGF, ALCAM, ALK, ALK-1, ALK-7, alpha-l-antitrypsin, alpha-V/beta-1 antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, ARC, ART, Artemin, anti-Id, ASPARTIC, Atrial natriuretic factor, av/b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B-lymphocyte Stimulator (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bel, BCMA, BDNF, b-ECGF, bFGF, BID, Bik, BFM, BLC, BL-CAM, BLK, BMP, BMP-2 BMP-2a, BMP-3 Osteogenin, BMP-4 BMP-2b, BMP-5, BMP-6 Vgr-1, BMP-7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1, BMPR-II (BRK-3), BMPs, b-NGF, BOK, Bombesin, Bone-derived neurotrophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, CIO, CA125, CAD-8, Calcitonin, cAMP, carcinoembryonic antigen (CEA), carcinoma-associated antigen, Cathepsin A, Cathepsin B, Cathepsin C/DPPI, Cathepsin D, Cathepsin E, Cathepsin H, Cathepsin L, Cathepsin O, Cathepsin S, Cathepsin V, Cathepsin X/Z/P, CBL, CCI, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL 14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9/10, CCR, CCR1, CCR10, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD4, CD5, CD6, CD7, CD8, CD10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, CD32, CD33 (p67 proteins), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80 (B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, <i>Clostridium botulinum </i>toxin, <i>Clostridium perfringens </i>toxin, CKb8-1, CLC, CMV, CMV UL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-associated antigen, DAN, DCC, DcR3, DC-SIGN, Decay accelerating factor, des(1-3)-IGF-I (brain IGF-1), Dhh, digoxin, DNAM-1, Dnase, Dpp, DPPIV/CD26, Dtk, ECAD, EDA, EDA-A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, EN A, endothelin receptor, Enkephalinase, eNOS, Eot, eotaxinl, EpCAM, Ephrin B2/EphB4, EPO, ERCC, E-selectin, ET-1, Factor IIa, Factor VII, Factor VIIIc, Factor IX, fibroblast activation protein (FAP), Fas, FcR1, FEN-1, Ferritin, FGF, FGF-19, FGF-2, FGF3, FGF-8, FGFR, FGFR-3, Fibrin, FL, FLIP, Flt-3, Flt-4, Follicle stimulating hormone, Fractalkine, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas 6, GCP-2, GCSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr-2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-2), GDF-7 (BMP-12, CDMP-3), GDF-8 (Myostatin), GDF-9, GDF-15 (MIC-1), GDNF, GFAP, GFRa-1, GFR-alpha1, GFR-alpha2, GFR-alpha3, GITR, Glucagon, Glut 4, glycoprotein IIb/IIIa (GP IIb/IIIa), GM-CSF, gp130, gp72, GRO, Growth hormone releasing factor, Hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMV gB envelope glycoprotein, HCMV) gH envelope glycoprotein, HCMV UL, Hemopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2/neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV) gB glycoprotein, HSV gD glycoprotein, HGFA, High molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp 120 V3 loop, HLA, HLA-DR, HM1.24, HMFG PEM, HRG, Hrk, human cardiac myosin, human cytomegalovirus (HCMV), human growth hormone (HGH), HVEM, 1-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF binding proteins, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-18, IL-18R, IL-23, interferon (INF)-alpha, INF-beta, INF-gamma, Inhibin, iNOS, Insulin A-chain, Insulin B-chain, Insulin-like growth factor 1, integrin alpha2, integrin alpha3, integrin alpha4, integrin alpha4/beta1, integrin, alpha4/beta7, integrin alpha5 (alphaV), integrin alpha5/beta1, integrin alpha5/beta3, integrin alpha6, integrin beta1, integrin beta2, interferon gamma, IP-10, 1-TAC, JE, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 15, Kallikrein LI, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), laminin 5, LAMP, LAP, LAP (TGF-1), Latent TGF-1, Latent TGF-1 bpl, LBP, LDGF, LECT2, Lefty, Lewis-Y antigen, Lewis-Y related antigen, LFA-1, LFA-3, Lfo, LIF, LIGHT, lipoproteins, LIX, LKN, Lptn, L-Selectin, LT-a, LT-b, LTB4, LTBP-1, Lung surfactant, Luteinizing hormone, Lymphotoxin Beta Receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCAM, MCK-2, MCP, M-CSF, MDC, Mer, a metalloprotease, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP-1-alpha, MK, MMAC1, MMP, MMP-1, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3, MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Mucl), MUC18, Muellerian-inhibiting substance, Mug, MuSK, NAIP, NAP, NCAD, N-Cadherin, NCA 90, NCAM, NCAM, Neprilysin, Neurotrophin-3, -4, or -6, Neurturin, Neuronal growth factor (NGF), NGFR, NGF-beta, nNOS, NO, NOS, Npn, NRG-3, NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, Parathyroid hormone, PARC, PARP, PBR, PBSF, PCAD, P-Cadherin, PCNA, PDGF, PDGF, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), PIGF, PLP, PP14, Proinsulin, Prorelaxin, Protein C, PS, PSA, PSCA, prostate specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK, RANKL, RANTES, Relaxin A-chain, Relaxin B-chain, renin, respiratory syncytial virus (RSV) F, RSV Fgp, Ret, Rheumatoid factors, RLIP76, RPA2, RSK, S100, SCF/KL, SDF-1, SERINE, Serum albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (tumor-associated glycoprotein-72), TARC, TCA-3, T-cell receptors (e.g., T-cell receptor alpha/beta), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, testicular PLAP-like alkaline phosphatase, TfR, TGF, TGF-alpha, TGF-beta, TGF-beta Pan Specific, TGF-beta RI (ALK-5), TGF-beta RII, TGF-beta RIIb, TGF-beta RIII, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta4, TGF-beta5, Thrombin, Thymus Ck-1, Thyroid stimulating hormone, Tie, TIMP, TIQ, Tissue Factor, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-alpha, TNF-alpha beta, TNF-beta2, TNFc, TNF-RI, TNF-RII, TNFRSF10A (TRAIL R Apo-2, DR4), TNFRSFIOB (TRAIL R2 DR5, KILLER, TRICK-2A, TRICK-B), TNFRSF10C (TRAIL R3 DcR1, LIT, TRID), TNFRSF10D (TRAIL R4 DcR2, TRUNDD), TNFRSF11A (RANK ODF R, TRANCE R), TNFRSF11B (OPG OCIF, TR1), TNFRSF12 (TWEAK R FN14), TNFRSF13B (TACI), TNFRSF13C (BAFF R), TNFRSF14 (HVEM ATAR, HveA, LIGHT R, TR2), TNFRSF16 (NGFR p75NTR), TNFRSF17 (BCMA), TNFRSF 18 (GITR AITR), TNFRSF19 (TROY TAJ, TRADE), TNFRSF19L (RELT), TNFRSFIA (TNF RI CD120a, p55-60), TNFRSFIB (TNF RII CD120b, p75-80), TNFRSF26 (TNFRH3), TNFRSF3 (LTbR TNF RIII, TNFC R), TNFRSF4 (OX40 ACT35, TXGP1 R), TNFRSF 5 (CD40 p50), TNFRSF6 (Fas Apo-1, APT1, CD95), TNFRSF6B (DcR3 M68, TR6), TNFRSF7 (CD27), TNFRSF8 (CD30), TNFRSF9 (4-1BB CD137, ILA), TNFRSF21 (DR6), TNFRSF22 (DcTRAIL R2 TNFRH2), TNFRST23 (DcTRAIL RI TNFRH1), TNFRSF25 (DR3 Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10 (TRAIL Apo-2 Ligand, TL2), TNFSF 11 (TRANCE/RANK Ligand ODF, OPG Ligand), TNFSF12 (TWEAK Apo-3 Ligand, DR3 Ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM Ligand, LTg), TNFSF15 (TLIA/VEGI), TNFSF18 (GITR Ligand AITR Ligand, TL6), TNFSFIA (TNF-&#x3b1; Conectin, DIF, TNFSF2), TNFSF1B (TNF-b LTa, TNFSF1), TNFSF3 (LTb TNFC, p33), TNFSF4 (OX40 Ligand gp34, TXGP1), TNFSF5 (CD40 Ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas Ligand Apo-1 Ligand, APT1 Ligand), TNFSF7 (CD27 Ligand CD70), TNFSF8 (CD30 Ligand CD153), TNFSF9 (4-1BB Ligand CD137 Ligand), TP-1, t-PA, Tpo, TRAIL, TRAIL R, TRAIL-R1, TRAIL-R2, TRANCE, transferring receptor, TRF, Trk, TROP-2, TSG, TSLP, tumor-associated antigen CA 125, tumor-associated antigen expressing Lewis Y related carbohydrate, TWEAK, TXB2, Ung, uPAR, uPAR-1, Urokinase, VCAM, VCAM-1, VECAD, VE-Cadherin, VE-cadherin-2, VEFGR-1 (flt-1), VEGF, VEGFR, VEGFR-3 (fit-4), VEGI, VFM, Viral antigens, VLA, VLA-1, VLA-4, VNR integrin, von Willebrands factor, WIF-1, WNT1, WNT2, WNT2B/13, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, XCL1, XCL2, XCR1, XCR1, XEDAR, XIAP, XPD, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3 (T cell immunoglobulin and mucin protein-3), hormone receptors and growth factors;</claim-text><claim-text>h. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen selected from the group consisting of: BCMA, CTLA4 (cytotoxic T lymphocyte antigen-4), PD1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), LAG-3 (lymphocyte activation gene-3), TIM-3, CD20, CD2, CD19, Her2, EGFR, EpCAM, Fc&#x3b3;RIIIa (CD16), Fc&#x3b3;RIIa (CD32a), Fc&#x3b3;RIIb (CD32b), Fc&#x3b3;RI (CD64), Toll-like receptors (TLRs), TLR4, TLR9, cytokines, IL-2, IL-5, IL-13, IL-6, IL-17, IL-12, IL-23, TNF&#x3b1;, TGFb, cytokine receptors, IL-2R, chemokines, chemokine receptors, growth factors, VEGF, and HGF;</claim-text><claim-text>i. the antibody or antigen-binding antibody fragment is comprised in a chimeric antigen receptor (CAR), which optionally comprises at least one transmembrane domain, and at least one intracellular domain from a T-cell receptor, optionally a CD3&#x3b6; subunit, and at least one co-stimulatory domain;</claim-text><claim-text>j. the antibody or antigen-binding antibody fragment comprises an scFv2-Fc2 and/or scFv-IgG;</claim-text><claim-text>k. the antibody or antigen-binding antibody fragment comprises an IgG constant domain; and/or</claim-text><claim-text>l. the antibody or antigen-binding antibody fragment comprises at least a second antigen binding domain that specifically binds to an antigen, wherein said antibody comprises a multispecific format selected from the group consisting of: Fab-Fc-scFv, &#x201c;bottle-opener, Mab-scFv, Mab-Fv, Dual scFv, central Fv, central scFv, one-arm central scFv, Fab-Fab, Fab-Fv, mAb-Fv, mAb-Fab, DART, BiTE, common light chain-IgG, TandAb, Cross-Mab, SEED, BEAT, TrioMab, and DuetMab.</claim-text></claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. An anti-cluster of differentiation three (&#x201c;CD3&#x201d;) antibody or antibody fragment according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said anti-CD3 antibody or antigen-binding antibody fragment comprises one or more CDRs of any one or more of Ab1-Ab50 and/or said anti-CD3 antibody or antigen-binding antibody fragment comprises one or more V<sub>H </sub>and/or V<sub>L </sub>chains comprising an amino acid sequence selected from those in Table 4.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. (canceled)</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. An isolated or recombinant nucleic acid encoding an antibody or antigen-binding antibody fragment according to <claim-ref idref="CLM-00016">claim 16</claim-ref> or an expression vector comprising said isolated or recombinant nucleic acid.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. (canceled)</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A host cell transfected, transformed, or transduced with a nucleic acid according to <claim-ref idref="CLM-00021">claim 21</claim-ref>, optionally a mammalian or yeast cell, or a vector containing said nucleic acid sequence.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A pharmaceutical composition comprising an antibody or antigen-binding antibody fragment according to <claim-ref idref="CLM-00016">claim 16</claim-ref>; and a pharmaceutically acceptable carrier and/or excipient.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A method of treating a disorder in a mammal in need of such treatment, wherein the disorder comprises a proliferative disorder, an oncological disorder, an immuno-oncological disorder, a neurological disorder, a neurodegenerative disorder, or an autoimmune disorder, comprising administering an effective amount of one or more antibodies or antibody fragments according to <claim-ref idref="CLM-00016">claim 16</claim-ref> or a host cell which expresses one of said antibodies or antibody fragments according to <claim-ref idref="CLM-00016">claim 16</claim-ref>, optionally an immune cell, further optionally a T or NK cell.</claim-text></claim></claims></us-patent-application>